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Abstract 
Brain tumours account for the most frequent type of solid tumours among children. 
Despite advances in surgery and chemotherapy, brain tumours are still the main cause 
of cancer deaths in children. Furthermore, little is known about DNA methylation 
changes in paediatric astrocytoma. Recent investigations suggest that many tumours 
are initiated not only by genetic abnormalities, but also caused by epigenetic changes. 
DNA methylation is a key epigenetic mechanism that controls the regulation of gene 
expression. Interestingly, unlike DNA mutations, epigenetic abnormalities are 
reversible. The reversibility of epigenetic abnormalities upon pharmacological 
unmasking has prompted interest in developing epigenetic therapy with the crucial 
goal of restoring the expression of aberrantly silenced genes. 
The focus of this study was to utilise a combination of different microarray strategies 
to develop an integrative candidate gene approach to identify several novel frequently 
methylated genes in a cohort of paediatric HGA (High grade glioma) samples. In 
addition, to investigate the potential of therapeutic efficacy of a DNA 
methyltransferase inhibitor, 5-Aza-dC in paediatric HGA. 
There were 147 genes commonly identified to be potentially methylated in IN699 cells 
using the two different array strategies integration; re-expression array and Illumina 
Infinium Human Methylation 450k array. Furthermore, using two complementary 
microarray strategies including methylation 450k array and expression array, this 
work identified 55 genes that were both methylated and under-expressed in these HGA 
cultures. Following validation with CoBRA and RT-PCR coupled with the response of 
hypermethylated promoters to the demethylating agent 5-Aza-dC, six novel genes 
(CXCL14, PRR5L, ELTD1, ITGA2, KRT8 and NTM) that are frequently silenced in 
paediatric astrocytoma were identified. This study suggests that re-expression of 
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CXCL14 inhibited the colony formation and cell growth and reduces the migration rate 
significantly in IN699 short term culture and likely have functional significance in the 
development of paediatric HGA and an excellent candidate gene for further analysis. 
In parallel, the efficacy of 5-Aza-dC treatment was examined in paediatric HGA aiming 
to introduce this epigenetic therapy as a potential mechanism in management of this 
tumours. This study demonstrated that, relatively low dose of 5-Aza-dC sharply 
reduced the colony formation and inhibited proliferation and not through the 
apoptotic effect. It is likely that this reduction in proliferation without cell death is due 
to using relatively low doses that do not acutely kill cells, thus, allow the sustained 
alterations in both gene expression patterns and appearance of a new phenotype to 
emerge. 
Taken together, this work contributes to a more detailed understanding of the effect 
of epigenetic silencing on paediatric HGA.  This investigation also demonstrated the 
use of epigenetic drug, 5-aza-dC to reverse the gene silencing for the potential 
treatment of paediatric HGA. 
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Aims 
 
This study aims to investigate whether aberrant methylation is the predominant 
mechanism driving down-regulation of gene expression in malignant paediatric 
astrocytoma by using a combination of three different microarray strategies and 
develop an integrated approach to identify methylated genes in short-term cell 
cultures derived from paediatric malignant astrocytoma. In parallel, to evaluate the 
reversal of gene silencing as a therapeutic strategy using clinically relevant doses of 5-
aza-2’-deoxycytidine (5-Aza-dC) on these tumour samples in an attempt to reactivate 
methylated genes and prevent tumour cell growth.  
1. To use Affymetrix U133 plus 2.0 Expression Array to determine global gene re-
expression following pharmacological unmasking of methylated genes with 5-
Aza-dC.  
2. To use the Illumina Infinium assay to create a list of hypermethylated genes 
within this cohort of paediatric HGA astrocytoma and identify potential 
hypermethylated candidate genes. 
3. To use the Affymetrix U133 Expression Array to shortlist the down-regulated 
genes.  
4. To integrate the identified gene list from the methylation and expression array 
to identify a panel of candidate genes that are both methylated and down-
regulated. 
5. To validate candidate hypermethylated genes. 
6. To identify candidate genes that could potentially be the causative factors for 
the development of paediatric HGA astrocytoma.  
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7. Subsequently, to assess the functional properties of these genes to understand 
the potential causative mechanism.  
8. Assess the 5-Aza-dC potential as a therapeutic agent in paediatric astrocytoma
 v 
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1 Chapter 1 
Introduction 
Around 28,000 children and presently diagnosed with brain tumour and 4,300 new 
cases of childhood CNS neoplasms are expected to be diagnosed in 2013, according to 
the Central Brain Tumour Registry of the United States. Brain tumours are the second 
most common malignancy among children, after leukemia and the most common solid 
tumour. Currently, paediatric brain tumours arise in 5.1 per 100,000 individuals, and 
occur slightly more frequently in males than females (Dolecek et al. 2012; CBTRUS 
n.d.). Astrocytoma account for about 40-60% of all CNS neoplasms in patients under 
19 years of age (Pfister & Witt 2009; Hargrave et al. 2006). 
1.1 Astrocytoma epidemiology, histological 
classification and clinical parameters 
The World Health Organization (WHO) guidelines classifies astrocytoma into four 
grades of malignancy, I-IV, according to historical criteria comprising nuclear atypia 
(enlarged, cigar-shaped, or irregular hyperchromatic nuclei), mitosis, microvascular 
proliferation and/or necrosis (Table 1.1). All astrocytoma consist of cells with 
phenotypical characteristics of astrocytes, although, the true cell of origin or 
progenitor cell of these tumours is not definitely known (Ichimura et al. 2004). The 
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most malignant astrocytomas are grade III anaplastic astrocytoma (AA) and grade IV 
glioblastoma multiforme (GBM), collectively known as high grade astrocytoma (HGA) 
(Dolecek et al. 2012). The least aggressive forms are grade I pilocytic astrocytoma (PA) 
and grade II diffuse astrocytoma (DA), referred to as low grade astrocytoma (LGA) 
(Dolecek et al. 2012). Approximately 90% and 80% paediatric patients with PA or DA 
respectively, survive 10 years after diagnosis. In contrast, children diagnosed with AA 
have a poor 10-year survival rate of approximately 50% whilst GBM patients have an 
even lower 10 years survival rate of just 14%. 
The understanding of the etiology of childhood astrocytoma is incomplete and stems 
predominantly from risk factors calculated from mixed pools of patients. Moreover, 
epidemiological studies have shown that 10 potential causes of a brain tumours 
originate from a number of risk factors, the most important of these being exposure to 
X-ray radiation (Ohgaki & Kleihues 2005; Braganza et al. 2011) and certain hereditary 
predisposing syndromes (Pfister & Witt 2009). For example, about 15% of children 
with the genetic syndrome Neurofibromatosis type I (NFI) are prone to development 
of astrocytoma, mostly in the optic nerve (Pfister & Witt 2009). Other factors 
contributing to the onset of astrocytoma among paediatric patients are genetic 
syndromes originating from mutations in the TP53 gene as in Li Fraumeni syndrome 
or MLH1, MLH1, PMS2 as in Turcot syndrome (Pfister & Witt 2009). Among, the first 
and second degree relatives of patients who developed astrocytoma, an increased 
incidence is observed with these genetic syndromes (Scheurer et al. 2010; Sadetzki et 
al. 2013).
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Astrocytoma WHO Malignancy 
Grade 
Pilocytic Astrocytoma I 
Pilomyxoid II 
Pleomorphic Xanthoastrocytoma II 
Diffuse Astrocytoma II 
Fibrillary  
Protoplasmic  
Gemistocytic  
Anaplastic Astrocytoma III 
Glioblastoma Multiform IV 
Giant Cell Glioblastoma  
Gliosarcoma  
Table 1.1 Astrocytoma tumour sub-groups and grades according to WHO 
guidelines. 
This study will use the terminology and definitions of the WHO classification of 2007 
(Louis et al. 2007) 
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1.1.1 Pilocytic astrocytoma grade I 
PA most commonly occur during childhood and they are the most frequent type of 
glioma in this age group. PA incidence is seen to peak among children between 5-9 
years of age.  They are slow-growing tumours with well-defined boundaries that only 
occasionally disseminate into the spinal cord (von Hornstein et al. 2011). PA exhibit 
low cellularity without necrosis or extensive microvascular proliferation. They 
commonly present a biphasic growth pattern that includes both compacted bipolar 
cells and regions with microcysts and more loosely textured cells (Figure 1.1). 
Rosenthal fibres and eosinophilic granular bodies are also characteristic. 
Oligodendroglial-appearing cells are often encountered in PA, and in some patients 
can encompass a large portion of the tumour (Takei et al. 2008). The lack of 
infiltration, along with the presence of specific features such as eosinophilic granular 
bodies, allows most cases to be distinguished from HGA (Louis et al. 2007). The 
majority of PA are curable by surgical resection and the 5- year survival rate is 97% 
(Øivind et al. 2010). However, a small minority of cases will recur or undergo 
malignant progression.  A number of potential histological and immunohistochemical 
prognostic markers have been identified. An elevated Ki67 proliferation index is 
associated with worse progression-free survival (Hayes et al. 1999; Bowers et al. 2003) 
as are anaplastic features, including hypercellularity, cytological atypia, high mitotic 
activity, and necrosis (Scheithauer et al. 2010; Louis et al. 2007). Morphological or 
immunohistochemical evidence of oligodendroglial differentiation may also predict 
aggressive behaviour of PA (Alshail et al. 1997; Takei et al. 2008).
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Figure 1.1 H&E stained paediatric pilocytic astrocytoma 
H&E stained pictures are credited to Professor T. Dawson. This picture illustrates the 
typical biphasic pattern of paediatric PAI. Magnification 20X.
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1.1.2 Diffuse astrocytoma grade II  
DA consist of three histological sub-types-fibrillary astrocytoma, protoplasmic 
astrocytoma and gemistocytic astrocytoma. They are well-differentiated tumours with 
a propensity to infiltrate neighbouring brain tissues and eventual progression into 
grade III tumours (Perry et al. 2003). Infiltrating fibrillary astrocytoma in children are 
similar in morphology, to their counterparts in adults. They present modest cellularity 
and a lack of significant mitotic activity, vascular proliferation or necrosis (Figure 1.2) 
(Louis et al. 2007). Due to their ability to spread diffusely, it is difficult to completely 
resect these tumours and they have worse outcomes than PA in children (Fisher et al. 
2008).  DA comprise only about 6% of low-grade tumours in children and 5-year 
survival is 76% (Øivind et al. 2010).
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Figure 1.2 H&E stained paediatric diffuse astrocytoma 
H&E stained pictures are credited to Professor T. Dawson. This picture illustrates a 
paediatric DAII with minimal nuclear atypia. Magnification 20X.
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1.1.3 Anaplastic astrocytoma grade III  
AA comprise poorly differentiated densely packed cells with focal or dispersed 
anaplasia and are characterised by nuclear atypia and/or enlargement and high 
mitotic activity (Figure 1.3).  (Kamnasaran 2009; Sievert & Fisher 2009; Louis et al. 
2007; Pfister & Witt 2009). Normal and abnormal mitoses often accompany 
multinucleation. The presence of gemistocytic cells may be seen in small numbers and 
inconsistent GFAP staining is frequently observed. 
1.1.4 Glioblastoma multiforme grade IV 
GBM is formed of poorly differentiated neoplastic cells with high mitotic index and 
nuclear atypia but show additional histological evidence of necrosis and extensive 
microvascular structures compared AA. (Figure 1.4). GBM most commonly presents 
between 45 and 70 years of age. Primary or de novo GBM usually arises in patients 
aged 60 years following a short clinical history. In contrast, secondary GBM is most 
commonly seen in patients in their 40's and progress from low-grade tumours over a 
period of months or even years (Kleihues & Ohgaki 1999). GBM is much rarer in 
children and HGA (including AA and GBM) account for approximately 4% of all CNS 
tumours and 20% of paediatric astrocytoma (Kaatsch et al. 2001; Louis et al. 2007). 
This included brain-stem astrocytoma or diffuse intrinsic pontine glioma comprise 
between 3 - 9% of astrocytoma diagnosed children (Pollack 1999; Louis et al. 2007).  
The 2-year survival rates for paediatric HGA range from 10% to 30% although this falls 
to >10% for DIPG (Diffuse Intrinsic Pontine Glioma) (Reddy 2003). 
HGA are most commonly found in the cerebral hemispheres, preferentially in the 
frontotemporal and parietal area. The basal ganglia or contralateral hemispheres can 
be infiltrated by this tumour. In rare circumstances, these tumours have also been 
located in the cerebellum or spinal cord.
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Figure 1.3 H&E stained paediatric anaplastic astrocytoma 
H&E stained pictures are credited to Professor T. Dawson. This picture illustrates a 
paediatric AAIII with cellular and nuclear anaplasia. Magnification 20X. 
 
Figure 1.4 H&E stained paediatric glioblastoma multiforme 
H&E stained pictures are credited to Professor T. Dawson. This picture illustrates a 
paediatric GBMIV. Magnification 20X. 
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1.2 Treatment of paediatric astrocytoma 
Surgical resection of tumours, coupled with adjuvant therapies like radiation and 
chemotherapy, when relevant, comprise standard care of paediatric patients with 
astrocytoma. Patient age, tumour location and tumour type most often determine the 
choice of therapy provided. For instance, the therapy for patients with tumours having 
an indolent course, such as optic pathway glioma in Neurofibromatosis type 1, may be 
restricted to observation alone as 50% of these tumours fail to progress further 
(Hargrave 2009). On the other hand, there are other tumours that require an 
aggressive treatment strategy for improved patient survival. Overall, paediatric 
astrocytoma patients respond to treatment better than adult patients (Ohgaki et al. 
2004) and this is probably due to inherent different molecular signatures and biology 
of tumours from these two age groups. 
Paediatric astrocytoma patients present with symptoms that are similar to those found 
with other solid brain tumours and which are dependent on the location of tumour 
and its growth rate. Seizures are a common symptom, although prior to this, more 
subtle changes in a patient may occur (Louis et al. 2007). Clinical manifestations may 
include changes in vision or other senses, developing speech difficulties, irritability, 
nausea, failure to thrive and progressive macrocephaly (Polak et al. 1992; Pollack 
1994; van den Bos et al. 2002; Raphael et al. 2007). These symptoms are often due to 
an increased intracranial pressure caused by the tumour or ventricular obstruction 
(Berger 1996). Frontal lobe tumours may present with behavioural and personality 
shifts (Aitken & Luce 1996). Patients with AA and GBM show the same symptoms as 
those with PA and DA but usually have a much shorter clinical history (Louis et al. 
2007). 
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1.2.1 Surgery 
Surgery remains the primary treatment for majority of paediatric astrocytomas 
(Khatua et al. 2012; Mueller & Chang 2009). It is often recommended for tumours 
with distinct boundaries that are amenable to gross total or near total resection such 
as those that are peripherally located in the cerebellar and cerebral cortex (Khatua et 
al. 2012; Mueller & Chang 2009). In general, surgical resection can sometimes 
immensely decrease tumour volume, and may increase tumour response to adjuvant 
irradiation and/or chemotherapy as the size of the tumour has a reverse relationship 
with response rates (Tomita et al. 1998). 
In addition, surgical resection provides the tumour tissues for histo-pathological 
diagnosis which is important for deciding follow-up therapies and also decreasing the 
size of the tumour mass relieves intracranial pressure to improve the overall quality of 
life for the patient (Hardesty & Sanai 2012; Stummer & Kamp 2009; Carapella et al. 
2011). 
With the exception of PA which have margins that are often well defined and clear to 
be seen, complete resection is often not possible. For instance, HGA present with 
infiltration and a tumour edge that is poorly defined and therefore only parts of this 
tumour can be removed (Robertson 2006).  The extent of paediatric tumour resection 
has been improved greatly in recent years with the aid of new methods such as 
radiography and electrophysiology (Robertson 2006). 
1.2.2 Radiotherapy 
Radiotherapy is used as a first line therapy or as a post-operative treatment for 
remaining disease (Urbański 2012; Mueller & Chang 2009; Khatua et al. 2012). 
However, the long term effects of irradiating such young children include decrease in 
IQ and damage to the thalamus and  pituitary gland (Duffner & Cohen; Robertson 
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2006).  Radiotherapy has undergone massive improvements and three- dimensional 
conformal RT and intensity-modulated RT are a therapeutic choice for patients with 
brain tumours (Swift 2002). The use of RT in paediatric oncology is a balance between 
the effects on tumour cells versus normal tissue within the irradiated volume, 
particularly in high-grade infiltrative tumours. RT is usually administered at a 
cumulative dose over several weeks to a target tumour volume, as normal tissue can 
tolerate several small doses of irradiation much better than one large dose (Larson et 
al. 1993; Swift 2002).  Advances in this field have been possible due to technology 
which administers the maximum therapeutic dose to a tumour mass whilst minimising 
the dose to surrounding normal brain.  Gamma knife and stereotactic radiosurgery are 
precise RT approaches used to treat paediatric tumours that require imaging (CT and 
MRI) and head immobilisation. A single large fraction of radiation is delivered to a 
discrete volume of tumour with accuracy using a large number of intersecting beams. 
These methods are used to treat small, well defined, unresectable tumours, in regions 
where possible damage to normal tissue is acceptable (Kida et al. 2000; Hodgson et 
al. 2004; Suh & Barnett 2003; Marcus et al. 2005). However, even though these 
developments have transformed radiotherapy, the toxic effects on normal tissues 
restricts its use patients who are younger than 3 years. Moreover, paediatric patients 
treated by radiotherapy are often at risk of developing secondary malignancies and 
often succumb to neurodevelopmental abnormalities including serious long-term 
neurocognitive and neuroendocrine sequelae (Kortmann et al. 2003). 
1.2.3 Chemotherapy 
Chemotherapy is often applied in parallel with radiotherapy. Generally, it is 
recommended for children with disease development after surgery/radiotherapy and 
also in young children (Burzynski et al. 2006). The use of chemotherapeutic agents 
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alone, in combination and combined with RT have significantly improved outcome in 
children with astrocytoma (Robertson 2006). Several studies have investigated the 
treatment of HGA in children with chemotherapy and RT in various combinations. 
However, there is no current FDA approved chemotherapeutic agents with efficacious 
treatment of paediatric astrocytomas by significantly improving overall survival even 
when used in conjunction with other chemotherapeutic agents. A clinical trial carried 
out by the Society of Paediatric Oncology in 1991 reported the outcome of pre-
irradiation chemotherapy for HGA. Patients received maintenance chemotherapy 
involving lomustine, vincristine and cisplatin (irradiation followed by chemotherapy) 
or sandwich chemotherapy (chemotherapy followed by irradiation) involving 
ifosfamide, etoposide, methotrexate, cisplatin and cytosine arabinoside. Patients who 
had extensive chemotherapy, via the sandwich arm of the study, had a better overall 
survival (median 5.2 years) compared to those patients in the maintenance arm 
(median 1.9 years). However, the extent of tumour resection was the most significant 
prognostic factor. Median survival was 5.2 years for patients who underwent a greater 
than 90% tumour resection, compared to 1.3 years for patients who had an incomplete 
tumour resection. This study revealed that intensive chemotherapy prior to RT, 
increases survival rates in patients with HGA that underwent total resection (Wolff et 
al. 2002). 
1.3 Genetic alterations 
In adults, GBM develops through two pathways that have different molecular profiles. 
Primary GBMs are characterized by loss of heterozygosity of 10q in 70% of cases, PTEN 
mutations in nearly 25%, p16INK4a deletion in 31% and EGFR amplification in 36% 
of the cases (von Deimling et al. 1992; Collins 2002). These genetic alterations are less 
frequent in secondary GBM which typically have mutations and/or deletions in TP53, 
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and chromosomal deletion with loss of 17p and mutations in IDH1 or its related gene, 
IDH2 (Riemenschneider et al. 1999; Pedersen et al. 2003; Ohgaki & Kleihues 2007; 
Nobusawa et al. 2009; Yan et al. 2009; Ichimura et al. 2004; Collins 2002; Ohgaki et 
al. 2004). However, in primary GBM, MDM2 is often overexpressed or amplified 
which targets p53 for ubiquitin-mediated degradation or homozygous 
deletion/mutation of p14ARF (Ichimura et al. 2000; Riemenschneider et al. 1999). 
Amplification of CDK4 and CDK6 is also frequent in primary GBM (Ichimura et al. 
2000). 
Histopathologically, paediatric HGA are similar to those in adults.  However, studies 
have shown that their molecular pathogenesis and biological behaviour is different to 
that of their adult counterparts. Studies investigating chromosomal aberrations in 
paediatric HGA have identified alterations that also occur in adult HGA and further 
changes that are unique to the paediatric tumours. Furthermore, some paediatric HGA 
show a normal karyotype, a characteristic uncommon in adult HGA (Bigner et al. 1997; 
Warr et al. 2001; Rickert et al. 2001). 
TP53 mutations in paediatric astrocytoma are less frequent than in adult astrocytoma 
in all grades (Sure et al. 1997; Cheng et al. 1999; Pollack et al. 2002; Hayes et al. 1999). 
However, there is correlation between TP53 protein over-expression and grade in 
paediatric astrocytoma (Pollack et al. 2001; Nakamura et al. 2007). Over-expression 
of the MDM2 protein has been found in 67% of paediatric HGA, although no 
amplification of the MDM2 gene has been reported (Sung et al. 2000). Similarly, over-
expression of EGFR protein has been frequently observed in paediatric HGA and has 
been associated with angiogenesis (Bredel et al. 1999; Khatua et al. 2003).  However 
amplification of EGFR is extremely rare (Kraus et al. 2002; Pollack et al. 2006; Khatua 
et al. 2003).  
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The Rb pathway is disrupted in 25% of paediatric HGA, a much lower frequency than 
that found in adult HGA (Sung et al. 2000). Although mutation of the PTEN gene has 
been linked to poor prognosis in paediatric HGA, it has been reported in only a few 
cases (Raffel et al. 1999; Kraus et al. 2002; Pollack et al. 2006). Deletion of CDKN2A 
was found in 10% of paediatric HGA and mutations of this gene were also found in 8% 
and 13% of AA and GBM, respectively (Newcomb et al. 2000; Sure et al. 1997; Raffel 
et al. 1999). Loss of CDKN2A expression was identified in 60% of paediatric GBM in 
one study (Sure et al. 1997). Disruption of the TP53 pathway through one or more of 
these mechanisms occurs in 95% of paediatric HGA, a similar frequency to that in the 
adult tumours. There are a great divergences between paediatric astrocytomas and 
their adult counterparts in spectrum and frequency of mutations. A wide range of 
prevalent genetic abnormalities in adult gliomas are absent in paediatric tumours, 
especially amplification or overexpression of EGFR and VEGFR and deletion or 
mutation of PTEN. Consequently, small tyrosine kinase inhibitors which are meant to 
affect these receptors could not be used in treatment of paediatric astrocytomas. 
Recently, new oncogenic mutations in BRAF, FGFR1, ACVR1, and PPDM1 and 
amplification or overexpression of MYB/MYBL1 and IGF1R in paediatric LGA and 
HGA are discovered by means of high-throughput screening, particularly whole-
genome and transcriptome sequencing analyses. For instance, upregulation of the 
RAS-RAF-MEK-ERK pathway through activating mutations is frequent in all grades 
of paediatric astrocytomas. In LGA, the predominant molecular alteration is an 
oncogenic KIAA1549-BRAF fusion protein, which lacks the N-terminus regulatory 
domain of BRAF while retaining the C-terminus BRAF kinase domain. About 20% of 
HGAs (and a subset of grade II astrocytomas) harbor the V600EBRAF mutation, 
which is mainly activated through a T to A mutation causing a valine to glutamate 
substitution at residue 600. MAPK signaling may be increased through gain-of-
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function mutations in FGFR1 as well, mostly in tumours existing in the midline or 
brainstem. Missense mutations or tandem duplications in the tyrosine kinase domain 
of FGFR1 result in constitutive activation of the receptor in a subset of approximately 
7% LGAs and 12% HGAs. Moreover, 25% of cerebral grade II diffuse astrocytomas 
have recently declared rearrangements truncating the C-terminal microRNA negative-
regulatory domain or amplification of the transcription factors MYB or MYBL1. 
Mutations in ACVR1, encoding a bone morphogenetic protein type 1 receptor, have 
been identified in 32% of DIPGs and 12% of midline HGAs in conjunction with the 
histone H3.1pLys27Met mutation. Here, missense mutations are located in either the 
kinase domain or the inhibitory glycine-serine–rich domain and induce ligand-
independent activation of the transforming growth factor β signaling pathway and 
increased SMAD phosphorylation.
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1.4 Epigenetics 
Epigenetic alterations have been associated with all cancer types. The spectrum of 
lesions includes gain and loss of DNA methylation including multicopy elements as 
well as single copy genes. DNA methylation and deacetylation of histones, change gene 
expression and genome stability through regulation of local chromatin structure. 
Recent data suggest that early epigenetic changes occur during tumourigenesis and 
that they may affect progenitor cells to further molecular changes that are involved in 
tumour promotion (Zhao et al. 2007).  
Given the high frequency of DNA methylation changes, these events may become ideal 
biomarkers for early molecular diagnostics. Previous studies demonstrated an 
association between GBM development and MGMT promoter methylation. MGMT 
has been observed to be hypermethylated in low-grade gliomas (grade II) further 
evolving to gliomas grade III and GBM (Brena et al. 2006; Wick et al. 2013).  This 
finding has potentially significant clinical implications (Cancer Genome Atlas 
Research Network, 2008). 
MGMT methylation is often associated with p53 mutations in secondary GBM. these 
p53 mutations were G:C to A:T transition mutations in about 70% cases and of those, 
most of them were at CpG sites (Ohgaki & Kleihues 2007). It is important to note that 
G:C to A:T p53 mutations happen in brain tumours in about 50% of cases, of which 
about 65% occur at CpG sites (Rivlin et al. 2011). 
In adults, the importance of CpG island promoter hypermethylation in GBM 
pathogenesis without gene mutation is highlighted by the epigenetic inactivation of a 
wide range of genes associated with tumour suppression (RB1, VHL, EMP3, RASSF1A, 
CITED4, BLU), DNA repair (MGMT, hMLH1), cell cycle regulation (p16INK4a, 
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p15INK4b), and tumour invasion and apoptosis (DAPK, TIMP3, CDH1)(Esteller et al. 
2001; Waha et al. 2005; Horiguchi et al. 2003). Interestingly, the three astrocytoma 
grades in adults (WHO II, III and IV) showed differences in the level of methylation 
status (CDKN2B, PTGS2, CALCA, MYOD1, THBS1, TIMP3 and CDH1) (Uhlmann et 
al. 2003). Similarly, methylation of MGMT is more frequent in secondary GBM than 
in primary GBM or LGA (Nakamura 2001).  
Epigenetic changes between primary and secondary GBMs found to be different, 
methylation silencing of the N-myc downstream-regulated gene 2 (NDRG2) that was 
associated with decreased mRNA levels in 62% of primary GBMs, didn’t noted in 
secondary GBMs or lower-grade astrocytomas (Tepel et al. 2008). 
1.5 DNA methylation 
DNA methylation is a chemical process defined as the covalent addition of a methyl 
group to the 5'carbon of a cytosine nucleotide, leading to the formation of 5-
methylcytosine at that position (Baylin 2005). The addition of methyl groups disrupts 
the epigenetic regulation of gene expression and serves not only to regulate normal 
DNA processes, but also to enable aberrant transcription (Jones 2002). Under normal 
circumstances, DNA methylation acts to inhibit transcription of non-coding or non-
expressing regions of DNA, acting as a means to control potentially harmful processes 
that would affect normal cellular replication and activity (Baylin & Jones 2011). 
However, aberrant DNA methylation can contribute to disease processes, particularly 
cancer.  
1.5.1 CpG islands  
DNA methylation is a predominantly stable modification of genetic material that 
occurs in the context of cytosine-guanosine (CpG) dinucleotides (Taberlay & Jones 
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2011). In mammalian cells, the occurrence of CpG dinucleotides is variable such that 
there are areas largely lacking CpG sites and others where CpG sites are located at a 
higher frequency, so-called CpG islands (CGIs) (Bird et al. 1985). These sites often co-
locate with specific gene promoter regions, upstream of the coding regions and 
account for around 4% of the total genomic DNA (Taberlay & Jones 2011). The 
distribution of DNA methylation through the mammalian genome is not uniform.  The 
majority of CpG sites are heavily methylated in the genome, except those that reside 
within CGIs which remain largely unmethylated (Baylin 2005).  
The lack of methylation in CGIs, at least in the germline, which ensures they do not 
undergo the mutational loss of CpGs (through deamination) that affects the rest of the 
genome (Bird 1986; Suzuki & Bird 2008). Mammalian CGIs have an average length of 
~1,000bp, are GC-rich in comparison to bulk genomic DNA and are typically 
associated with gene promoters or regulatory elements (Guenther et al. 2007; Weber 
et al. 2007). 
1.5.2 DNA methylation machinery 
The process of DNA methylation is complex and consists of a number of distinct stages 
and regulatory mechanisms involving multiple cellular proteins (Bird et al. 1985). 
Essentially the process can be broken down into the following stages: writing, erasing 
and reading (Figure 1.5) (Chi et al. 2010). Writing DNA methylation is defined as the 
process of introducing methyl groups to the relevant genetic material (Goldberg et al. 
2007) and is a process carried out by a family of enzymes termed DNA 
methyltransferases (DNMTs) (Chi et al. 2010). Three distinct forms of DNMT are 
critical in DNA methylation: DNMT1, DNMT3a and DNMT3b (Mizuno et al. 2001). 
The activity of DNMT1 has been most extensively studied and has been shown to have 
a preference for hemi-methylated DNA over unmethylated substrates (Jeltsch 2006). 
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When DNA replicates, DNMT1 methylates the newly synthesised DNA at the site of 
the replication fork during replication (Moore et al. 2013). By copying the existing 
methylation pattern exactly, DNMT1 maintains existing methylation levels in 
replicating DNA, preventing potentially lethal effects, as observed in DNMT1-
knockout mice (Robert et al. 2002). DNMT1 is essential for maintaining epidermal 
progenitor cell function and its loss leads to premature differentiation (Sen et al. 
2010). There are two functional isoforms of DNMT1 including the longer form that is 
found in somatic and embryonic stem (ES) cells and the shorter form in oocytes and 
pre-implantation embryos (Gaudet et al. 1998). 
DNMT1 is over-expressed in many cancers, for example, cervical cancer (Sawada et al. 
2007), hepatocellular carcinomas (Saito et al. 2003) and stomach cancer (Etoh et al. 
2004). However, down-regulation of DNMT1 may also contribute to carcinogenesis by 
causing hypomethylation. For example, introduction of a hypomorphic allele of 
DNMT1 in mice has been shown to cause genomic hypomethylation along with the 
carcinogenic agent cadmium, causes down-regulation of DNMT1 in a mouse testicular 
cell line (Singh et al. 2009). 
In contrast, DNMT3a and 3b generate new DNA methylation, rather than using hemi-
methylated DNA as a template, and can therefore add new methylation patterns and 
act during embryonic development and cellular differentiation where cellular 
differentiation is achieved through high levels of de novo DNA methylation in 
promoter regions of pluripotency genes (Watanabe et al. 2002; Jeong et al. 2009) 
A second major mechanism of methylation processing is the erasure of DNA 
methylation, which can be classified as either passive or active (Moore et al. 2013). 
Passive DNA demethylation takes place in dividing cells and involves a multiple-stage 
enzymatic process cleaving the methyl group from the 5’ carbon (Law & Jacobsen 
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2010). The base excision repair (BER) pathway is involved in this process, although 
many of the enzymes involved are as yet undetermined (Cortellino et al. 2011). Active 
DNA demethylation occurs in non-proliferating cells and is a complex process 
involving ten-eleven translocation (TET) enzymes, which add a hydroxyl group to the 
methyl group and thereby initiate a series of reactions. It is thought that TET enzymes 
can mediate oxidation of 5mC to 5hmC and then to 5-formylcytosine (fC) and 5-
carboxylcytosine (caC), which might be converted to C by a decarboxylase resulting in 
a return to the native cytosine residue (Sedgwick 2004). Although the mechanisms of 
demethylation remain poorly elucidated, this is a key process in regulating the extent 
to which DNA is methylated under normal circumstances.  
In addition to the DNMTs (writers) and DNA demethylases (erasers), the other main 
component of DNA methylation machinery is the family of methyl-CpG binding 
proteins (MBPs) which act as ‘readers’ of methylation patterns (Robertson 2005). 
More specifically, these proteins bind to the methyl group and inhibit subsequent 
transcription factor binding (Moore et al. 2013). These proteins also possess unique 
binding sites that allow them to engage repressor complexes, thereby further 
inhibiting gene expression at the relevant position on the DNA strand (Cortellino et al. 
2011). Although methylation itself may prevent transcription from occurring, the 
presence of MBP provides a more robust mechanism for transcription disruption (Law 
& Jacobsen 2010). Other members of ‘readers’ have also been identified, including 
ubiquitin-life, containing PHD and RING finger domain (UHRF) proteins and zinc 
finger domain proteins, all of which act in a similar manner to MBPs, although these 
are poorly characterised as yet (Moore et al. 2013). These components of the DNA 
methylation machinery are further controlled by the cell cycle and the presence of 
histone modifications, which act as epigenetic factors in the regulation of DNA 
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methylation (Sedgwick 2004). These factors will be discussed in greater detail in 
subsequent sections. The following section will consider the major machinery 
component, DNMTs, and their contribution to disease, and particularly cancer.
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Figure 1.5 Epigenetic enzymes and their inhibitors. 
The figure illustrates the interactions writers, erasers and reader enzymes and nucleosomes. The nucleosome core contains of a 
histone octamer which is wrapped by a nuclear DNA strand. DNA methylations are represented as red circles. DNA methylation is 
induced by DNMTs. To inhibit DNA methylation, DNMTis are being used to target and suppress DNMTs. Histone tails can be post 
transcriptionally modified using enzymes such as HATs. Histone acetylation can be inhibited by HDACs and HDACis can be used as 
HDACs suppressors. Re-using of this figure needs the author’s permission. 
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1.5.3 DNA methyltransferases and cancer 
The two-hit hypothesis of cancer (Knudson 2001; Jones & Laird 1999), suggests that 
loss of function of both alleles of a given gene is required to ensure malignant 
transformation. Typically, the first hit is delivered through mutation of a critical gene, 
which is then followed by loss of the wild-type allele through deletion or other 
mechanisms (Knudson 2001). Aberrant methylation of promoter regions also leads to 
gene inactivation, including those genes that may protect against cancerous 
mechanisms (Esteller 2007). 
Accordingly, DNMT activity has been associated with the development of cancer in a 
number of contexts (Esteller 2005a). The members of the DNMT family variably 
contribute to DNA damage response mechanisms, which act to maintain chromosomal 
stability through identification of common replication errors and correction of these 
errors (Miremadi et al. 2007). Targeted deletion of any of the three main DNMTs in 
animal models is associated with destabilisation of the genome, including enhanced 
telomere recombination, microsatellite instability and increased chromosomal 
translocations (Miremadi et al. 2007). All of these processes are associated with 
oncogenesis, while the observation that cancer cells are associated with promoter 
hypermethylation and silencing of DNA repair genes suggests a strong link between 
DNMT activity and the DNA damage repair system in cancer (Jin & Robertson 2013). 
The DNA damage response (DDR) is a complex signaling network that defends cells 
from potentially mutagenic DNA derived from either endogenous or exogenous 
sources. The DDR usually functions through cell cycle checkpoints, DNA repair and 
damage tolerance pathways to activate cell death pathways if excessive damage exists 
(Jackson & Bartek 2009).  Like the cellular DNA methylation machinery, an intact 
DDR is crucial for preventing cancer. Evidence is mounting to support a link between 
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the DNA methylation and DNA damage repair systems, as first suggested by promoter 
hypermethylation and silencing of DNA repair genes in multiple types of cancer 
(Jacinto & Esteller 2007). More importantly, DNMT1 may be directly involved in DNA 
damage repair in a DNA methylation-independent manner (Unterberger et al. 2006; 
Loughery et al. 2011; Kim et al. 2004). A further link between DNMT activity and 
cancer has been noted involving a methylation-independent process (Jin & Robertson 
2013). When DNA double strand breaks occur, DNMT1 is rapidly recruited to the site 
of the break and interacts with key components of the DNA damage repair system, 
including proliferating cell nuclear antigen, to repair the break and prevent 
chromosomal instability (O’Hagan et al. 2008). As cancers are associated with 
multiple forms of DNA damage, often resulting in aberrant cellular growth and tissue 
function, this suggests that the DNMT family may play an important role in the 
systems available to prevent such DNA damage and in the corresponding repair 
mechanisms (O’Hagan et al. 2008). 
A study by Chen et al (2007) demonstrated the necessity of functioning DNMT1 in 
cancer cells. A conditional DNMT1 knockout colorectal cancer cell line, HCT116, was 
generated that demonstrated a reduction of CpG-CpG dyads within the genome and 
arrest at the G2 phase of the cell cycle, suggesting DNMT1 is essential for maintenance 
of methylation in cancer cells and required for proliferation and survival (Chen et al. 
2007). Whilst inhibition of DNMT3a and 3b appear to have a lesser effect on cancer 
cells (Rhee et al. 2002), downregulation of the miRNA (miR)-29 family (29a, 29b, and 
29c), which have complementary sites within the 3’-UTRs of DNMT3a and DNMT3b, 
in lung cancers have shown upregulation of DNMT3a and 3b, associated with worse 
prognosis (Fabbri et al. 2007). Upon re-expression of the miRNAs, normal patterns of 
DNA methylation were restored, as was the expression of some methylation-silenced 
tumour suppressor genes (Fabbri et al. 2007) 
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1.5.4 DNA methylation and gene expression 
DNA methylation is a fundamental regulator of gene expression, where inappropriate 
methylation may lead to deactivation of important tumour suppressor genes, 
contributing to malignancy (Jin & Robertson 2013). However, although the role of 
DNA methylation in the context of gene silencing or transcription interruption is well 
known, there is emerging evidence that suggests this may be an overly simplistic 
interpretation of gene regulation through methylation (Foret et al. 2012). By 
considering the site of methylation within the transcriptional unit, it has been noted 
that some methylation sites may act to promote gene expression, rather than suppress 
it, while other sites may also influence splicing, suggesting that DNA methylation may 
control gene expression in a diverse manner (Jones 2012). The known impact of DNA 
methylation on gene expression includes long term silencing of genes, such as X-
chromosome inactivation and genes involved in the germ line, while methylation 
outside of CpG islands may be more tissue-specific and dynamic in nature, leading to 
splicing variations and variable effects in target tissue (Jones 2012). Many of these 
mechanisms remain unclear however, and the functional capacity of DNA methylation 
to silence gene expression has predominated in the literature, due to its association 
with cancer biology (Jones 2012). However, the role of methylation alone is not robust 
in terms of gene silencing and the recruitment of DNA binding proteins ensures a more 
stable process. 
Repression of gene expression can be brought about by DNA methylation by either 
direct blocking of transcription factor binding or, as is more common, via the actions 
of methyl DNA binding protein (Clouaire & Stancheva 2008). Although this 
mechanism is rare in vivo, direct blocking of transcription factor binding by the 
presence of DNA methylation has been described in some instances. For example, 
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GFAP (glial fibrillary acidic protein) is a developmentally regulated gene activated 
during astrocyte differentiation. The GFAP gene promoter contains a STAT3 
transcription factor binding site and upon removal of DNA methylation within this 
region, GFAP is expressed due to STAT3 binding (Shimozaki et al. 2005). 
1.5.5 Mechanisms of repression by DNA methylation 
Two primary models have emerged to describe the mechanism through which DNA 
methylation at regulatory sequences can influence transcription in mammalian cells. 
Firstly, methylated CpGs may directly preclude some transcription factors and 
regulatory proteins from binding to DNA. Depending on the genomic context and 
nature of the protein excluded from DNA, this can have either positive or inhibitory 
effects on transcription (Bell & Felsenfeld 2000; Watt & Molloy 1988). Secondly, DNA 
methylation can create docking sites for proteins that specifically recognise 
methylated CpGs. These proteins, known as methyl-CpG binding proteins (MBPs), 
recruit co-repressors that modulate chromatin structure and modify histones leading 
to local heterochromatization and transcriptional repression (Boyes & Bird 1991) 
Additionally, methyltransferases by itself may directly contribute to repression at 
methylated and non-methylated sequences (Figure 1.6) (Rountree et al. 2000; Fuks et 
al. 2000).
 28 
 
 
Figure 1.6 Putative mechanisms of DNA methylation-mediated 
repression. 
Unmethylated CpGs and methylated CpGs are presented as white and red circles 
respectively. Purple cylender represent core histones complexed with DNA. a.) 
Unmethylated promoters are permissive to transcription in the presence of 
appropriate transcription factors. DNA methylation can go through repression and 
chromain condensation through one of several putative mechanisms comprising b.) 
Methyl-CpG binding proteins (MBP) can identify methylated DNA and target co-
repressor complexes to silence transcription that causes chromatic modification c.) 
Transcriptional activation can inhibited directly when DNA methylation in the 
recognition site of some transcription factors can block them from binding DNA d.) 
DNMT can recruit co-repressors such as HDAC and histone HMT to repress 
transcription during de novo or maintenance methylation activity. Re-using of this 
figure needs the author’s permission.
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1.5.6 Recruitment of methyl DNA binding proteins 
The most common mechanism for DNA methylation to induce repression of gene 
expression is via the recruitment of DNA binding proteins and subsequent 
modification of chromatin organisation. There are three families of methyl DNA 
binding proteins: the Kaiso-like family of proteins, the SRA (SET- and RING-
associated) domain proteins and the methyl binding domain family of proteins. The 
Kaiso-like family currently consists of three members, Kaiso, ZBTB4 and ZBTB38. 
Kaiso-like family members show affinity for both unmethylated and methylated DNA 
suggesting multiple roles are likely for this family (Yoon et al. 2003). Little is known 
about the SRA (SET- and RING-associated) domain family of proteins other than one 
of the mammalian homologues, Np95, may have an important role in epigenetic 
inheritance and that the SRA domain is able to bind to CpNpG in addition to CpG 
(Johnson et al. 2007). The methyl binding domain proteins are by far the biggest 
players in bringing about gene repression as a result of DNA methylation. The family 
consists of 5 members; MBD1, MBD2, MBD3, MBD4 and MeCP2, although not all can 
bind methylated DNA. The methyl binding domain is 75 amino acids long with a 
binding affinity dependent upon the presence of four specific residues, the loss of one 
of these residues in MBD3 renders it unable to bind methylated DNA (Hendrich & Bird 
1998). MBPs represent a key link between DNA methylation and transcriptional 
regulation in mammalian cells (Klose & Bird 2006). Research in the late 1990s 
revealed that MBPs repressed the transcription of methylated DNA by recruiting 
histone deacetylase-containing complexes (HDAC), which mechanically connect 
methylation and transcriptional repression through modification of chromatin 
(Ganesan et al. 2009). 
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There is some evidence that the recognition of DNA methylation sites is not a universal 
process for all MBPs, with some demonstrating a high level of specificity for certain 
binding sites, depending on surrounding DNA sequences and other genetic factors 
such as cellular reproductive stage (Sharp et al. 2011; Esteller 2005a). Overall, these 
processes are poorly understood, and further work is needed to identify the factors 
that guarantee recruitment of these proteins to methylated DNA sites, thereby 
solidifying the link between chromatin remodelling and methylation. 
Of these proteins, only mammalian MBD3 lacks the capacity to bind methylated CpGs 
due to a substitution of a key binding residue (Saito et al. 2003). The structure of the 
MBD domain complexes with methylated DNA suggested MBD proteins would 
recognise methyl-CpG regardless of genomic context (Ohki et al. 2001). However, it 
has since emerged that MeCP2 preferentially binds methyl-CpGs flanked by A/T rich 
sequences and that MBD1 may bind unmethylated CpGs (Klose et al. 2005). MBD 
proteins repress transcription, at least in part, through targeting histone deacetylases, 
lysine methyltransferases and chromatin remodelling factors to methylated DNA 
which promotes an inactive chromatin structure (Ng et al. 2000; Nan et al. 1998). Each 
MBD protein interacts with characteristic co-repressors, although it is unclear whether 
all co-factors are in the same complex. For example MeCP2 is found associated with 
ATRX, the Sin3a/HDAC complex and H3K9 methyl-transferase activity (Jones et al. 
1998; Fuks et al. 2000). 
1.6 DNA methylation in normal development  
Although DNA methylation is an important mechanism underlying mammalian 
oncogenesis, it is also important for the development of normal cellular architecture 
and tissue throughout the lifespan (Figure 1.7) (Esteller 2005a). 
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1.6.1 Genomic imprinting   
Genomic imprinting describes a process whereby genes are expressed from only one 
of the two inherited parental chromosomes (Li et al. 1993). DNA methylation is part 
of the epigenetic control mechanism underlying genomic imprinting, whereby gene 
silencing of the imprinted allele results from selective methylation, leading to 
expression of the unimprinted allele (Anon 2002). This may result in the expression 
of a functional allele from the maternal chromosome (e.g. H19 or CDKN1C) or from 
the paternal chromosome (e.g. IGF-2) (Jin & Robertson 2013). 
Generally, one parentally derived allele is extensively methylated while the other 
exhibits little of no methylation at CpG-rich regulatory sequences (DMRs) (Plass & 
Soloway 2002). Imprinted DNA methylation is introduced during gametogenesis, 
according to sex, by DNMT3a and DNMT3L. Following fertilization, imprinted DMRs 
are preserved by DNMT1o during cleavage divisions and then by the somatic form of 
DNMT1 in embryonic and adult tissues (Howell et al. 2001). Imprinted methylation 
affects expression of genes in several, often complex ways, which vary at different 
imprinted loci. In the simplest cases, DMRs, which overlap the CGI promoter of an 
imprinted gene, can directly silence expression when methylated. 
1.6.2 X-chromosome inactivation 
The process of X-chromosome inactivation occurs in females, who possess two copies 
of the X-chromosome (Heard 2004). Inactivation of one copy occurs through 
transcriptional silencing, while the other remains active, a differential control 
mechanism that persists throughout the lifespan of the organism in most cases (Heard 
2004). The main reason for X-inactivation is to serve as a dosage compensation 
mechanism, ensuring the equal inheritance of chromosomes between XY males and 
XX females (Heard & Disteche 2006). Although both the active and inactive X-
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chromosomes have similar patterns of global methylation, there is a notable difference 
in terms of CpG island methylation patterns: the inactive chromosome has methylated 
CpG islands, while the majority are unmethylated on the active copy (Sharp et al. 
2011). 
1.6.3 Tissue-specific genes 
The control of tissue-specific gene expression is one of the hallmarks of human 
development, allowing for the formation of different tissues and complex organs and 
structures to occur in a regulated manner (Jones 2001). Although the overall 
developmental process is governed by complex interactions of genes and their 
products, according to morphogenetic concentrations and receptor translocation, the 
role of DNA methylation in tissue-specific gene expression has also been noted 
(Maegawa et al. 2010). When the methylation patterns of cells from different tissues 
are compared in a single organism, there are distinct differences in methylation 
patterns, but these patterns are conserved between individuals on a tissue-specific 
basis (Jones 2001). This suggests that there is a conserved methylation profile for 
certain tissues within the same species. Whether or not these differences in 
methylation are caused by cellular differentiation during development, or are a cause 
of such differentiation remains unclear, but the difference in methylation patterns on 
a tissue-by-tissue basis is consistent across studies, highlighting the value of DNA 
methylation in tissue-specific gene expression (Suzuki & Bird 2008).  
1.6.4 Germ line-specific genes 
DNA methylation is a heritable characteristic that can be passed on to ova and sperm 
cells (De Smet et al. 1999). However, the methylation states at pre-existing imprinted 
loci need to be reset prior to germ cell development, as the germ cell differentiation 
process demands the formation of haploid eggs or sperm depending on the sex of the 
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host organism (Heard 2004). The process of X-inactivation must also be reversed to 
facilitate this process and therefore demethylation is a vital aspect of germ cell line 
specific gene activity, to ensure the viability and formation of suitable haploid germ 
cells (De Smet et al. 1999). However, DNA methylation is then a key component in the 
maintenance of normal gene expression in germ cells, repressing the expression of 
genes that are restricted to male or female lineages and are not expressed later in adult 
tissue (Jin & Robertson 2013). Therefore, DNA methylation is important in 
establishing germ cells, representing one of the few instances of methylation being 
used as a regulator of normal gene expression in development (Maegawa et al. 2010).  
1.7 DNA methylation in cancer 
Global disruption of the epigenetic landscape, resulting in aberrant gene expression 
and function, is a hallmark of human cancer (Jones & Baylin 2002). The cancer 
methylome is highly disrupted, featuring hypermethylation and aberrant silencing of 
tumour suppressor genes, and hypomethylation of repetitive sequences, transposons, 
and oncogenes, which contributes to tumourigenesis by increasing chromosomal 
instability and activating aberrant transcription  (Eden et al. 2003; Gaudet 2003; 
Sharma et al. 2009). The first observation linking DNA methylation with cancer 
identified that tumours were hypomethylated shortly after oncogenic mutations 
occurred in a human cancer cell line (Feinberg & Vogelstein 1983).  The majority of 
cancer epigenetic studies have concentrated on focal CpG island hypermethylation and 
identified many tumour suppressor genes. 
1.7.1 Hypomethylation, genomic instability, gene activation, 
and loss of imprinting 
In general, tumour genomes are hypomethylated in comparison with normal cells, 
suggesting of dysregulation of DNMT activity, leading to aberrant expression of 
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normally silenced genes and promotion of oncogenesis (Gaudet 2003). The 
hypomethylation of the cancer genome predominantly occurs in the body of genes 
(coding regions and introns) and the repetitive DNA sequences found in most genomic 
material (Esteller 2008a; Gaudet 2003). As tumour cells progress through malignant 
stages, the degree of hypomethylation increases, suggesting that this is closely 
associated with invasion and metastasis of tumours (Esteller 2005b). 
There are three mechanisms that may account for the link between oncogenesis and 
DNA hypomethylation: the introduction of chromosomal instability; reactivation of 
genes; and, a loss of imprinting (Heard 2004). Increased chromosomal instability and 
abnormal transcriptional regulation can result from DNA hypomethylation occurring 
at repetitive elements, retrotransposons, CpG poor promoters, introns and gene 
deserts (Rodriguez et al. 2006). This is particularly true of hypomethylation in the 
centromere DNA sequences, which can directly result in disruption of chromosomal 
patterning, causing aneuploidy (Sharma et al. 2010). Reactivation of genes may occur 
in a number of contexts, including the potential reactivation of genomic parasitic DNA, 
which is normally repressed through methylation lying outside of CpG islands (Gaudet 
2003). Other genes that are normally repressed, including tumour-specific genes, may 
also become activated through hypomethylation, leading to abnormal cellular biology, 
promoting the progression of cancer (Jin & Robertson 2013). Finally, the 
hypomethylation of imprinted genes can lead to aberrant expression of gene products 
that are detrimental to cellular function (Sharma et al. 2010). Although these changes 
are seen in cancer, it is not clear if they cause cancerous changes or if they are 
modulators or consequences of existing oncogenic changes in cell activity (Gaudet 
2003). 
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1.7.2 Hypermethylation and gene silencing 
Expression of tumour suppressor genes is controlled by promoter regions co-located 
with CpG islands (Esteller 2005b) and transcription is permitted when CpG islands 
are unmethylated (Jin & Robertson 2013). However, during the early stages of 
malignancy there is a dense hypermethylation of CpG islands associated with tumour 
suppressor genes, leading to gene silencing (Esteller 2005b). The degree of 
hypermethylation is often correlated with the malignant potential of the tumour, while 
the presence of hypermethylation, though variable, is specific to the tissue of origin of 
the tumour (Raynal et al. 2012). 
The precise nature of hypermethylation in the context of cancer remains largely 
uncertain, as the selection or methylation of specific genes may be either a random 
event, or may be a selective event (Herman & Baylin 2003). The targeting of a gene 
that confers a selective advantage to the survival of cancer seems likely from a 
Darwinian perspective, while it has also been proposed that fusion proteins can recruit 
DNMTs and HDACs to specific CpG islands in order to facilitate aberrant 
hypermethylation (Raynal et al. 2012). Whatever the mechanism, a number of genes 
involved in the control of the cell cycle, or other aspects of cancer biology are affected 
by hypermethylation events and thereby facilitate the emergence of malignancy 
(Herman & Baylin 2003).  There are a number of genes that are hypermethylated in 
cancers, including cell cycle regulators, genes of the p53 network, cadherin or catenin 
pathway genes, DNA repair genes, hormone response genes, cytokine signaling genes, 
and other biochemical pathways that regulate normal cellular processes (Esteller 
2005b). The cell cycle inhibitor gene, p16INK4a, is hypermethylated in a large number 
of primary tumours including colorectal, lung, and breast carcinomas (Witcher & 
Emerson 2009; Belinsky et al. 1998). This modification leads to cells escaping 
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senescence and allowing for unchecked proliferation (Esteller 2005b). 
Hypermethylation of p14ARF a tumour suppressor gene that acts to inhibit the 
oncogenic MDM2 protein, which degrades p53 is often seen in leukaemia and almost 
50% of somatic tumours (Nakamura 2001). Many classic tumour suppressor genes are 
silenced in a variety of cancers by DNA hypermethylation occurring at their promoters, 
including p16, MLH1, and BRCA1 (Baylin 2005; Jones & Baylin 2002; Jones & Baylin 
2007) . Such genes play important roles in maintaining normal cellular physiology by 
controlling when the cells are allowed to divide. When DNA damage is detected, wild 
type tumour suppresser genes would delay cell replication until the damage is repaired 
or trigger apoptosis if the damage cannot be fixed. Silencing of those genes would lead 
to continued cell replication and accumulation of DNA damage, consequently leading 
to cancer formation (Sherr 2004). Additionally, aberrant hypermethylation can 
indirectly silence genes by silencing transcription factors that control them. Silencing 
of transcription factors GATA4 and GATA5 often occur in colon cancer and gastric 
cancer, resulting in subsequent repression of their downstream target genes (Akiyama 
et al. 2003).  
Similarly, the cadherins and catenins, which regulate cellular pathways involving cell 
growth and communication, are hypermethylated in tumours of the breast, lung, colon 
(Esteller 2005b). DNA repair genes are also commonly hypermethylated, including 
the mismatch repair gene hMLH1, which is involved in the pathogenesis of colorectal 
cancer, gastric tumours and endometrial cancer (Watanabe et al. 2007). Furthermore, 
the breast cancer gene BRCA1, is hypermethylated as an event preceding the onset of 
irregular cell growth, leading to disruption of the normal function of BRCA1, which is 
to repair double stranded DNA breaks (Turner et al. 2006). 
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Further genes which are hypermethylated include oestrogen, progesterone and 
prolactin receptors, leading to cancer unresponsiveness to these hormones, (Turner et 
al. 2006). Alterations in cytokine pathways represent one way in which cancer cells 
escape normal cellular control of growth, and the hypermethylation of the suppressor 
of cytokine signaling protein family leads to aberrant signaling and expansion of 
tumour cells in certain tissue types (Esteller 2005b). Finally, other pathways affected 
include apoptosis regulators, key pathways of angiogenesis, and numerous growth 
factors, all of which have the potential to enhance tumour growth where their activity 
is aberrant (Esteller 2005b). 
1.7.3 DNA hypermethylation events as biomarkers 
In order to effectively translate knowledge of DNA methylation from the laboratory to 
clinical practice, a number of researchers have sought to utilise hypermethylated CpG 
islands as biomarkers for individual forms of cancer (Esteller 2005a). This could 
provide a highly specific form of cancer screening, diagnostic information or 
prognostic data for patients based on the unique methylation profiles associated with 
malignancies (Lofton-Day et al. 2008). For instance, the single hypermethylation 
marker GSTP1 is associated with up to 90% of prostate cancer (Jerónimo et al. 2001). 
The application of hypermethylation detection tools that are non-radioactive, easy to 
use, fast and sensitive is therefore essential in understanding the effects of 
hypermethylation and exploiting the potential of earlier diagnosis and prognostication 
(Lofton-Day et al. 2008). The use of specific polymerase chain reaction (PCR) primers 
has been shown to be a useful approach to hypermethylation detection (Kristensen & 
Hansen 2009), while the use of specific CpG island microarrays has also been shown 
to provide a large-scale analysis of hypermethylation in key domains of the genome 
(Irizarry et al. 2008). By monitoring hypermethylation events over the course of 
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tumour development (even preceding development in some cases) it may be possible 
to assign pathogenic roles to specific hypermethylation events, thereby completing the 
existing knowledge base of their role in cancer biology (Esteller 2005a). This might 
not only be useful in identifying cells that are likely to become cancerous in the future, 
but may also be suggestive of the behaviour of tumours (Robertson 2005). By 
monitoring the methylation patterns of key tumour associated genes, it may be 
possible to assign prognostic data to tumours. This has been performed with 
p16INK4a, which has been shown to predict highly aggressive lung and colon cancer 
behaviour in observed patients (Esteller 2008b). This has been partly shown with the 
MGMT gene, which normally controls guanine biology in the synthesis of DNA, but 
becomes aberrantly hypermethylated in multiple forms of cancer (Shen et al. 2005). 
Alkylating agents that specifically target guanine have been shown to be effective 
against some tumour cells, and have shown even greater efficacy in cells that have lost 
MGMT function, as the guanine damage caused by alkylating agents cannot be 
repaired (Weller et al. 2009). While this specific example is one of the few instances 
where hypermethylation events can predict treatment responses in practice, future 
research is needed to explore this potential on a gene-by-gene basis (Esteller 2005a).
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Figure 1.7 The consequence of DNA methylation in normal and malignant 
cells. 
DNA methylation is responsible for several different biological assets in Normal cell 
as well as cancer cell. The epigenetic equilibrium of normal and cancer cell shown in 
red and blue respectively. Re-using of this figure needs the author’s permission. 
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1.8 Epigenetic therapies and DNA demethylating 
agents 
Considering the importance of DNA methylation and histone acetylation in the 
initiation and progression of human cancer, these mechanisms are identified as novel 
therapeutic targets. In contrast to genetic alterations, epigenetic changes in cancer are 
potentially reversible. This resulted in the development of pharmacologic inhibitors of 
DNA methylation and histone deacetylation. By inducing demethylation of DNA and 
histone acetylation, these compounds can reverse the epigenetic silencing of tumour 
suppressor genes, resulting in reactivation of these genes in tumour cells and 
restoration of crucial cellular pathways (Hellebrekers et al. 2007). To date, four   
epigenetic drugs have been approved by FDA for cancer treatment: two DNMT 
inhibitors, vidaza (5-azacitidin) and decitabine (5-Aza-dC) and two HDAC   inhibitor, 
vorinostat and romidepsin. Moreover, there inhibitors of HATs and HMTs have been 
researched intensively (Figure 1.8).
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Figure 1.8 Epigenetic drugs for cancer treatments 
This figure illustrates epigenetic drugs and the enzymes they inhibit in epigenetic 
machinery. Re-using of this figure needs the author’s permission. 
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1.8.1 DNMT inhibitors 
Due to the intrinsically reversible nature of DNA methylation and chromatin 
modifications, compounds or drugs designed to readjust the cancer acquired changes 
in these gene expression modifiers are attractive therapeutic targets for restoring more 
normal expression. Drugs designed to block the DNA methyltransferases (DNMTs) 
have proved to be useful in cancer management, against haematological malignancies 
in particular. 
There are two broad categories of DNMT inhibitors: mechanistic inhibitors, including 
nucleosides and their derivatives; and, non-nucleoside inhibitors (Kim et al. 2012). 
Mechanistic inhibitors incorporate into DNA and act as suicide inhibitors by forming 
covalent bonds (Medina-Franco & Caulfield 2011). Two clinical versions of 
mechanistic inhibitors have been developed to date: 5-azacytidine and a similar 
analogue of this molecule, 5-Aza-dC, both of which have been approved for the 
treatment of myelodysplastic syndrome. A large abundance of drugs designed to block 
chromatin modifications are also being developed. HDAC inhibitors are currently the 
most heavily researched, falling into one of four categories; short chain fatty acids, 
hydroxamic acids, cyclic peptides and benzamide derivatives. Two HDAC inhibitors 
have so far been accepted for patient treatment, ‘Vorinostat’ and ‘Romidepsin’. As with 
the DNMT inhibitors, the most promise for HDAC inhibitors has been observed in 
haematological malignancies. The HDAC inhibitors most commonly bring about anti-
cancer effects via cell cycle arrest at the G1or G2-M phase, induction of differentiation 
and apoptosis (Rodríguez-Paredes & Esteller 2011).  A range of other targets for drug 
induced blocking of chromatin modifications are also being investigated, for example, 
inhibitors of histone acetylases, methylases and demethylases along with SIRT 
inhibitors (Rodríguez-Paredes & Esteller 2011). 
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These cytosine nucleosides can arrest DNMTs through a covalent mechanism leading 
to cytotoxicity and it was therefore assumed that cells with excessive DNMTs would be 
more sensitive to the drug, leading to specific cancer cell death (Kiziltepe et al. 2007) 
(Figure 1.9). While this principle remains valid in theory, there are other mechanisms 
associated with the drug, including interference with RNA synthesis, complicating the 
use of the drug for the purposes of demethylation alone (Esteller 2005a). However, 
clinical trials are ongoing with this agent, although cellular toxicity and clinical side 
effects are common and will likely limit the application of this agent in practice (Lyko 
& Brown 2005). An analogue to 5-azacytidine, 5-Aza-dC (decitabine) is often used for 
demethylation in cultured cells (Esteller 2005a). In contrast with 5-azacytidine, this 
drug does not interact with RNA and therefore has fewer side effects in terms of 
disrupted cellular mechanisms and signaling pathways (Flotho et al. 2009). However, 
in vivo testing of this agent has revealed a significant flaw, in that cytidine deaminase, 
which is found at high levels in the liver and spleen, can deactivate the DNMT 
inhibitory effects of the drug (Flotho et al. 2009). Therefore, the half-life of the drug 
in vivo is often only 15 minutes, potentially reducing any beneficial effects in patients 
with aberrant DNMT activity (Esteller 2005a). The development of non-nucleoside 
DNMTis, which do not incorporate into DNA, is being actively pursued (Cortez & 
Jones 2008). Non-nucleoside DNMT inhibitors, including procainamide, procaine 
and hydralazine, are also used in clinical studies (Medina-Franco & Caulfield 2011). 
These drugs are likely to have an effect on cofactors involved in DNMT activity or 
recruitment, effectively blocking their ability to methylate DNA sequences (Medina-
Franco & Caulfield 2011). These small molecules exert their inhibitory effects either by 
blocking the active site of DNMT1 or by binding to the mRNA of DNMT1 to prevent its 
translation (Datta et al. 2009). However, these drugs are not well tested and their 
routine use for cancer specific applications is not clear at present (Chuang et al. 2005).
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Figure 1.9 Cytosine analogue 5-Aza-dC as a DNMT inhibitor 
The cytosine analogues 5-azacytidine and 5-Aza-dC are the currently most advanced 
drugs for the epigenetic therapies. These substances act as DNA methyl transferase 
inhibitors and have demonstrated significant efficacy in reactivating epigenetically 
suppressed gene expression.  Figure shows the comparison between Cytosine and 5-
Aza-dC and their relevant mechanism of actions. DNMT enzyme shown in Grey. Re-
using of this figure needs the author’s permission.
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1.8.2 HDAC inhibitors 
HDACs are crucial regulators of gene expression and act to remove acetyl groups from 
histones, while upregulation of HDACs has been seen in many tumour types (West & 
Johnstone 2014). Disruption of HDAC activity causes cells to enter the apoptotic 
pathway, leading to cell death, and therefore classes of drug that disrupt HDAC activity 
may be useful anti-cancer agents (Khan & La Thangue 2012). Two drugs of this type 
have been shown to be useful in haematological tumours, with vorinostat and 
romidepsin approved for use in cutaneous T-cell lymphomas in patients with 
advanced or recurrent disease (West & Johnstone 2014; Khan & La Thangue 2012). 
However, the effects of HDAC inhibitors against solid tumours have generally been 
disappointing in clinical trials, while emerging therapeutic approaches and novel 
HDAC inhibitors have been shown to have the potential to target these tumour types, 
despite a lack of clinical data to date (West & Johnstone 2014). Therefore, this is an 
area of future research importance in cancer treatment. 
1.9 Histone modifications, chromatin remodelling 
Chromatin is the fundamental unit of the genome, with DNA base pairs wound around 
a histone protein (Wang et al. 2007). Chromatin remodelling and modifications can 
be facilitated by methylation events on lysine or arginine residues, leading to 
alterations in DNA transcription (Kouzarides 2007). Covalent histone modifications 
play an important role in chromatin remodelling and are often caused by DNA 
methylation activity, leading to silencing of key genes that facilitate normal cell cycle 
activity, apoptosis and chromosome condensation (Bannister & Kouzarides 2011). In 
hypermethylated histone DNA, the chromatin state leads to heterochromatin 
assembly and subsequent gene silencing (Bannister & Kouzarides 2011). Therefore, 
these mechanisms play an important role in cancer biology, as many tumour-
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associated features may be affected adversely by histone modifications and chromatin 
remodelling (Wang et al. 2007). 
1.10 Epigenetic inhibitors as potential anti-
glioblastoma therapeutics 
To date, there are a few studies with promising result, testing the effect of the histone 
modifying enzymes inhibitors on HGA (Ugur et al. 2007; Eyüpoglu et al. 2005). For 
instance the HDAC inhibitor, suberoylanilide hydroxamic acid crossed the blood-brain 
barrier, repressed the proliferation of intracranial gliomas and increased survival in 
mice (Rohle et al. 2013). Through a genome-wide analysis AGI-5198 identified as a 
R132H-IDH1 inhibitor that induced demethylation of histone H3K9me3 and 
expression of genes linked with gliogenic differentiation. Blockade of a mutant IDH1 
impaired the growth of IDH1-mutant, but not IDH1-wild-type, glioma cells (Rohle et 
al. 2013). Understanding the significance role of epigenetic alterations in pathobiology 
of HGA, and evidence from studies showing that epigenetic modifiers are 
therapeutically drugable will drive rigorous preclinical and clinical studies with the 
aim to new therapeutics for HGA. 
 47 
 
2 CHAPTER 2 
Materials and Methods 
This study was conducted under ethical approval granted by the Life Sciences Ethics 
Committee, University of Wolverhampton, LSEC/22/0909.   
2.1 Samples 
Tumour biopsy samples were collected with informed consent from patients at Great 
Ormond Street Hospital between 1980 and 2008 (Great Ormond Street REC 
04/Q0508/98).   Additional consented tumour samples were taken from the Brain 
Tumour North West and Walton Research Tissue Banks (REC 09/H0304/8).  Samples 
were obtained from tumour tissue removed during surgery, surplus to diagnosis and 
were anonymised at source. All tumour samples were directly adjacent to tumour 
tissue processed for routine histological evaluation and were first examined 
macroscopically to ensure that no frankly normal tissue was present. Tumours were 
classified according to WHO classification (Louis et al. 2007) following review by two 
neuropathologists. 
Short-term cell cultures were prepared from biopsy tissue immediately after receipt in 
the laboratory as described previously (Lewandowicz et al. 2000).  At the time of this 
study, all tumour biopsy and short-term cell culture samples had been collected and 
stored in liquid nitrogen. Details of all samples used in this study, including clinical 
features, are given in Table 2.1. Normal human foetal astrocytes were obtained from 
Cambrex Bio Sciences.
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Tumour 
number 
Agea Sexb 
Grade at 
diagnosisc 
Location 
Sample 
typed 
Affymetrix  
U133A 
Expression 
array 
analysis 
IN178 13 M GBM IV Left 
temporal 
CC  
IN179 13 M GBM IV Base of skull CC  
IN699 15 M GBM IV Right 
thalamus 
CC  
IN1163 0.2 M GBM IV Right 
parietal 
CC  
IN1262 14 M GBM IV Left parietal CC  
IN1419 8.5 F GBM IV Supratentori
al 
CC  
IN1523 10 F GBM IV Left parietal CC  
IN1566 6.4 F GBM IV Posterior 
fossa 
CC  
IN1930 13 F AA III Temporal CC  
IN3032 9.5 F AA III Left thalamic CC  
IN3046 15.9 M AA III Left frontal CC  
IN3180 9.8 M AA III Supratentori
al 
CC  
IN3182 10.2 M GBM IV Right 
parietal 
CC/B  
IN3183 6.6 M GBM IV Right frontal CC/B  
IN3205 unkno
wn 
M AA III Right 
temporal 
CC/B  
870 18 M GBM IV Left fr ntal B  
885 18 M GBM IV Left 
temporal 
B  
Table 2.1 Clinical and pathological data of the HGA in this study 
a: Age in years at diagnosis; b: M = Male, F = Female; c: AA III =anaplastic astrocytoma, 
GBM IV = glioblastoma multiforme; d: CC = cell culture, B = solid biopsy
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2.2 Cell culture procedures 
All cell culture procedures were carried out in a sterile class II laminar flow cabinet 
(Telstar, UK).  All equipment was cleaned with 70% ethanol before use. 
2.2.1 Maintenance and passaging of cell cultures 
All short-term cultures were maintained in HEPES buffered Hams F10 nutrient mix 
(Life Technologies Ltd, UK) supplemented with 10% selected fetal calf serum (FCS) 
(Invitrogen, UK) at 37 ˚C in a non-CO2 incubator. Cells were fed every two days by 
aspirating media and replacing with the appropriate volume of fresh pre-warmed 
media (25cm2 flasks- 10ml media, 75cm2 flasks- 15ml media, 175cm2 flasks-35ml 
media). When cell cultures reached approximately 90% confluency, they were split by 
a 1:3 ratio with a concurrent increase in the passage number by one.  Following 
aspiration of old media, cells were washed with 4mls pre-warmed Hanks’ buffered 
saline solution (HBSS) (Sigma-Aldrich Company Ltd, UK).  Cultures were incubated 
with 3ml pre-warmed 0.25% Trypsin-EDTA at 37˚C for approximately 5 minutes until 
detachment of cells from the flask surface. The action of trypsin was inhibited by 
flooding the culture vessel with 3.5ml of media and cells were transferred to a 10ml 
universal tube and centrifuged at 1,000 RPM for 5 minutes. Supernatant discarded 
and cells were re-suspended in 10ml media transferred to flasks with the appropriate 
volume of media according to the following split ratio: 
• 1 x 25cm2 flask to 3 x 25cm2 flask  or  1 x 75cm2 flask 
• 1 x 75cm2 flask to 3 x 75cm2 flask or 1 x 175cm2 flask 
• 1 x 175cm2 flask to 3 x 175cm2 flask 
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2.2.2 Reviving cells from storage in liquid nitrogen 
The cell suspension was thawed at 37 ˚C in the cryovial and slowly pipetted in to a 
universal containing 10ml pre-warmed media.  Following centrifugation at 1,000rpm 
for 5 minutes, the supernatant was removed and the cell pellet resuspended in 10ml of 
fresh media before transferring to a 25cm2 flask.   The flask was incubated at 37 ˚ C and 
the media was changed after 24 hours when the cells had attached. 
2.2.3 Mycoplasma detection analysis 
All cell cultures were routinely tested for the presence of prokaryote mycoplasma. 
Mycoplasma contain DNA and hence, in infected  cultures, the mycoplasma on the 
surface of cells or between cells will appear as dotted or filamentous blue fluorescence, 
distinct from the much larger fluorescing cell nuclei. Briefly, cells were grown until 
60% confluency on sterile 13mm coverslips in a 24-well plate for 3 days in 1ml Hams 
F10 media at 37 ˚C. The cells were then washed with PBS and fixed in ice-cold 
methanol at -20 ˚C for 10 minutes. Next, cells were rinsed with PBS and incubated 
with Hoechst dye (250ng/ml) for 30 minutes. The coverslips were rinsed with PBS and 
later with water and mounted in 50% glycerol in PBS onto glass slides. The coverslips 
were viewed immediately under fluorescence microscopy (Zeiss, UK) with a DAPI 
filter. All the cells used in this study were negative for mycoplasma. 
2.2.4 Preparation of cells for storage in liquid nitrogen 
Cells were detached, centrifuged and resuspended as described above and cell number 
was calculated using a haemocytometer. Following centrifugation at 1000rpm for 5 
minutes and removal of the supernatant, the cell pellet was resuspended in FCS 
containing 10% (v/v) dimethyl sulphoxide (DMSO) to act as a cryopreservant, to a final 
concentration of 1x106 cells per ml. One millilitre of the suspension was then 
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transferred to a cryovial and stored at -70˚C for 24 hours prior to long-term storage in 
liquid nitrogen. 
2.2.5 Treatment of cell cultures with 5-Aza-dC 
5-Aza-dC is a potent DNA demethylating agent. It is an aza-nucleoside that is 
incorporated into replicating DNA, replacing cytosine residues and once incorporated, 
it forms a covalent bond with DNA methyltransferase enzymes, inhibiting 
methyltransferase function (Stresemann & Lyko 2008). As 5-Aza-dC is effective only 
during DNA replication, short-term cultures were grown to only 30-50% confluency 
prior to starting 5-Aza-dC treatment. A 5mM stock solution of 5-Aza-dC (Sigma-
Aldrich Ltd, UK) in sterile water was prepared and aliquots stored at -70˚C. Cell 
cultures were treated with the appropriate concentration of 5-Aza-dC for 72 hours with 
fresh media plus 5-Aza-dC being added at 24 hour intervals. 
2.2.6 Analysis of cell viability and proliferation using the MTT 
assay 
In this assay, the reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) to formazan is catalysed by mitochondrial dehydrogenase enzymes 
and is therefore a measure for cell viability (Mosmann 1983). For calculation of 
doubling time, 5x103 cells per well were seeded into 96 well plates and allowed to 
adhere for 24 hours at 37ºC.  Cell viability was assessed on a daily basis by adding 20μl 
of filter sterilised MTT (5 mg/ml in PBS) to a single row of six wells. Following a 5 h 
incubation period with MTT, media was removed and the blue formazan crystals 
trapped in cells dissolved in sterile DMSO (100μl) by incubating at 37ºC for 30 min. 
The absorbance at 550nm was measured with a plate reader (Fluoroskan Ascent FL, 
Thermo Labsystems, UK). The growth curve was constructed by plotting absorbance 
against time. 
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The MTT assay was also used to assess the in vitro cytotoxicity of 5-Aza-dC used in 
this study. In brief, IN699 cells (5x103 cells/well) were seeded into 96 well plates as 
before and allowed to adhere for 24 hours. The medium was replaced with filter 
sterilised complete medium containing the required concentration of 5-Aza-dC and 
cells were incubated for 72 hours with replacement of fresh media containing 5-Aza-
dC every 24 hours. A negative control consisting of cells with medium only was also 
included in these experiments. After 72 hours, the plates were processed with MTT 
and read as described above. 
2.2.7 Colony formation assay 
The colony formation assay was used to determine the effects of 5-Aza-dC treatment 
or expression of CXCL14 on cell proliferation. Serial dilutions of 1/10, 1/50, 1/100 and 
1/200 were made from an initial stock of 1×106 transfected or 5-Aza-dC treated cells 
and seeded into 100-mm tissue-culture dishes in order to determine the optimum 
seeding density. Cells were maintained in Hams F10 nutrient mix with 10% FCS. After 
21 days, colonies were fixed in 75% ethanol and stained with 0.4% crystal violet in 50% 
methanol and counted. 
2.2.8 Long term growth assay 
Short-term cultures were treated with 100nM of 5-Aza-dC for 72 hours in triplicate as 
described above. Following this, 2 x 105 cells were plated in drug-free medium for a 
week and the proliferation rate was checked by calculating the population doubling 
level. 
𝑃𝐷𝐿 =
(𝑙𝑜𝑔 𝑋𝑒 − 𝑙𝑜𝑔 𝑋𝑏)
𝑙𝑜𝑔 2
 
Where Xe is the cell number at the end of the incubation time and Xb is the cell number 
at the beginning of the incubation time. 
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At the end of the week, 2 x 105 cells were re-plated in drug-free media and the analysis 
was repeated. This procedure was carried out for 10 weeks with IN699 cells and for 7 
weeks for IN3182 and IN178 cells. 
2.2.9 Scratch test in vitro migration assay 
Cells were seeded on 10cm plates (4.5x105) and allowed to reach confluency. Using a 
p200 pipette tip, the cell monolayer was scraped in a straight line to create a scratch. 
Cells were washed twice with 1 ml of sterile PBS to remove debris. The area of the 
scratch imaged was marked on the outer bottom of the dish. 
The cells were then incubated at 37 °C for 24 hours with periodic checking. To analyse 
cell migration into the scratched area, pictures were taken at 0 and 24 hours using a 
digital camera system coupled to a microscope (Nikon eclipse TS100, Nikon 
Instruments Europe B.V., UK). The size of the scratch was evaluated using the software 
ImageJ (http://rsbweb.nih.gov/ij). Briefly, the images acquired at 0 and 24 hours 
were converted in 8-bit mode and opened with ImageJ program. The image scale was 
setup to pixel and the size values were set up 0 -1.0 (in a scale between 1X105 and 
5X107). The area measurements were made using “analyse particle” mode of the 
software. The “pre-migration area” is the area free of cells at time zero, while the 
“migration area” is the area free of cells after 24 hours. 
2.2.10 Transwell assay in vitro migration assay 
Cell migration was analysed using a CytoSelect™ Cell Migration Assay containing 
polycarbonate membrane inserts (8μm pore size) in a 24-well plate (Cell Biolabs). The 
membrane serves as a barrier to discriminate migratory cells from non-migratory 
cells. Migratory cells are able to extend protrusions towards chemoattractants (via 
actin cytoskeleton reorganization) and ultimately pass through the pores of the 
polycarbonate membrane. Briefly, 4.5 x 104 cells were seeded on to the membrane 
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insert in serum-free medium and 500μl of medium containing 10% FCS was added to 
the lower well of the migration plate and incubated for 24 hours at 37°C. The non-
migratory cells were removed from the top of the membrane with a cotton swab 
(moistened with sterile distilled water) and the migratory cells on the membrane were 
stained using 0.4% crystal violet and counted under x10 magnification. The 
experiment was performed in triplicate. 
2.3 Nucleic acid isolation and quantification 
2.3.1 Isolation of DNA from cultured cells and biopsy tissues 
DNA was extracted from cultured cells and biopsy tissue using the Qiagen DNeasy 
Blood and Tissue Kit. For cultured cells, the protocol procedure was followed. Briefly, 
1 million cells were resuspended in 200μl phosphate buffered saline (PBS) and 
incubated with 20μl proteinase K and 200μl buffer AL at 56˚C for 10 minutes. For 
biopsy tissue, 180μl of buffer ATL added into a 2ml tube, following the addition of 
10mg tissue. The tissue was homogenized by vigorous mixing and passing several 
times through a hypodermic syringe. The sample was centrifuged to ensure that all the 
tissue was on the bottom of the tube and then 20μl proteinase K was added to the tube 
and incubated at 56˚C for 10 minutes. 
Subsequently, 200μl 100% ethanol was added and samples were vortexed before 
transferring the solution to a DNeasy Mini spin column and centrifuging for 1 minute 
at 11,200rpm. Flow-through was then discarded and a clean 2ml collection tube was 
attached to the spin column. The column was washed with 500μl buffer AW1, then 
samples were centrifuged for 1 minute at 11200rpm, the flow-through was discarded 
again and a new 2ml collection tube was attached to the spin column. Next, 200μl 
buffer AW2 was added to the column and samples were centrifuged for 3 minutes at 
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11200rpm. This last flow-though was discarded and DNA was eluted from the 
membrane by adding 50μl of buffer AE and centrifugation at 11,200rpm for 1 minute. 
The DNA was stored at -20°C until further use. 
2.3.2 Isolation of total RNA 
Total RNA was extracted from 1 million cells using PureLink RNA Mini Kit (Life 
technologies Ltd.UK). Cells were re-suspended in 1ml of Lysis buffer reagent. 
Following the addition of 200μl chloroform, samples were incubated at room 
temperature for 5 minutes and were then shaken for 15-30 seconds and incubated on 
ice for 5 minutes. Afterwards, centrifugation at 12,000rpm for 5 minutes at 4˚C 
separated the homogenate into 3 different phases; a lower blue phenol-chloroform 
phase, an opaque, white interphase and an upper colourless aqueous phase. The 
aqueous phase (containing total RNA) was transferred into a clean RNase free 1.5ml 
microcentrifuge tube. To precipitate the RNA, 1 volume 70% ethanol was added to each 
volume of RNA suspension and vortexed. 700μl of the sample transferred to the spin 
cartridge and centrifuged at 12,000rpm for 15 seconds. Flow-through was removed 
and this step repeated. Afterward, 700μl of wash buffer added to the spin cartridge 
and centrifuged for 12,000rpm for 15 seconds and repeated. The spin cartridge was 
centrifuged at 12,000rpm for 1-2 minutes to dry the membrane with attached RNA.  
The supernatant was removed and samples were allowed to momentarily air-dry 
before re-suspension in 50μl RNase free water. The spin cartridge was centrifuged for 
2 minute at 12,000 x g to elute the RNA. The extracted RNA was then stored at -70°C. 
2.3.3 Assessment of DNA and RNA 
The quality and quantity of DNA and RNA was determined using a NanoDrop ND-
2000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA). Samples with an 
A260/280 ratio of 1.8-2.0 and A260/230 of more than 2.0 were considered good 
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quality DNA. Only RNA samples with an A260/A280 ratio ≥1.8 and an A260/A230 
ratio of ≥2.0 were used. 
2.4 Bisulphite modification of DNA 
Unmethylated cytosines are converted into uracil through treatment with sodium 
bisulphite (BS), while methylated cytosines remain unaltered. This causes a 
conversion of the epigenetic methylation mark into a genetic characteristic that is 
stable through PCR amplification. Bisulphite conversion of DNA samples was 
performed using an EZ DNA Methylation-Gold™ Kit (Zymo Research, Cambridge, 
UK) according to manufacturers’ instructions. Briefly, 130μl of the conversion reagent 
and up to 1μg of DNA in 20μl were incubated for 10min at 98°C and 2.5 hours at 64°C. 
The product and 600μl M-Binding buffer were added to a Zymo-Spin IC Column 
before centrifuging at >10,000g for 30s. The flow-through was discarded and the 
column was washed with 100μl of M-Wash buffer. Subsequently, the DNA was 
desulphonated by 30min incubation with 200μl M-Desulphonation buffer at room 
temperature before washing twice with 200μl M-Wash buffer. The DNA was eluted 
with 20μl M-Elution buffer and stored at -20°C. Positive controls were generated by 
incubating gDNA with DNA methyltransferases in the presence of s-Adenosyl 
methionine (SAM) (New England Biolabs, USA) for 2 hours at 37°C prior to bisulphite 
conversion. 
2.5 Combined Bisulphite Restriction Analysis (CoBRA) 
2.5.1 CoBRA primer design 
CoBRA primers were designed to be within a UCSC (https://genome.ucsc.edu/) 
defined CpG island and situated upstream of, and in some cases, incorporating the 
transcription start site. The primers were positioned in the CpG island within the 
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promoter region.  The publicly accessible MethPrimer software 
(http://www.urogene.org/methprimer/index1.html) was used to design primers. 
2.5.2 CoBRA amplification 
A PCR amplification method was designed specifically for bisulphite-modified DNA, 
which requires minimum optimization.  Touch-Up (TU) gradient PCR produces 
specific products through a defined temperature range throughout the amplification 
process (Rowther et al. 2012). 
In this amplification protocol, the initial cycling is started a few degrees below the 
target annealing temperature and is increased by 0.5°C/cycle for the first 10 cycles. 
The loop of 10 cycles is repeated 4 more times at the end of this initial cycling. The 
initial cycles of the loop provide lenient conditions for amplification, whereas the later 
cycles enable a more stringent amplification. The leniency and stringency are repeated 
at different parts of the gradient loop without compromising the specificity of the 
reaction. This type of cycling has produced specific products the first time for all of the 
genes assessed. A 10-cycle loop, consisting of 95°C for 30 seconds, 48°C for 30 seconds 
(_0.5°C every cycle), and 72°C for 1 minute, was carried out and was repeated five 
times (50 cycles). 
Amplified products were separated using 2% agarose gel electrophoresis containing 
0.25mg/ml ethidium bromide at 180V for 1 hour and using a 100bp ladder. 
Amplification products were visualized under UV light. 
2.5.3 Restriction digestion of CoBRA amplification products 
CoBRA amplification products were digested with either BstUI (CGCG sites) or TaqI 
(TCGA sites) (Thermo Scientific) (Figure2.1). BstUI digests were carried out with 1ᴜ 
BstUI (1μl), 1x 10X buffer R (2μl) and 10μl PCR product (~0.1-0.5μg of DNA) to a final 
volume of 25μl with distilled water and incubated for 6 hours at 37˚C. For TaqI, 
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digestion mixes were incubated at 65˚C for 6 hours with 1ᴜ Taq1 (1μl), 1x 10X buffer R 
(2μl) and 10μl PCR product (~0.1-0.5μg of DNA) to a final volume of 25μl with distilled 
water. Undigested and digested PCR products were separated by gel electrophoresis 
as described above.
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Figure 2.1 CoBRA assay for analysis of single gene methylation status 
This figure shows a representative sequence of DNA in a methylated and unmethylated 
state as it goes through the bisulphite modification, subsequent PCR and digestion 
with a CG containing restriction endonuclease, in this example BstUI. 
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2.6 Gene expression analysis 
2.6.1 cDNA synthesis  
cDNA was synthesised from 1μg total RNA using the QuantiTect cDNA synthesis kit 
(Qiagen) according to manufacturer’s instructions. Genomic DNA was eliminated 
using DNase treatment comprising incubation with 7 x gDNA Wipeout Buffer at 42°C 
for 2 minutes. RNA was reverse transcribed using a master mix prepared from 
Quantiscript Reverse Transcriptase, Quantiscript RT Buffer, and RT Primer Mix and 
template RNA and incubated at 42°C for 30 minutes and 95°C for 3 minutes. 
Quantiscript Reverse Transcriptase has a high affinity for RNA and is optimized for 
efficient and sensitive cDNA synthesis from 10pg to 1μg of RNA. This high RNA 
affinity, in combination with Quantiscript RT Buffer, enables high cDNA yields, even 
from templates with high GC-content or complex secondary structure. RT Primer Mix 
ensures cDNA synthesis from all regions of RNA transcripts, even from 5' regions. This 
allows high yields of cDNA template for real-time quantitative PCR (Q-PCR) analysis 
regardless of where the target region is located on the transcript. 
2.6.2 Reverse transcript polymerase chain reaction (RT-PCR) 
primer design 
Since cDNA is synthesised from the 3’ end, primers were preferentially designed to be 
located towards the 3’ end to guarantee the best quality for amplification of template 
cDNA. The primer sequences were designed to lie on different exons of the transcript 
(mRNA) sequence at the intron-exonic boundary in order to ensure specificity for the 
mRNA transcript, rather than for the genomic (DNA) sequence of each gene. The 
Ensembl Genome Browser program (http://www.ensembl.org/index.html) was 
utilized to access the transcript sequences of these genes. In most cases, primers were 
designed using Primer 3 program (http://frodo.wi.mit.edu/primer3/) with settings 
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chosen to design primers for products between 250-400bp and not mis-match against 
repeats within the human genome. The following guidelines were used to design 
primers; making primers 20-25bp long, not having long strings of complimentary 
bases (i.e. As with Ts or Gs with Cs) to avoid hairpin loops, an overall 50% GC content 
and a 3’ end containing either CC, CG, GG or GC. 
2.6.3 Semi quantitative RT-PCR 
RT-PCR reactions were carried out using 1μl prepared cDNA, 2μl 10X buffer (500mM 
Tris-HCL (pH 8.3), 2mM magnesium chloride, 2.5mM dNTP mix, 0.8μM forward 
primer, 0.8μM reverse primer and 0.5ᴜ FastStart Taq DNA polymerase to a final 
volume of 25μl with distilled water.  PCR cycling conditions consisted of an initial 
activation step at 95˚C for 15 min, then 35 cycles of 94˚C denaturing for 30 seconds, 
primer annealing at 52–56˚C (gene-dependent) for 30 seconds, product extension at 
72˚C for 30 seconds, and a final extension at 72˚C for 10 minutes.  ß-actin or GAPDH 
were used as a reference control using the same amplification conditions. 
Amplification products were separated on 2.0% agarose gels as described above. 
2.6.4 Real-time Q-PCR 
Real-time quantitative Q-PCR allows quantification of PCR products during each PCR 
cycle, yielding an accurate measurement of PCR products accumulated during the 
course of the amplification. These reactions are carried out in a thermocycler that 
permits measurement of a fluorescent detector molecule such as FAM and VIC in a 
TaqMan probe based detection system. Briefly, each assay consists of a pair of 
unlabelled PCR primers and a TaqMan® probe with FAM or VIC at the 5’ end and 
minor groove binder (MGB) non-fluorescent quencher (NFQ) on the 3’ end. When Taq 
DNA polymerase extends from the 3’ end of the primer it degrades the probe that has 
annealed to the template and thus releasing the fluorophore (FAM/VIC). This activity 
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of the Taq DNA polymerase is called 5' to 3' exonuclease activity and resultant 
separation of fluorophore molecule from NFQ results in increase in fluorescence at the 
end of each cycle of amplification. The amount of fluorophore released at the end of 
each cycle is therefore directly proportional to the amount of DNA template present. 
Q-PCR was carried out using an ABI 7500 Real-time PCR System (Applied Biosystems, 
Warrington, UK). Reactions were prepared containing 1X TaqMan gene expression 
assay for each gene (1µL) (Life Technologies, UK), 1X TaqMan gene expression master 
mix (10µL), 7µL of nuclease-free water. The reaction mixture was added to the 
required wells of a 96-well PCR plate (Applied Biosystems) followed by 2µL of the 
template cDNA or nuclease free water or no-RT control. All samples were analysed in 
triplicate. The reaction conditions consisted of 2minutes hold at 50°C followed by 
initial denaturation at 95°C for 10 minutes. This was followed by 40 amplification 
cycles at 95°C for 15 seconds and 55°C for 1min. The target gene levels were normalised 
to an endogenous control and relative quantification was carried out using 2-CT 
methods. For the 2-CT difference in cycle threshold CT for the gene of interest and the 
endogenous control is calculated (the CT) followed by subtraction of the control CT 
from the treated CT which yields the CT. The negative value of this subtraction, -
CT, is used as an exponent of 2 in the equation to determine the fold change in 
expression between control and study samples. A mean of duplicate experiment 
consisting of samples run in triplicate was used to determine the fold change, standard 
deviation and statistical significance. 
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2.7 Western blot analysis 
2.7.1 Protein extraction for western blots 
For Western blot analysis, cells were harvested from confluent 75 cm2 flasks. The 
medium was removed, and cells were rinsed once with PBS and then detached with 
trypsin-EDTA. Cell medium was added to the flask and cells were collected and 
centrifuged at 1500rpm for 5 minutes. The subsequent cell pellet was washed in PBS. 
Cells were centrifuged again at 1500 rpm for 5 minutes. The cell pellet was 
resuspended in 100μl of cold lysis buffer (RIPA buffer) and mixed. The cells lysate then 
were transferred into 1.5 ml centrifuge tube and centrifuged at 15000rpm, 4°C for 15 
minutes. The supernatant were transferred into a new eppendorf tube and keep on ice. 
2.7.2 Protein determination 
The Bio-Rad DC protein assay (Bio-Rad Laboratories, USA) was used to normalise for 
protein concentration. The assay was performed as per the manufacturer’s 
instructions with the samples plated in triplicate on a 96-well plate. Briefly, a point 
standard line was prepared with Bovine serum albumin (BSA) in 5 different 
concentration standards (i.e. 0, 0.25, 0.50, 0.75, 1.0, 1.5 and 3.0 mg/ml). All samples 
were diluted in RIPA buffer as necessary for the sample concentrations to fall within 
the standard curve. 5μl of each sample (in triplicate) were added per well. Bovine 
serum albumin (BSA) standard (Bio-Rad) used to maintain protein viability. 25μl of 
“S+A” reagent mix (30μl reagent “S” + 970μl reagent “A”) and 200μl of reagent “B” 
were then added to each well that contains standards and samples. The plate was 
incubated for 15min in the dark at room temperature to allow the colorimetric 
reaction. The relative absorbance and wavelength of 650nm was obtained using a plate 
reader (Microplate Reader Thermo Multiskan Ascent 96 & 384). The relative 
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concentration of each sample was determined relative to the absorbance of the BSA 
standards. 
2.7.3 Western blotting 
During the western blotting process, gel-separated proteins from cell extracts are 
immobilised onto a solid support. The presence of a specific protein is identified 
through the binding and detection of a specifically raised antibody. Similar to RT-PCR, 
levels of protein expression are measured in different samples by normalisation to an 
endogenous control. 4 µg/µl (2µl) of total protein extract was diluted in 12µl of sample 
buffer and 10µl of water. Samples were boiled for 30 minutes at 96°C to denature the 
protein, followed by centrifugation. The samples, as well as a SeeBlue molecular 
weight marker (Life technologies) were loaded on a polyacrylamide gel containing a 4 
% stacking layer and separated at 200 V for 1 hour in running buffer (100 ml TRIS-
Glycine-SDS and 900ml ultrapure water). 
Separated proteins were transferred to a PVDF membrane by electro-blotting using a 
transfer sandwich (Transfer cassette, foam pad, 2 blotting papers, gel, membrane, 2 
blotting papers) at 100 V for 1 hour.  The membrane was incubated in a 5% blocking 
solution (20ml PBS, 1g Marvel milk, 20μl Tween-20) in a container for 1 hour at room 
temperature on a rocker and then rinsed for 5m with PBS-Tw (0.1%). The membrane 
was incubated with the primary antibody (rabbit polyclonal  Anti-CXCL14 antibody) 
(Abcam) at a dilution of 1:1000 in 1% blocking solution (10ml PBS, 2μl Tween, 0.1g 
Marvel) for 1 hour at room temperature, followed by 3 x 10m washes in PBS-Tw (0.1%). 
The membrane was then incubated with a 1:1000 dilution of the secondary antibody 
(swine anti-rabbit-HRP conjugate) (Sigma) in 1% blocking solution (10ml PBS, 2μl 
Tween, 0.1g Marvel) for 30 minutes and rinsed with 3 x 10m washes in PSB-Tw (0.1%). 
ECLPlus chemiluminescence reagent (GE Healthcare) was used for detection. Two ml 
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of chemiluminescence reagent was added to each membrane and incubated for 5 
minutes at room temperature before exposure to X-ray film for 10 seconds. Films were 
developed by immersion into 100ml of developing solution (Kodak) for 5 minutes and 
then 100ml of fixing solution (Kodak) for a further 3 minutes. Based on the intensity 
of the signal detected, this procedure was repeated with appropriate exposure times. 
2.8 Immunocytochemistry 
Cells were grown 70-80% of confluency in the six well plate followed by removing the 
media. Cells (1.2x106) were incubated with 1ml of 4% Paraformaldehyde (PFA) for 3 
minutes room temperature. Next, 1ml of 0.01% Triton X-100 added and Incubated for 
10 minutes at 4°C. One ml of 10% normal serum (Goat serum) was added and 
incubated for 1 hour at room temperature before adding 1ml of primary Antibody 
(GFAP) and Incubating for 1 hour at room temperature. In the dark, 1ml of secondary 
Antibody (Alexa 488) was added and incubated for 30 minutes at room temperature. 
One ml of H.B (counterstain) added to each well and Incubated for 20 seconds, washed 
in PBS and mounted onto microscope slide with a small amount of vectashield. Each 
well were washed three time with PBS after each step. The samples were analysed with 
confocal microscopy (Zeiss, UK). 
2.9 Transfection of CXCL14 
2.9.1 Description of pCMV6-CXCL14-myc-DDK plasmid 
Full-length C-terminal Myc-DDK-tagged CXCL14 cDNA (GenBank accession number 
NM_004887.3) in a pCMV6 entry plasmid (RC202533) was obtained from Origene. 
The myc-DDK tag is attached to the C-terminal of the protein and the open-reading 
frame is flanked by a polyA signal at the 3’ end. The expression of CXCL14 is driven by 
a CMV promoter. A kanamycin resistance gene is the antibiotic selection marker for 
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Escherichia coli and a G-418 resistance gene provides antibiotic selection in 
mammalian cells. 
2.9.2 Transformation of chemically competent cells 
The pCMV6-ENTRY-CXCL14 and empty plasmid vector (pCMV6-mock) plasmids 
were propagated through E. coli by transforming competent bacteria and growing 
successful transfectants. Bacteria from the surface of the agar stab cultures 
corresponding to pCMV6-ENTRY-CXCL14 and empty plasmid vector (pCMV6-mock) 
were streaked on pre-warmed Luria-Bertani (LB) agar plates containing 25µg/ml of 
kanamycin and incubated at 37°C for overnight. Briefly, 50μl of chemically competent 
Escherichia coli cells (Life Technologies) was thawed on ice and 0. 5μl of the 
mutagenesis reaction (or 50ng of DNA for the empty and WT plasmids) was incubated 
with the competent cells on ice for 30 minutes before being heat-shocked at 42°C for 
30 seconds. The competent cells were placed on ice for 2 minutes and 350μl of pre-
warmed SOC medium (Life Technologies) was added aseptically. The cells were 
incubated at 37°C with shaking at 225 rpm for 1 hour. 100μl aliquots plated on selective 
agar plates (25μg/ml kanamycin) and incubated overnight at 37°C. The following day, 
single individual colonies were picked and inoculated into a tube containing 2 ml of 
LB broth with 25µg/ml of kanamycin to produce sufficient starting material to isolate 
purified plasmid for stable transfection. These starter cultures were grown for 8 hours 
on a shaking incubator at 37°C (approx. 300rpm). 300μl of starter culture was added 
to 250 ml of LB broth with 25µg/ml of kanamycin and grown overnight at 37°C in a 
shaking incubator (approx. 300 rpm). Bacterial cells were harvested by centrifugation 
at 6000 x g for 15 minutes at 4°C. The bacterial pellet was resuspended in 10ml Buffer 
P1 containing RNase A, following the addition of 10 ml of buffer P2 and mixed 
thoroughly and incubated at room temperature for 10 minutes. 
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2.9.3 Maxiprep isolation of plasmid DNA 
To achieve high-quality plasmid DNA for mammalian cell transfection, plasmid DNA 
from pCMV6-ENTRY-CXCL14 and empty plasmid vector (pCMV6-mock) was purified 
from the cell pellets obtained from overnight bacterial cultures using the Maxiprep kit 
(Qiagen) as per the manufacturer’s instructions. Plasmid DNA purity and 
concentration were determined with a NanoDrop-2000 as described above. 
The presence of CXCL14 within the plasmid constructs was confirmed by restriction 
mapping with EchoR1 and Xho1. pCMV6-ENTRY-CXCL14 and empty plasmid vector 
(pCMV6-mock) were digested with EchoR1 and Xho1 restriction enzymes in a reaction 
mix containing 2μl 10X restriction enzyme buffer 4 (Promega), 0.5μl of each 
restriction enzyme Ecor1 and Xho1 (Promega), and 300ng plasmid DNA, made up to 
20μl final volume with water. The reaction was incubated at 37°C for 2 hours before 
digested products were separated through a 1% agarose gel with 1 Kb DNA ladder 
(Norgen Biotek). Uncut samples were run alongside the digested samples for 
comparison. The bands of the expected size were obtained, confirming that no 
recombination had occurred. 
2.9.4 Stable transfection with Lipofectamine 2000 
Lipofection is a method of injecting nucleic acids into cells by means of liposomes, 
vesicles that are composed of a phospholipid bilayer that enables them to easily merge 
with the mammalian cell membrane. It is suitable for carrying out both transient and 
stable transfection procedures. Lipofectamine 2000 (Life technologies) was used to 
introduce plasmid DNA into cells. Cells were seeded at a density of 2xl05 cells per well 
in 6 well plates so that cells would be approximately 50% confluent at the time of 
transfection. Lipofectamine 2000 (10µl for 6 well) (10µl) was diluted in 250µl Opti-
MEM I reduced serum medium (Life technologies). In a separate tube 4ug of plasmid 
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DNA were combined with 250µl of Opti-MEM I reduced serum medium and both sets 
of tubes were incubated at room temperature for 10 minutes before mixing and 
incubation for 20 minutes at room temperature. Cells were washed with FCS-free 
Hams F10 before adding 1.5ml of FCS-free Hams F10, and the Lipofectamine 2000 
and nucleic acid complexes were added drop wise to the wells. After gentle mixing, the 
plates were incubated at 37°C for 48 hours prior to testing for transient transgene 
expression. 
For stable transfection, the transfected cells were transferred from each well of the 6-
well plates into 90mm dishes and incubated in selection drug-containing medium for 
10 days (Geneticin Selective Antibiotic (G418 Sulfate) (250µg/ml)) (Life technologies).  
Colonies were picked using cloning cylinders and the transfected clones transferred 
into T 25 flasks containing 10ml of selection medium to enlarge the cell population. 
2.10 FACS analysis 
2.10.1 Apoptosis analysis by Annexin-V binding 
FACS analysis was performed using Annexin V-FITC and PI allowing discrimination 
of viable and non-viable cells and apoptotic cells from necrotic cells (Vermes et al. 
1995). Annexin-V is a Ca2+ dependent dye that binds to phosphotidylserine upon 
initiation of apoptosis and propidium iodide (PI) is a membrane-impermeant dye that 
stains the non-viable cells by intercalating into ds-DNA (Chou et al. 1987)., Apoptotic 
cells take up the Annexin-V but not PI and necrotic/late apoptotic cells take up both 
Annexin-V and PI. Viable cells do not take up any stain, however non-viable cells take 
up only PI. 
Annexin V-FITC Apoptosis Detection Kit (eBioscience) was used to detect and quantify 
apoptosis in 5-Aza-dC-treated cells compare to control cells according to the 
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manufacturer’s protocol. Briefly, the cells were harvested and the number of the cells 
adjusted to roughly 1 million per sample. Annexin-V conjugate was diluted 1 in 100 in 
Annexin binding buffer and each cell pellet re-suspended in 500μl of Annexin 
conjugate/binding buffer and kept at room temperature for 20 minutes. Finally, 50μl 
of 50μg/ml of PI solution was added to each sample before the cells were diluted with 
0.5ml of HBSS buffer and analysed with a flow cytometer (BD Biosciences, 
Facscalibur). The flow cytometer settings used were an excitation wavelength of 488 
nm and bandpass filter of 530nm for fluorescein (green) detection. For PI, a bandpass 
filter of 600nm was employed. For detection of early apoptosis and late 
apoptosis/necrosis, cells were gated into four populations: Annexin-/PI-, 
Annexin+/PI-, Annexin+/PI+ and Annexin-/PI+. The first quadrant shows the 
healthy population (negative staining for both Annexin-V and PI). Early apoptotic cells 
that are only positive for Annexin-V fall in the second quadrant. The third quadrant 
consists of late apoptotic cells that are both positive for Annexin-V and PI and the 
fourth quadrant shows the cells and debris that are positive staining only for PI. 
2.11 Array analysis 
2.11.1 Affymetrix U133 plus expression array 
Gene expression profiling was performed using the Affymetrix GeneChip® Human 
Genome U133 Plus 2.0 array (Affymetrix). This array comprises 54,675 probe sets 
which analyses the expression level of approximately 47,400 transcripts and variants 
representing approximately 39,000 of the most well-characterized human genes. 
Transcripts were derived and selected from GenBank®, dbEST, and RefSeq and 
sequence clusters were generated from the UniGene database (Build 133, April 20, 
2001). The selection was then refined by analysis and assessment with a number of 
other publicly available databases. Further information is available on the Affymetrix 
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Inc. homepage, www.affymetrix.com. In situ synthesised probes on the GeneChip are 
25 nucleotides long. For each transcript a probe set is created consisting of 11-16 probe 
pairs to permit multiple and independent measurements. A probe pair is made up of 
a perfect match and a mismatch, which contains a single mismatched base. The 
mismatch probe functions as an internal control to quantify levels of non-specific 
hybridisations of perfect match. The intensity of hybridized mismatch is subtracted 
from the intensity of the hybridised perfect match probe to be capable to control and 
correct for the noise in the array results. 
The short-term culture IN699 was used for whole genome expression analysis 
following treatment with the demethylating agent 5-Aza-dC as described above. Total 
RNA from 1 x 106 treated and untreated cells was extracted using the PureLink RNA 
Mini Kit according to the manufacturer’s instructions. All RNA samples were treated 
with DNase I (Thermo Scientific). For microarray analysis, total RNA (5ug) was 
reverse transcribed with the MessageAmp™ II-Biotin Enhanced Single Round aRNA 
Amplification Kit following manufacturer’s instructions (Ambion, Life Technologies 
Ltd. UK) and hybridised to the Human Genome U133 Plus 2.0 oligonucleotide array 
(Affymetrix UK Ltd.). The arrays were washed and stained using the GeneChip Fluidics 
Station 450 and scanned with the GeneChip Scanner 3000 7G (Affymetrix) according 
to standard manufacturer protocols at UCL (Figure 2.2). Experiments were performed 
in duplicate from biological replicates for both treated and untreated cell cultures. 
2.11.1.1 Expression microarray data analysis 
Raw microarray data from Affymetrix CEL files from each cell culture were initially 
normalised using the MAS5 (Affymetrix Microarray Suite, version 5.0) algorithm. 
Analysis of the comparative gene expression of untreated and treated cells can identify 
genes that are up-regulated following de-methylation, suggesting hypermethylation is 
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restricting expression. Affymetrix U133A plus 2.0 array data were analysed according 
to absent/present signals and genes were identified in which the signal was absent in 
both untreated replicates and showed re-expression in both replicates after treatment 
with 5-Aza-dC.
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Figure 2.2 Scheme for the workflow of expression analysis using an 
Affymetrix GeneChip®. 
RNA is extracted from cells, cDNA is produced and in an IVT reaction. cRNA is created 
and biotinylated (target). After fragmentation the template is hybridised to the probes 
on the GeneChip®, the chip is stained and finally scanned using a laser scanner.
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2.11.2 Infinium 450k methylation array 
The 450K DNA Methylation microarray interrogates the methylation status of 
approximately 475,000 CpG sites covering a total of 21,231 UCSC RefeGenes. The 
content of the 450K array was selected with the guidance of a consortium of DNA 
methylation experts and provides comprehensive coverage across the complete gene 
and CpG island regions (Bibikova et al. 2011). Probes were designed covering multiple 
gene sub-regions as defined by Illumina; promoter regions at 200bp and 1500bp 
blocks upstream of the transcription start site (annotated TSS200 and TSS1500, 
respectively) as well as the 5’ and 3’ UTR, first exon and gene body regions are targeted 
by probes. The array represents ninety-six per cent of CpG islands along with CpG 
island shores (regions 0-2kb from CpG islands) and CpG island shelves (regions 2-4kb 
from CpG islands). Shore and shelf regions located upstream and downstream of their 
associated CpG island are annotated “north” (N_Shore and N_shelf) and “south” 
(S_Shore and S_shelf) respectively. Isolated CpGs in the genome were also included 
in the CpG islands, island shores and island shelves defined by Illumina. It has been 
shown previously that some non-coding RNAs and intergenic regions are biologically 
significant or informative (Lim et al. 2007b; Bibikova et al. 2011). Probe were designed 
to target these, in addition to coding RNA transcripts. The 450k methylation 
microarray assay is a bead array assay based on Illumina’s BeadArray Technology.  The 
array platform has nearly 30 beads per target sequence. As the beads are pull together 
randomly, their location and identity is determined by applying a decoding algorithm, 
thus allowing for high density packing on a miniaturised platform (Gunderson et al. 
2004). 
The Infinium beads have long target-specific probes designed for individual CpG sites. 
The Illumina Infinium HumanMethylation450 BeadChip contains 2 chemistry 
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technologies (135,000 probes from Infinium I array and 350,000 probes from 
Infinium II). The Infinium I methylation-specific assay uses two bead types per CpG 
locus, one aimed against the unmethylated site and one against the methylated site. 
The 3’ end of the probe is designed to match either the methylated cytosine or the 
thymine resulting from bisulphite conversion (unmethylated) and incorporates a 
fluorescent label for detection (Figure 2.3.A). The Infinium I assay has been designed 
based on the theory that CpG sites adjacent to the target locus have the same 
methylation status (Bibikova et al. 2011). The Infinium II assay uses one bead type per 
locus for CpG sites located in areas of low CpG density. The underlying CpG sites are 
represented by a degenerate R-base, allowing the methylation status of the target locus 
to be measured individually of assumptions on the status of neighbouring sites. The 3’ 
end of the probe matches the base directly upstream of the target site and a single base 
extension adds either a labelled G or A base depending on the methylation status of 
the cytosine residue in the targeted CpG site (Figure 2.3.B).
 75 
 
 
Figure 2.3 Principles of the Illumina Infinium 450K methylation array 
technology. 
The Illumina Infinium HumanMethylation450 BeadChip contains 2 chemistry 
technologies (135,000 probes from Infinium I array and 350,000 probes from 
Infinium II). (A) Infinium I assay: two bead types match up to each CpG locus on the 
target bisulphite-converted gDNA, one to the methylated state ”C” and the other to the 
unmethylated state (recognised as a C/T polymorphism). Following corresponding 
recognition of the methylated or unmethylated state the probe incorporates a 
fluorescently labelled nucleotide. Probe design accepts the same methylation status 
for adjacent sites. (B) Infinium II assay: one bead type match to each target CpG site 
and the probe can contain up to 3 underlying CpG sites, signified by a degenerate R 
base corresponding to “C” in the CpG site. Methylation state is detected by single base 
extension with labelled “A” base incorporated at an unmethylated site and labelled “G” 
at a methylated site. Infinium II assay allows target loci to be measured independently 
of neighbouring CpG site status and is used in regions of low CpG density. This figure 
has taken from (Bibikova et al. 2011).
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The performance of the 450K methylation array has been validated by whole genome 
bisulphite sequencing (WGBS) and has been found to be highly reproducible for 
technical replicates (average R2=0.99). The array can reliably identify a modification 
in beta value of 0.2 with 99% confidence (Bibikova et al. 2011). There are currently two 
methods for measuring and reporting on the methylation levels determined by the 
Infinium 450K array. The first one is the β-value which is the ratio of the fluorescent 
signal from the methylated allele to the sum of the fluorescent signals of both 
methylated and unmethylated alleles and provides a continuous measure of 
methylation levels ranging from 0 (completely unmethylated) to 1 (completely 
methylated). 
Microarray analysis was performed on the Illumina Infinium HumanMethylation450 
BeadChip at the Cambridge Genomic Services, UK according to the manufacturer’s 
protocols. In this study, the methylome of 20 paediatric HGA samples (comprising 15 
short-term cell cultures and 5 fresh frozen biopsies) and NHA cells were analysed 
using the Illumina Infinium HumanMethylation450k Bead Chip. All the short term 
cultures used for this experiment grown in the Hams F10 nutrient mix supplemented 
with 10% selected fetal calf serum (FCS) to reach the 80-90% confluence following by 
harvesting the cells and extracting DNA. Genomic DNA were bisulphate-modified as 
described above and 500ng aliquots and sent to the Cambridge Genomic Services for 
array hybridisation. Array quality control measures and normalisation processes were 
carried out using GenomeStudio initially by Dr Julien Bauer, Cambridge Genomic 
Services, UK and β value was given to be used in this study.  The Illumina methylation 
data were imported to Partek genomic suite. Illumina normalization is the default 
method used by Partek Genomic Suite and it includes background subtraction and 
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control normalization. Control normalization utilizes Illumina control probes as 
follows: 
𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 =  𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑣𝑎𝑙𝑢𝑒 × 
𝑡𝑎𝑟𝑔𝑒𝑡 𝑚𝑒𝑎𝑛
𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑚𝑒𝑎𝑛
 
Where target mean is the mean of all the arrays and all the channels, while the control 
mean is the mean intensity of the control probes of a channel of an array. 
2.12 Bioinformatics 
2.12.1 Gathering gene information 
General gene structure information was obtained from the UCSC genome browser 
(http://genome.ucsc.edu/) using the most up to date human genome reference (either 
hg18 or hg19 for the work in this thesis). CpG island information was gathered from 
UCSC genome browser (http://genome.ucsc.edu/) and the European Bioinformatics 
Institute (EBI) CpG plot program (http://www.ebi.ac.uk/Tools/emboss/cpgplot/). 
2.12.2 Functional annotation of gene lists 
The freely available Database for Annotation, Visualization and Integrated Discovery 
(DAVID) database was used for analysing large lists of genes to mine for functionally 
related groups of genes and genes within pathways. 
2.12.3 Individual gene information 
The National Centre for Biotechnology Information (NCBI) website 
(http://www.ncbi.nlm.nih.gov/) and GeneCards (http://www.genecards.org/) were 
used to gather information on the functions, published work and general information 
for individual genes. 
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2.12.4 Gene mutation and methylation information 
The PubMeth: Reviewed methylation database in cancer website 
(http://www.pubmeth.org/) was used to partially assess the known levels of 
methylation in selected individual genes and was performed by specific literature 
searches using the NCBI PubMed website (http://www.ncbi.nlm.nih.gov/pubmed/).
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3 Chapter 3 Results 
Identification and Characterisation of 
Epigenetically Silenced Genes in Paediatric 
High-Grade Astrocytoma 
3.1 Introduction 
Extensive studies have been performed to attempt to elucidate the genetic basis of 
paediatric high-grade astrocytoma (HGA) (Gerges et al. 2013) Recently, there has been 
increased interest in understanding the epigenetic mechanisms that contribute to this 
disease. However, little is known about DNA methylation, a key epigenetic mechanism 
that controls the regulation of gene expression in tumours. Understanding the 
underlying epigenetic changes in paediatric HGA could be a fundamental step in 
developing novel therapeutic approaches for these patients. Therefore, this study aims 
to identify frequently methylated genes that contribute to the development of 
paediatric HGA.  
Twenty paediatric HGA tumour samples were utilised to identify tumour-specific gene 
methylation, comprising 5 fresh frozen biopsy samples and 15 short-term cultures 
derived from fresh tumour biopsy material as detailed in Table 2.1. A short-term cell 
culture derived from normal human astrocytes (NHA) was used as a normal control. 
With recent technological advances in array-based platforms, it has become possible 
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to use a lower amount of tumour material and to analyse more samples concurrently 
for a relatively low cost. (Christensen et al. 2011; Noushmehr et al. 2010; O’Riain et al. 
2009). A combined approach of three complementary microarray analysis strategies 
was used, including Illumina-Infinium 450K methylation array to identify DNA 
methylation, Affymetrix U133 expression array to determine levels of gene expression 
and Affymetrix U133 Plus 2.0 expression array to identify genes re-expressed after 
pharmacological unmasking with 5-Aza-dC. The results of these three analyses were 
integrated to identify a panel of candidate genes down-regulated through promoter 
hypermethylation. 
3.2 Global gene re-expression following 
pharmacological unmasking of gene methylation 
Initially, we planned to use a pharmacological unmasking approach through treatment 
with the demethylating agent 5-Aza-dC followed by global expression microarray 
analysis to identify targets of epigenetic silencing mediated by CpG island methylation 
in 3-5 paediatric HGA cell cultures. However, as 5-Aza-dC acts only during S phase, 
cells need to complete at least two divisions within the 72 hours of the 5-Aza-dC 
treatment in order to elicit a 75% reduction in global methylation (Bender et al. 1999). 
Hence, the doubling time of the target cells should be less than 36 hours.  Of the cohort 
of short-term cultures utilized in this study, only IN699 had a suitable proliferation 
rate for the pharmacological unmasking experiment.  The doubling time of IN699 was 
34 hours as illustrated in (Figure 3.1) compared to the remaining cell cultures with a 
range of doubling times from 48 (IN1566) to 96 (IN1523) hours (John Darling, 
personal communication). Consequently, only 1 short-term culture, IN699, was used 
for demethylation and re-expression array analysis. Subsequently, global methylation 
analysis using the Illumina Infinium Human Methylation 450k Bead Chip was 
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performed on a cohort of 20 HGA cultures in order to overcome the limitations of 
using only 1 sample in the re-expression experiment.
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Figure 3.1 Assessment of IN699 cells doubling time using MTT assay 
Doubling time was calculated based on an exponential growth curve fitting of the cells 
growth rate. Each value represents the mean of 3 independent experiments, error bars 
represent standard error.
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3.2.1 Effect of demethylation treatment with 5-Aza-dC on cell 
viability using MTT assay 
The MTT cell viability assay was used to determine a suitable treatment concentration 
of 5-Aza-dC for IN699 cells that was effective at inducing demethylation with minimal 
cytoxicity.  Previous research has demonstrated that low micromolar concentrations 
of 5-Aza-dC effectively demethylate DNA with acceptable toxicity in leukemic, renal 
carcinoma and colon cancer cells (Cheng et al. 2003; Zhou et al. 2002; Covey & 
Zaharko 1984; Davis et al. 1989; Issa et al. 2004; Momparler & Laliberté 1990). In the 
present study, treatment of IN699 cells with 5μM 5-Aza-dC reduced cell viability by 
only 18% after 72 hours (Figure 3.2).
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Figure 3.2 Determination of cell viability using MTT assay 
Result of MTT assay for evaluation of IN699 cell viability following exposure to 5µM, 
5-Aza-dC for 72 hours. The values are expressed relative to the value of untreated cells 
for that day (considered 100% as a reference). Each value represents the mean of 3 
independent experiments, error bars represent standard error.
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3.2.2 Confirmation of gene re-expression following 5-Aza-dC 
treatment 
To confirm that treatment with 5µM 5-Aza-dC for 72 hours effectively demethylated 
gDNA and reconstituted mRNA expression in IN699 cells, 4 genes were screened for 
re-expression as they have been previously reported to be methylated including 
KLHL35 in renal cell carcinoma, DIO1 in malignant thyroid tumours, MCJ in 
malignant paediatric brain tumours (medulloblastomas and ependymomas) and 
LHX9 in paediatric malignant astrocytoma (Arnaldi et al. 2005; Morris et al. 2011; 
Lindsey et al. 2006; Vladimirova et al. 2009). All 4 genes were shown to be methylated 
in IN699 cells by CoBRA analysis (Figure 3.3). As expected, in untreated IN699 cells, 
mRNA for each gene was undetectable due to the promoter being methylated. 
However, 72 hours of 5-Aza-dC treatment (5µM) resulted in re-expression of the 4 
genes detected by RT-PCR (Figure 3.3).
 86 
 
KLHL35 
Expression CoBRA 
-         + U         C 
  
 
DIO1 
Expression CoBRA 
-         + U         C 
  
 
MCJ 
Expression CoBRA 
-         + U         C 
  
 
LHX9 
Expression CoBRA 
-         + U         C 
  
 
Control 
Expression 
(GAPDH) CoBRA (+ve) 
-         + U         C 
  
 
 
Figure 3.3 Expression and CoBRA analysis for selected methylated genes. 
Expression results are shown for 4 methylated genes comprising KLHL35, MCJ, DIO1 and LHX9. For each gene expression results 
are given with (+) and without (-) treatment with 5µM 5-Aza-dC. RT–PCR analysis showed re-expression of silenced genes in IN699 
culture following treatment with 5-Aza-dC. CoBRA results for the selected genes in IN699 cells are also shown alongside with 
undigested (U) products run next to digested products (C). GAPDH served as an internal control and in vitro methyltransferases 
treated gDNA used as a positive control (+ve).
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3.2.3 Global gene expression microarray analysis 
Gene expression profiling was completed for the short-term culture HGA IN699 
following treatment with 5µM 5-Aza-dC for 72 hours. Comparison of gene expression 
between untreated control and 5-Aza-dC treated cells can identify genes that are up-
regulated following de-methylation, indicating hypermethylation is restricting 
expression. Affymetrix U133A plus 2.0 array data from 2 replicates of control and 5-
Aza-dC treated IN699 cells were analysed according to absent/present signals and 
genes were identified in which the signal was absent in both control replicates and 
which showed re-expression in both replicates post treatment with 5-Aza-dC. 
Raw microarray data from Affymetrix CEL files from each replicate culture were first 
imported to GeneSpring GX 7.3.1 in which probeset intensities can be viewed (several 
probes are grouped together to form a probeset which represents 1 transcript). 
Imported data was summarised and normalised using MAS5 and probeset level data 
were generated. MAS5 scales the intensity of each array by default so that they all have 
the same mean and normalises each array independently and sequentially (MAS5 does 
not use multi chip model). MAS5 provides the most faithful cellular network 
reconstruction (Lim et al. 2007a). For Affymetrix data in GeneSpring, the normalised 
data is represented with a log2 transformation for each probe set and the perfect-
match (PM) intensities per probe set were background-corrected, summarised and 
signal intensities for each probe set were normalised using median signal intensity to 
fit a linear model. Hierarchical clustering was performed initially upon the all these 
54,613 probes to cluster the 5-Aza-dC treated IN699 and untreated IN699 cells (each 
sample in duplicate). The correlation values between the samples were calculated and 
two-way clustering was performed using the correlation values to produce two clusters 
separating the replicate samples of untreated and 5-Aza-dC treated cells (Figure 3.4).  
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MAS5 summarises the expression data with ‘flags’ which indicate whether the level of 
each probeset is ‘present’, ‘marginal’ or ‘absent’. The flag was used to analyse the data 
in this study by creating an interpretation containing duplicate untreated samples and 
another containing duplicate treated samples. ‘Filter on flags’ then applied on each of 
these interpretations separately to determine whether the samples should be ‘present’ 
or ‘absent’ in all of the samples within the interpretation to get 2 entity lists – ‘present 
in treated’ and ‘absent in untreated’ and overlapping entities between the 2 lists were 
identified. A total of 3155 probes (2539 genes) were up-regulated following treatment 
with 5-Aza-dC. Hierarchical clustering using these 2539 genes revealed two distinct 
groups, 5-Aza-dC-treated and untreated (Figure 3.5).  The list of 2539 genes from the 
re-expression array analysis was integrated with the list of 3188 genes found to be 
methylated in IN699 using the Illumina Infinium Human Methylation 450k Bead Chip 
as described in the following section and detailed in Table 3.1. There were 147 genes 
commonly identified to be potentially methylated in IN699 cells using the two 
different array strategies, detailed in Appendix.    
The Database for Annotation, Visualization and Integrated Discovery (DAVID) 
algorithm (http://david.abcc.ncifcrf.gov/) was used to assess functional properties of 
genes within the list (Huang et al. 2007).This functional annotation clustering 
algorithm measures the relationships between GO annotation terms and groups them 
into GO annotation groups, facilitating a more focused biological interpretation of the 
data (Huang et al. 2007). Using the DAVID functional algorithm, methylated genes 
were found to be involved in a number of cancer-associated cellular processes 
including: 
G-protein coupled receptor protein signaling pathway (NMU, ELTD1, EDNRB), 
cytokine-cytokine receptor pathway (CD70, BMPR1B, CCL8, CXCL14, IL18, TNFSF10, 
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TNFRSF11B), p53 signaling pathway (CCNG2), Wnt signaling pathway (DAAM2), 
regulation of cell development (NEFL, HOXD3), cell-cell adhesion (PCDH17, 
PCDHB5, PCDHB7), cell adhesion (NTM, ITGA2, COL7A1, PCDH17), cell migration 
(EDNRB, THBS4, POU3F2, POU4F1), regulation of apoptosis (GAL, TNFSF10, SCIN, 
PYGS2, POU4F1), regulation of cell death (CD70, EDNRB, TNFSF10, ID3),  cell cycle 
process (DMC1, CCNG2, FMN2), cell-cell signaling (GPR176, CCL8, CXCL14, IL18, 
CD70, TNFSF10) and G-protein coupled receptors (ELTD1, EDNRB).
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Figure 3.4 Re-expression array analysis of IN699 short term culture 
pre/post 5-Aza-dC. 
Hierarchical clustering was performed initially upon the all 54,613 probes to cluster 
the 5-Aza-dC treated IN699 and untreated IN699 samples (each sample in duplicate). 
The correlation values between the samples were calculated and two-way clustering 
was performed using the correlation values to produce multiple distinct clusters. The 
dendrogram colour saturation is proportional to the magnitude of the difference from 
the mean, ranging from red (under-expressed) to green (over-expressed). 
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Figure 3.5 Re expression array analysis of IN699 short term culture 
pre/post 5-Aza-dC. 
Hierarchical clustering using 3155 up-regulated probes revealed two distinct groups, 
5-Aza-dC-treated IN699 and untreated IN699 samples (each sample in duplicate). The 
correlation values between the samples were calculated and two-way clustering was 
performed using the correlation values to produce multiple distinct clusters. The 
dendrogram colour saturation is proportional to the magnitude of the difference from 
the mean, ranging from red (under-expressed) to green (over-expressed). 
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3.3 Identification of methylated genes in paediatric 
HGA using the Illumina Infinium 
HumanMethylation 450k Bead Chip 
In this study, the methylome of 20 paediatric HGA samples (comprising 15 short-term 
cell cultures and 5 fresh frozen biopsies) and NHA cells were analysed using the 
Illumina Infinium HumanMethylation450k Bead Chip. 
3.3.1 Quality control and array normalization 
Bead summary data was analysed at the Cambridge genomic service.  Prior to 
normalisation the data was log2 transformed to stabilise variance. Boxplots of the 
average probe signal intensity levels and the average number of beads per probe type 
were constructed to assess any obvious differences in sample performance within and 
between BeadChips. Normalisation of high-throughput microarray data is important 
to correct for variation of non-biological origin across a chip and between chips so that 
all samples in an experiment are comparable. The goal of the quantile method is to 
make the distribution of intensities for each array in a set is the same and given that 
genes do not change between arrays and intensity distribution between arrays should 
be the same, this method is deemed appropriate (Bolstad et al. 2003). The Illumina 
methylation data (idat files) were imported to Partek Genomic Suite. Illumina 
normalization is the default method used by Partek Genomic Suite and it includes 
background subtraction and control normalization. Control normalization utilizes 
Illumina control probes as follows: 
𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 =  𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑣𝑎𝑙𝑢𝑒 × 
𝑡𝑎𝑟𝑔𝑒𝑡 𝑚𝑒𝑎𝑛
𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑚𝑒𝑎𝑛
 
Where target mean is the mean of all the arrays and all the channels, while the control 
mean is the mean intensity of the control probes of a channel of an array. 
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The methylation status of over 480,000 cytosines in the human genome was 
determined by the constant variable (β value) ranging between 0 and 1 representing 
the ratio of methylated signal to unmethylated signal, in which 1 indicates complete 
methylation and 0 indicates no methylation (Houseman et al. 2008). Previous 
microarray-based DNA methylation studies have assigned a β-value less than 0.25 
representing unmethylated DNA and a β > 0.75 representing  methylated DNA 
(Ammerpohl et al. 2012; Lu et al. 2014; Hennessey et al. 2011; Martinez et al. 2009; 
Valencia-Morales et al. 2015; Martin-Subero et al. 2009). 
The total number of methylated probes in the 20 tumour samples, including biopsies 
and short-term cultures, and the NHA cell culture was compared and the results are 
presented in Table 3.1. The highest number of methylated probes was present in 
culture IN179 (178046), whereas IN3205-s had the least number of methylated probes 
(93542). There was no difference in the overall number of methylated between cell 
culture and biopsy tumour samples (P=0.169 including NHA and P=0.1947 excluding 
NHA).
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HGA 
sample 
Sourcea 
Overall number of 
methylated probes 
Number of methylated 
probes after removal 
of X-linked and 
unknown genes 
Number of methylated 
probes located in 
promoter regionbc 
IN179 CC 178046 7603 2597 (1742 genes) 
IN3180 CC 162213 9262 2845 (1855 genes) 
IN3183 CC 158769 7974 2409 (1645 genes) 
IN1566 CC 158765 6939 2035 (1362 genes) 
IN3032 CC 157715 7752 2553 (1808 genes) 
IN3182 CC 157335 8094 2452 (1686 genes) 
IN699 CC 156762 13186 6345 (3188 genes ) 
885 B 155868 11574 3756 (2241 genes) 
870 B 155687 11474 3719 (2235 genes) 
IN1419 CC 155433 6513 2014 (1448 genes) 
IN1262 CC 155231 6874 2071 (1446 genes) 
IN1163 CC 154558 7743 2432 (1669 genes) 
IN3046 CC 153974 6221 1908 (1375 genes) 
IN1523 CC 152737 6796 2014 (1383 genes) 
IN3205 CC 145940 6094 1922 (1388 genes) 
IN3183-s B 141359 9344 3193 (2025 genes) 
IN178 CC 138521 6154 1829 (1277 genes ) 
IN3182-s B 136028 8947 3202 (1949 genes) 
IN1930 CC 130247 7701 2412 (1640 genes) 
IN3205-s B 93542 5971 1893 (1318 genes) 
NHA CC 176251 133972 40294 (14651 genes) 
Table 3.1 Number of methylated probes in each HGA sample 
a CC cell culture, B biopsy; b equivalent number of genes is given in brackets; c located within promoter or divergent promoter region 
(5'UTR, first exon, TSS200 and TSS 1500)
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3.3.2 Comparison of methylation in paired biopsy and cell 
culture HGA samples 
One of the challenges facing research in the field of paediatric malignant brain 
tumours is the difficulties in collecting a large cohort of fresh frozen tumour tissue for 
experimental investigations. Tumour cell cultures often remain the sole source of 
available material for research. These samples are useful since they increase the 
availability of tumour RNA and DNA and provide means to investigate cell 
characteristics such as cell surface markers, proliferation rate, cell motility, 
chemoresistance and response to stimuli, including growth factors, extracellular 
matrix components, proteases and adhesion molecules.  However, there are 
reservations regarding how well experimental models such as short-term cell cultures 
and established cell lines represent the tumour in vivo.  Artificial growth conditions 
invariably induce changes when tumour cells are cultured in vitro and the variations 
between biopsy and cultured tumour samples are well documented (Mueller et al. 
2007; Bignotti et al. 2006) Several investigations have revealed fewer differences in 
gene expression levels between primary tumour tissue and derived short-term cell 
cultures than established cell lines (Ismail et al. 2000; Bignotti et al. 2006), suggesting 
that these cultures may better represent the tumour in situ than established cell lines. 
Culture would invariably impact gene expression, however, derived short terms 
cultures at low passage are less prone to acquire additional DNA alternations (Strom 
et al. 2003; Potter et al. 2009; Hickman et al. 2014). 
To establish whether paediatric astrocytoma derived short-term cultures retain a gene 
methylation pattern characteristic of the tumour biopsy and/or whether additional 
methylation is induced by cell culture, the gene methylation profiles generated from 
the Illumina 450k array for 3 paired biopsy and culture HGA samples were compared. 
The degree of similarity between each paired biopsy and derived short-term culture is 
 96 
 
illustrated in scatter plots in Figure 3.6 and the data is summarised in Figure 3.7, 3.8 
and 3.9.  A scatter plot displays the degree of correlation between values of two 
variables for a set of data. The data is shown as a group of points whose coordinates 
consist of the value of the one variable for its position on the horizontal axis and the 
value of the other variable for its position on the vertical axis. If the points’ pattern 
draws from lower left to upper right, it presents a positive correlation between the 
variables. Scatter plots of all β values for a single sample against another demonstrates 
the amount of correlation between the two samples. For all 3 pairs of samples, there 
was a high degree of similarity with methylation being maintained in the cell cultures 
for the majority of probes. For tumour sample IN3182, 136028 probes were 
methylated in the biopsy, of which 109390 (80.4%) were also methylated in the cell 
culture.  Similarly, 111685 of 141359 (79%) probes that were methylated in the IN3183 
biopsy maintained this methylation status in the IN3183 culture. For tumour IN3205, 
70.5% (65913 of 93542) of probes that were methylated in the biopsy sample were also 
methylated in the short-term culture. However, in all 3 cases, there were a greater 
number of methylated probes overall in the cell culture compared to the biopsy.   This 
was particularly striking in the IN3205 cell culture in which 54% of methylated probes 
(80027 of 145940) were unmethylated in the biopsy from which it had been derived.  
IN3182 and IN3183 cell cultures had 30.5% (47945 of 157335) and 29.6% (47084 of 
158769) probes, respectively, which were uniquely methylated compared to their 
paired biopsies. This data indicates that the methylation status of short-term cell 
cultures is representative of the tumours from which they were derived.  However, it 
is apparent that the in vitro environment induces additional methylation events. 
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Figure 3.6 Scatter plots demonstrate degree of similarity of methylation between paired biopsy and short-term 
culture samples of HGA 
Scatter-plot showing the correlation between β-value of paired biopsy and culture; 3183, 3182 and 3205. For all 3 pairs of samples 
comprising 3183 paired biopsy/culture, 3182 paired biopsy/culture and 3205 paired biopsy/culture there was a high degree of 
similarity with methylation being maintained in the cell cultures for the majority of probes. R2=correlation coefficient.
3183 biopsy vs culture (R2=0.88) 3182 biopsy vs culture (R2=0.90) 3205 biopsy vs culture (R2= 0.78) 
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Figure 3.7 Comparison of extent of methylation between paired biopsy 
and short-term cell cultures for HGA IN3183  
Plots showing the comparison between methylation profile of paired biopsy and short 
term culture; IN3183. The majority of methylated probes in biopsy maintained 
methylated in short term culture as well (111685 probes commonly being methylated 
in both Biopsy and short term culture).  –s indicates biopsy and –c indicates short 
term culture.
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Figure 3.8 Comparison of extent of methylation between paired biopsy 
and short-term cell cultures for HGA IN3182 
Plots showing the comparison between methylation profile of paired biopsy and short 
term culture; IN3182. The majority of methylated probes in biopsy maintained 
methylated in short term culture as well (109890 probes commonly being methylated 
in both Biopsy and short term culture). –s indicates biopsy and –c indicates short term 
culture
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Figure 3.9 Comparison of extent of methylation between paired biopsy 
and short-term cell cultures for HGA IN3205  
Plots showing the comparison between methylation profile of paired biopsy and short 
term culture; IN3205. There was 65913 methylated probes in biopsy maintained in 
short term culture. –s indicates biopsy and –c indicates short term culture.
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There were 11631 probes (5518 genes) that were commonly methylated in all cultures 
and not methylated in any of the biopsies. Probes located in unknown genes or outside 
around CpG islands were removed, resulting in 2375 probes (1844 genes).  These genes 
were analysed by DAVID function algorithm and methylated genes were found to be 
involved in a number of pathways: Axon guidance (EPHA2, FYN, PTK2, ABLIM3, 
PAK1, PAK2, PAK4, PAK6, PLXNB1, PLXNB2, RHOD, SEMA3F), Jak-STAT signaling 
pathway (JAK1, JAK2, CSF2, IL12B, IL13RA2, IL15, IL21R, IL6 , IL7R,LEPR, 
LIFR,OSM,STAT5A,SOCS2), Focal adhesion (FYN, PTK2, RAP1A, RAP1B, ACTB, 
COL6A2, DOCK1, EGF, IBSP, MYLK2, PAK1, PAK2, PAK4, PARVG, BCAR1, TNXB, 
VWF), Cell adhesion molecules (CAMs) (CD22, CD4, CD6, ICOS, ITGB2, ICAM1, 
NRXN2, NLGN2, SELPLG), Complement and coagulation cascades (CPB2, F10F12, 
C1QB, C1QC, C3AR1, C7, MASP2),  ECM receptor-interaction (AGRN, COL4A2, 
COL5A1, COL5A2, COL5A3, LAMB4, SDC2, SDC3, TNXB, THBS2, VWF)(Figures 
3.10; 3.11; 3.12; 3.13; 3.14 and 3.15).
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Figure 3.10 This figure illustrates the KEGG pathway, AXON GUIDANCE 
The genes that are commonly methylated among all 3 cultures and not methylated in biopsies in this pathway presented by red star.
 103 
 
 
Figure 3.11 This figure illustrates the KEGG pathway, JAK-STAT signaling pathway 
The genes that are commonly methylated among all 3 cultures and not methylated in biopsies in this pathway presented by red star.
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Figure 3.12 This figure illustrates the KEGG pathway, Focal adhesion 
The genes that are commonly methylated among all 3 cultures and not methylated in biopsies in this pathway presented by red star.
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Figure 3.13 This figure illustrates the KEGG pathway, cell adhesion molecules (CAMs) 
The genes that are commonly methylated among all 3 cultures and not methylated in biopsies in this pathway presented by red star.
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Figure 3.14 This figure illustrates the KEGG pathway, Complement and coagulation cascades 
The genes that are commonly methylated among all 3 cultures and not methylated in biopsies in this pathway presented by red star.
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Figure 3.15 This figure illustrates the KEGG pathway, ECM-receptor 
interaction 
The genes that are commonly methylated among all 3 cultures and not methylated in 
biopsies in this pathway presented by red star
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3.3.3 Identification of tumour-specific methylation in HGA 
In order to control for the effects of the in vitro cell culture environment on 
methylation status, initially the methylation profiles of the 15 HGA short-term cell 
cultures were compared with the NHA control culture to identify genes specifically 
methylated in HGA. Using the criteria of a β-value > 0.75 in ≥10 of 15 short-term 
cultures and a β-value < 0.25 in the NHA culture, 8494 methylated probes 
representing 5508 genes were identified. 
3.3.4 Principal Component Analysis (PCA) 
Principal Component Analysis (PCA) is a commonly used statistical multivariate data 
reduction approach used for simplifying complex data sets with several conditions 
such as microarrays (Raychaudhuri et al. 2001). PCA converts a number of correlated 
variables to a smaller set of uncorrelated variables or principal components in order 
to identify patterns within a data set (Yeung & Ruzzo 2001; Raychaudhuri et al. 2001). 
It transforms the data to a new coordinate system such that the greatest variance by 
any projection of the data comes to lie on the first coordinate (called the first principal 
component), the second greatest variance on the second coordinate, and so on. With 
typical datasets, lower-order components contain the most important essence of the 
data and higher-order components contain the least important essence. 
PCA was performed on the sample cohort using the 8494 filtered methylated probes 
in Partek Genomics Suite. The samples separated into 3 distinct groups based on their 
methylation patterns comprising HGA short-term cultures, HGA biopsies and the 
NHA culture. As can be seen on the axes, the total variance accounted for in the sample 
set was 79.5% (Figure 3.16).
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Figure 3.16 PCA cluster plot of HGA samples using 8494 differentially 
methylated probes. 
In order to identify methylated genes in HGA, 8494 probes representing genes  with a 
β > 0.75 in 10 or more out of 15 short-term cultures and a β-value < 0.25 in the NHA 
culture were identified. Principal component analysis (PCA) was performed on the 
samples and the three components were plotted. Biopsies are highlighted in red, cell 
culture samples are highlighted in yellow and NHA highlighted in blue. 
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Hierarchical clustering, similar to PCA, is a statistical approach for identification of 
similar features within a data set. However, in contrast to the data reduction approach 
used in PCA, hierarchical clustering relies on grouping of the similar features and 
generating a tree with all the data points present (Raychaudhuri et al. 
2001).Hierarchical clustering was performed upon the 8494 hypermethylated probes 
to cluster the 20 tumour samples (15 short-term cultures and 5 biopsies) and the NHA 
culture into groups showing the greatest similarity in methylation profiles. The 
correlation values between the samples were calculated and two-way clustering was 
performed using the correlation values to produce multiple distinct clusters. 
Performing two-way hierarchical clustering, the data are grouped based on their 
similarity. The distance between the two pieces of data is considered as a factor of 
similarity. The data is clustered along the columns of data, then cluster along the rows 
of row-clustered data. Hence, both gene clusters and sample clusters are counted 
(Figure 3.17).
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Figure 3.17 Hierarchical clustering of HGA samples using 8494 differentially methylated probes. 
Hierarchical clustering  groups 8494 probes representing genes with a β > 0.75 in 10 or more out of 15 short-term 
cultures and a β-value < 0.25 in the NHA culture were identified using Partek Genomic Suite.  The above figure 
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represents the two-way clustering of the samples. This clustering was generated by calculating the correlation value 
among the samples based on the methylated filtered genes and performing two-way clustering on those correlation 
values. Colour gradients represent the continuous β-values between 0: completely unmethylated (GREEN) and 1: 
completely methylated (RED). The NHA cell culture sample separated from the highly methylated HGA biopsies and 
short-term cultures. The tumour samples grouped in 5 branches; the first three branches each only with 1 tumour 
sample (IN179 culture, pink, 3205 biopsy, black and IN699 culture, blue). Four remaining biopsies, yellow and 13 short 
term cultures, purple cluster together respectively. –s indicates biopsy. 
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As expected, the NHA cell culture sample separated from the highly methylated HGA 
biopsies and short-term cultures. Further three branches, each with only 1 tumour 
sample consisted of IN179 culture, 3205 biopsy and IN699 culture. The remaining 17 
samples grouped into 2 main clusters. The first clustering consisted of the 4 remaining 
biopsies while the second included the other 13 cultures. The samples with greatest 
similarities in their methylation profiles were the biopsies 870 and 885. In the group 
of short-term cultures, IN1523 and IN1566 had the most similar profiles. 
The removal of entries that did not signify known and annotated genes and X 
chromosome-linked genes resulted in 5190 probes representing 2204 genes. Probes 
that did not map to an official gene symbol or chromosome location according to 
Illumina’s annotation were removed as they were considered uninformative for 
downstream analysis (Shoemaker et al. 2010; Coolen et al. 2007). It was important to 
consider probes that mapped to the sex chromosomes because females who are diploid 
X carry a methylated silenced X chromosome (Wutz & Gribnau 2007), while the single 
X chromosome of males is largely unmethylated. Probes that mapped to the sex 
chromosomes were removed to eliminate the potential for gender-specific differences 
to confound differential analysis. Finally, all probes that were not located within a 
promoter or divergent promoter region (5'UTR, first exon, TSS200 and TSS 1500) 
were eliminated, resulting in 1546 probes representing 1115 genes. 
3.4 Expression microarray analysis of HGA cell 
cultures 
Previously in our laboratory, the, Affymetrix U133A array was used to determine global 
gene expression patterns in different grades of malignancy in paediatric astrocytoma 
cell cultures (Potter et al., unpublished data). Under-expression of genes in HGA 
cultures was determined using similar analysis to that performed to identify up-
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regulated genes in 5-Aza-dC treated IN699 cells. The Affymetrix U133A array data was 
reanalysed for 11 HGA short-term cultures (detailed in Table 2.1) and 2 NHA cultures 
based on their absent/present signal and 1947 genes were identified for which there 
was no expression in at least 5 of 11 HGA cultures and expression in at least 1 of 2 NHA 
cultures.  These criteria were slightly less stringent than those set for the analysis of 
methylation array data (i.e. down-regulation in 5/11 HGA cultures compared to 
methylation in 10/15 HGA cultures) to take account of the smaller number of samples. 
3.5 Integration of methylation and expression gene 
lists 
The list of genes derived from the methylation and expression array analyses of 15 and 
11 HGA short-term cultures (comprising 1115 genes and 1947 genes, respectively) were 
integrated to identify candidate genes that are silenced by methylation. There were 55 
genes that were both methylated and under-expressed in these HGA cultures, 
according to the criteria described previously. These genes and their functions are 
detailed in Table 3.2.
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GENE SYMBOL Gene Function Methylated in Biopsies CpG island 
MICAL2 structural constituent of cytoskeleton actin binding 5 TRUE 
CXCL14 chemokine (C-X-C motif) ligand 14 5 TRUE 
FABP5 transporter activity and fatty acid binding 5 TRUE 
ITGA2 receptor activity and collagen binding 5 TRUE 
PTPRE protein homodimerization activity and transmembrane receptor protein tyrosine phosphatase activity 5 TRUE 
RUNX1T1 sequence-specific DNA binding transcription factor activity, protein binding 5 TRUE 
ATF3 activating transcription factor 3 5 TRUE 
ANGPT1 angiopoietin 1 5 FALSE 
NTM neurotrimin 5 TRUE 
RANBP17 intracellular protein transport 5 TRUE 
MYO5C structural constituent of cytoskeleton, protein binding, enzyme regulator activity 5 TRUE 
PDE4D phosphoric diester hydrolase activity 5 TRUE 
PRR5L Associates with the mTORC2 complex that regulates cellular processes including survival and organization of the cytoskeleton 5 TRUE 
KRT8 structural constituent of cytoskeleton 4 TRUE 
ELTD1 G-protein coupled receptor activity 4 TRUE 
GPR12 G protein-coupled receptor 12 4 TRUE 
CNNM1 cyclin M1 4 TRUE 
CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2 4 TRUE 
IL16 interleukin 16 (lymphocyte chemoattractant factor) 4 FALSE 
LPHN2 G-protein coupled receptor activity 4 TRUE 
MGMT DNA-methyltransferase activity, nucleic acid binding 4 TRUE 
S100A2 calcium ion binding 4 FALSE 
SLC6A1 solute carrier family 6 (neurotransmitter transporter, GABA), member 1 4 TRUE 
XYLT1 transferase activity, transferring glycosyl groups 4 FALSE 
ZFAND6 nucleic acid binding receptor binding 4 FALSE 
CDK16 non-membrane spanning protein tyrosine kinase activity 3 FALSE 
EPB41L3 erythrocyte membrane protein band 4.1-like 3 3 TRUE 
FAM49A family with sequence similarity 49, member A 3 TRUE 
GPRC5A receptor activity 3 TRUE 
NRXN3 neurexin 3 3 TRUE 
OLFML1 receptor activity 3 FALSE 
PKNOX2 DNA-directed RNA polymerase activity 3 TRUE 
S100A12 PBX/knotted 1 homeobox 2 3 TRUE 
TNS1 phosphoprotein phosphatase activity 3 FALSE 
TNXB Extracellular space 3 TRUE 
HLA-DPA1 cellular defense response 2 TRUE 
PRODH2 oxidoreductase activity 2 TRUE 
SCN11A voltage-gated  calcium channel activity 2 TRUE 
SLC16A7 transmembrane transporter activity 2 TRUE 
MYO1A structural constituent of cytoskeleton, protein binding, enzyme regulator activity 1 TRUE 
PLCH2 calcium ion binding, receptor binding, small GTPase regulator activity, guanyl-nucleotide exchange factor activity 1 TRUE 
SBNO2 nucleic acid binding 1 TRUE 
SEMA5A sema domain, seven thrombospondin repeats (type 1 and type 1-like),  1 TRUE 
SIPA1L3 catalytic activity, protein binding, small GTPase regulator activity 1 TRUE 
ZNF423 sequence-specific DNA binding transcription factor activity 1 TRUE 
GHR intracellular protein transport 1 TRUE 
FAR2 fatty acyl CoA reductase 2 1 TRUE 
ATP10A hydrolase activity, cation transmembrane transporter activity 0 TRUE 
EGF ATPase, class V, type 10A 0 TRUE 
EPHB6 epidermal growth factor (beta-urogastrone) 0 TRUE 
PPFIBP2 PTPRF interacting protein, binding protein 2 (liprin beta 2) 0 TRUE 
SOX9 sequence-specific DNA binding transcription factor activity 0 TRUE 
ZBTB25 sequence-specific DNA binding transcription factor activity 0 TRUE 
PION pigeon homolog (Drosophila) 0 TRUE 
ANXA3 Annexin A3 0 TRUE 
Table 3.2 List of 55 genes obtained from methylation and expression array analysis. 
55 genes were identified using integration of the list of genes obtained from methylation and expression array analysis. The table 
above enlists the names of these genes, their corresponding functions, their methylation status in fresh frozen biopsies and presence 
of CpG islands. Only the genes with CpG islands and those that were methylated in 4 or more out of 5 of the biopsies were selected 
for further analysis.
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3.5.1 Methylation status of candidate genes in HGA biopsies 
The methylation status of these 55 candidate genes was verified in the 5 fresh frozen 
HGA biopsies in order to reduce the possibility of false positive artefacts induced by 
the in vitro environment. Twenty five genes were methylated in 4 of 5 biopsies, of 
which 20 had CpG islands within their promoter regions (Table 3.2). These included a 
number of genes already known to be methylated in other cancers including MGMT, 
PDE4D, CXCL14 and KRT8 (Xie et al. 2015; Wu et al. 2013; Huang et al. 2013; 
Tessema et al. 2010; Salhia, Kiefer, Ross, Metapally, Martinez, Kyle N. Johnson, et al. 
2014) suggesting the gene list created was appropriate for further analysis. 
3.5.2 Functional analysis of the 20 identified genes 
Using the DAVID functional algorithm, to the following cancer-associated cellular 
processes were identified including: biological adhesion (ITGA2, NTM), signaling 
(CXCL14, ELTD1, ITGA2, PTPRE, ELTD1), regulation of cell proliferation (ATF3, 
ITGA2), regulation of cell death (MGMT), g-protein coupled receptor (ELTD1, 
GPR12), DNA binding (RUNX1T1, MGMT), immune response (KRT8, PDE4D, 
CXCL14, MICAL2), development (ITGA2), neuron development and differentiation 
(NTM), cytoskeletal protein binding (MYO5C, KRT8), transcription regulation (ATF3, 
RUNX1T1), cellular process including organization (FABP5, ITGA2, PRR5L). Fourteen 
of these genes were selected for further validation based on their functional properties, 
literature searching and their known fundamental role in cancer and methylation 
comprising ATF3, RUNX1T1, MICAL2, PRR5L, PDE4D, PTPRE, KRT8, FABP5, NTM, 
ITGA2, GPR12, ELTD1, CXCL14 and MYO5C (Figure 3.19). 
3.5.3 Expression analysis of 14 selected genes 
The expression levels of 14 candidate genes were examined in HGA short-term cell 
cultures by RT-PCR in order to confirm that methylation resulted in down-regulation. 
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Normal human astrocyte was used as a confirmation of the gene expression. As one of 
the criteria for identifying the 14 candidate genes was underexpression in 5 of 11 
samples from the Affymetrix U133 array analysis, it would be expected that down-
regulation would be observed by RT-PCR analysis in at least 33% of cultures (5 out of 
15). Only 2 genes, RUNX1T1 and GPR12, were down-regulated in fewer cell cultures, 
(14% and 0%, respectively) as shown in Figure 3.18 and Table 3.3, indicating a good 
correlation between these two techniques. However, the other criterion was 
methylation in 10 of 15 samples from the Illumina 450K array analysis and only 4 
genes were non-expressing in more than two thirds of samples.  KRT8 and NTM were 
silenced in 12 of 15 (80%) cultures and PRR5L was silenced in 10 of 15 (67%) cultures. 
The next most commonly silenced genes were ELTD1 and CXCL14, down-regulated in 
8 of 15 (53%) of samples. Although downregulation of MYO5C and PDE4D were 
detected in 14 of 15 (93%) and 10 of 15 (67%) cultures respectively, these genes were 
not expressed in the NHA control and hence were discarded from further analysis. 
ITGA2, which was silenced in 7 of 15 (47%) cultures, was the last selected gene to be 
worked on. Based on the criteria of under expression in 7 or more of the samples and 
expression of NHA, final 6 candidate genes were selected for further analysis including 
KRT, NTM, PRR5L, ELTD1, CXCL14 and ITGA2.
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Gene Name 
Number of HGA culture 
samples with no expression 
Expression in 
NHA culture 
MYO5C 14 N 
KRT8 12 Y 
NTM 12 Y 
PRR5L 10 Y 
PDE4D 10 N 
CXCL14 8 Y 
ELTD1 8 Y 
ITGA2 7 Y 
PTPRE 7 Y 
ATF3 7 Y 
FABP5 6 Y 
MICAL2 6 N 
RUNX1T1 2 Y 
GPR12 0 Y 
Table 3.3 Summary of expression of 14 candidate genes determined by 
RT-PCR
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Figure 3.18-i- Expression analysis of 14 candidate genes using RT-PCR.
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Figure 3.18-ii- Expression analysis of 14 candidate genes using RT-PCR.
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Figure 3.18-iii- Expression analysis of 14 candidate genes using RT-PCR.
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GAPDH 
 
Figure 3.18 Expression analysis of 14 candidate genes using RT-PCR. 
The expression level of 14 candidate genes (ATF3, RUNX1T1, MICAL2, PRR5L, PDE4D, PTPRE, KRT8, FABP5, NTM, ITGA2, GPR12, 
ELTD1, MYO5C, CXCL14) was assessed using RT-PCR to validate the expression array analysis. Normal Human Astrocyte (NHA) 
was used as a confirmation for gene expression. Each of the above pictures represent the expression of one gene in 15 short term 
cultures. GAPDH was used as an internal control. 
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Illumina Infinium HumanMethylation450 BeadChip array 
Probes selected with β-value > 0.75 in 10 of 15 short-
term cultures and a β-value < 0.25 in the NHA culture  
 8494  probes (5508)
Removed all the probes with not known and annotated 
genes, located on X chromosome
  5190  probes (2204 genes)
Removed all the probes that are not situated on or 
around promoter region 
1546 probes (1115 genes)
Integration with Expression Array (Aﬀymetrix U133 
plus 2.0)
 55 genes
 genes methylated in 4 out of 5 biopsies
25 genes
Presence of CpG island
20 genes
Functional properties and literature search
14 genes
Under expression in 7 or more 15 of the samples and 
expression in NHA
6 genes
 
Figure 3.19 Flow-through of array analysis. 
This diagram illustrates the method used to generate a working list of candidate genes 
from the array data. 
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3.5.4 Re-expression of 6 genes following demethylation with 5-
Aza-dC 
To assess whether methylation was responsible for the silencing of these 6 genes in 
HGA, differential gene expression was determined for each following treatment with 
5µM 5-Aza-dC in 3 HGA short-term cultures (IN699, IN178 and IN3182) (Figure 
3.20). Re-expression was observed for 5 genes after 5-Aza-dC treatment in all samples 
in which there was no expression in the untreated cultures (PRR5L in IN699 and 
IN3182; CXCL14 in IN699 and IN178; ITGA2 in IN699, IN178 and IN3182; KRT8 in 
IN699 and IN178; NTM in IN699 and IN3182). Additionally, there was an increase in 
intensity of staining of RT-PCR amplification products for all 3 cultures for ELTD1, as 
well as PRR5L and NTM in IN178 and CXCL14 and KRT8 in IN3182, indicating  up-
regulation of gene expression in all cases. This provided substantial evidence that 
methylation does indeed play an important role in down-regulation of these 6 genes.
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PRR5L ITGA2 
IN699 IN178 IN3182 IN699 IN178 IN3182 
-          + -          + -          + -         + -         + -         + 
      
GAPDH GAPDH 
      
CXCL14 KRT8 
IN699 IN178 IN3182 IN699 IN178 IN3182 
-         + -         + -         + -         + -         + -         + 
      
GAPDH GAPDH 
      
ELTD1 NTM 
IN699 IN178 IN3182 IN699 IN178 IN3182 
-         + -         + -         + -         + -         + -         + 
      
GAPDH GAPDH 
      
Figure 3.20 Expression analysis of 6 candidate genes pre/post 5-Aza-dC using RT-PCR 
RT-PCR was utilized to assess expression level of the 6 final candidate methylated genes, comprising PRR5, CXCL14, ELTD1, ITGA2, 
KRT8 and NTM in 3 short term cultures (IN699, IN178 and IN3182) with (+) and without (-) 5-Aza-dC treatment. GAPDH was used 
as an internal control. 
 126 
 
3.5.5 DNA methylation analysis of 6 genes using CoBRA 
The methylation status of the 6 genes most frequently methylated and down-regulated 
by Illumina 450k array analysis and RT-PCR, respectively, was validated in 13 HGA 
short-term cultures by CoBRA, detailed in Figure 3.21 and Table 3.4. Only CXCL14 
was methylated in more than 50% of cultures (7 of 13 samples) and digested bands 
were present in only 3 of 13 cultures for ELTD1 (23%).   The frequency of methylation 
detected by CoBRA was much lower than had previously been recorded using the 
Illumina 450k array, from which a minimum of 9 of 13 cultures had methylated probes 
(Table 3.4).
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  699 178 179 1163 1419 1930 1523 1566 3032 3046 3180 3182 3183 NUMBER OF 
METHYLATED 
CULTURES 
PRR5L 
array M 
M 
M 
M 
 M M  M M 
M 
 M 
M 
M M M 10 
4 CoBRA  
CXCL14 
array M 
M 
M 
M 
M M 
M 
 
M 
 M 
M 
M M 
M 
 M 
M 
M M 10 
7 CoBRA 
ITGA2 
array M 
M 
M 
M 
 
M 
M M M 
M 
M M M M M M M 12 
4 CoBRA 
NTM 
array M 
M 
 
M 
M 
M 
M M M    M M 
M 
M M 9 
4 CoBRA 
KRT8 
array M 
M 
M M 
M 
M  
M 
 
M 
M M 
M 
M M M M 
M 
M 11 
6 CoBRA 
ELTD1 
array M 
M 
  M M  M M 
M 
M M M M M 
M 
10 
3 CoBRA 
Table 3.4 Summary of methylation of six candidat genes determined by CoBRA 
The methylation frequency of 6 candidate genes according to 450k methylation array and COBRA shown in red and blue 
respectively. 
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ELTD1 
 
 
 
CXCL14 
 
 
 
Figure 3.21-i- Methylation analysis of 6 candidate gens using CoBRA
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PRR5L 
 
 
 
KRT8 
 
 
 
Figure 3.21-ii- Methylation analysis of 6 candidate gens using CoBRA
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ITGA2 
 
 
 
NTM 
 
 
Figure 3.21 Methylation analysis of 6 candidate gens using CoBRA 
CoBRA results are shown for 6 genes, PRR5, CXCL14, ELTD1, ITGA2, KRT8 and NTM 
in a cohort of 13 tumour samples. Un cut products (U) are shown together with Cut 
products (C). in vitro methyltransferases treated gDNA used as a positive control. 
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3.5.6 CoBRA and mapping 
As stated previously, the accepted definition of a CpG island is a region having a GC 
content greater than 50% and an observed CpG to expected CpG ratio of greater than 
60% (Gardiner-Garden et al. 1998). There are estimated to be approximately 27 000 
CpG islands within the human genome (Lander et al. 2001) with approximately 50-
60% of genes having at least one CpG island associated with them, a large number of 
which are important housekeeping genes (Wang et al. 2004; Larsen et al. 1992).  
Typically, it is believed that CpGs in CpG islands are under selective pressure to remain 
unmethylated and hence, active (Bird 2002). Therefore, they are less prone to 
methylation than other CpGs throughout the genome. Although it has now been shown 
that CpG islands can be methylated in normal tissues (Weber et al. 2005), this may 
relate to different types of cell differentiation and activity. Recent investigations have 
revealed regions of DNA known as CpG shores and CpG shelves that are up to 2 kb 
away from CpG islands (Irizarry et al. 2009). These regions are responsible for the 
majority of differential methylation between different tissue types (Irizarry et al. 
2009). Figure 3.22 illustrates examples of the locations of notable CpG regions and the 
CpG shores and CpG shelves within the genome.
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Figure 3.22 Distribution of CpG dinucleotides throughout the genome. 
The figure above represents the relative position of the CpG islands and whether they are methylated in normal or cancerous tissue. 
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Although the expression levels of 14 genes were analysed by RT-PCR, only 6 genes 
were analysed using CoBRA to determine their methylation status in short-term 
cultures. In general, the correlation between CoBRA analysis and Illumina 450k 
methylation array analysis was not satisfactory. This could be because of several 
reasons. It is possible that the methylation array has some degree of intrinsic false 
positive rate. It is important to note that the aim of this study was to identify 
functionally relevant methylation and hence, the focus centred on probes either on or 
around the CpG islands. In order to have a better understanding of selected 14 genes, 
the methylated probes in close proximity to CpG islands, including TSS1500 and 
TSS200, were carefully examined. Methylation arrays include probes that are not only 
on or around the CpG islands. Briefly, the CpG island sequence including the TSS200 
and TSS1500 regions for each of the 14 genes was taken from UCSC genome browser 
(https://genome.ucsc.edu/). From the 450k methylation array data, the sequence for 
each probe in every gene probes was obtained. The location of the methylated probes 
were identified and methylated [CG] was highlighted on the CpG sequence as 
illustrated in Figure 3.23 to Figure 3.36 where the dark green section represents the 
CpG island. All [CG] in the sequence are highlighted in bright green. The underlined 
region is the CpG island and the bold region is the TSS. All the probes from 450k 
methylation array were identified for this gene and allocated on the sequence to 
pinpoint the location exactly. The cg in the red circle is the methylated probe according 
450k methylation array. 
Interestingly, it was found that many of the methylated probes were away from the 
CpG island region (Table 3.5). However, the CoBRA primers were designed upstream 
of and around the transcription start site (CpG island) as seems to be the most likely 
region for hypermethylation that results in gene inactivation, thus having biological 
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relevance. This means that region in which the methylated probes were located may 
not have been covered by CoBRA analysis. This could possibly explain why CoBRA 
analysis did not compare well with methylation array analysis. CoBRA might have 
assessed regions that did not contain any methylated probes. Having said that, this 
study successfully selected the most relevant regions (CpG island) with respect to 
identifying epigenetic gene silencing. Overall, we believe that the stringent criteria 
used for the global approaches in this study have enhanced the possibility of 
identifying true methylated target genes.
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GENE 
TOTAL 
NO. OF 
PROBES 
NO. OF METHYLATED PROBES 
TSS1500 TSS200 
Body 
(Promoter 
associated) 
3’ 
UTR 
5’ 
UTR 
CXCL14 8 3 0 0 0 0 
PRR5L 33 3 0 0 0 0 
ELTD1 10 2 1 0 0 0 
ITGA2 15 3 0 0 0 0 
NTM 27 8 0 0 0 0 
FABP5 16 3 2 1 0 1 
GPR12 18 4 0 0 0 1 
MICAL2 15 0 0 0 0 2 
PTPRE 35 2 0 0 0 0 
RUNX1T1 12 1 0 0 0 0 
ATF3 32 1 0 0 0 0 
KRT8 16 3 0 1 0 0 
PDE4D 13 0 0 0 0 1 
MYO5C 7 2 0 0 0 0 
Table 3.5 Summary of the number of methylated probes according to 
450k methylation array for 14 genes. 
The table shows the total number of probes for each gene.  Number of methylated probes in 
each region (TSS1500, TSS200, Body, 3’ UTR, 5’ UTR) is also presented.
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Figure 3.23 CXCL14 probe mapping 
For CXCL14, out of 8 probes, 3 were identified to be methylated and that in TSS1500 and no probe were identified to be methylated 
around the promoter region
 137 
 
 
Figure 3.24 PRR5L probe mapping 
For PRR5L, out of 33 probes, 3 were identified to be methylated and that in TSS1500 and no probe were identified to be methylated 
around the promoter region.
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Figure 3.25 ELTD1 probe mapping 
For ELTD1, out of 10 probes, 3 were identified to be methylated, 2 probes in TSS1500 and 1 in TSS200.
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Figure 3.26 ITGA2 probe mapping 
For ITGA2, out of 15 probes, 3 were identified to be methylated and that around the TS1500.
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Figure 3.27 NTM probe mapping 
For NTM, out of 27 probes, 8 were identified to be methylated and that around the TS1500.
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Figure 3.28 FABP5 probe mapping 
For FABP5, out of 16 probes, 3 were identified to be methylated and that around the TS1500, 3 around TS200, one in the body and 
one in the 5 UTR.
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Figure 3.29 GPR12 probe mapping 
For GPR12, out of 18 probes, 4 were identified to be methylated and that around the TS1500 and 1 in 5 UTR.
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Figure 3.30 MICAL2 probe mapping 
For MICAL2, out of 15 probes, 2 were identified to be methylated in 5UTR.
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Figure 3.31 PTPRE probe mapping 
For PTPRE, out of 35 probes, 2 were identified to be around TSS1500.
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Figure 3.32 RUNX1T1 probe mapping 
For RUNX1T1, out of 12 probes, one methylated probe were identified around TSS1500.
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Figure 3.33 ATF3 probe mapping 
For ATF3, out of 32 probes, one probe identified to be methylated around TS1500.
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Figure 3.34 KRT8 probe mapping 
For KRT8, out of 16 probes, three probes identified to be methylated around TS1500 and one in body.
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Figure 3.35 PDE4D probe mapping 
For PDE4D, out of 13 probes, one was methylated at 1st exon.
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Figure 3.36 MYO5C probe mapping 
For MYO5C, out of 7 probes, 2 were identified to be methylated and that around the TSS1500. 
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3.6 Functional analysis of CXCL14 in paediatric HGA 
Overexpression of CXCL14 in the IN699 short-term culture was achieved using a 
pCMV6-ENTRY vector containing the CXCL14 open reading frame (ORF) (Origene). 
Cells transfected with empty plasmid vector (pCMV6-mock) were used as controls. 
The pCMV6-ENTRY-CXCL14 and pCMV6-mock vectors were amplified in E. coli by 
transforming competent bacteria and growing successful transfectants. Individual 
transformed bacteria will grow into a single colony in which each individual cell will 
contain identical copies of the transformed plasmid. Cells were plated on agar 
containing 25µg/ml of kanamycin and incubated overnight at 37°C.  Individual 
colonies were picked and grown in liquid culture containing kanamycin (250µg/ml) to 
produce sufficient starting material to isolate purified plasmid for transient and stable 
transfections. 
The presence of CXCL14 inside the plasmid was confirmed by restriction mapping with 
EcoR1 and Xho1 (Figure 3.37).  pCMV6-ENTRY-CXCL14 was digested with EcoR1 and 
Xho1 restriction enzymes to isolate the CXCL14 coding sequence and digests of 
pCMV6-ENTRY-CXCL14 were separated on 2% (w/v) agarose gels (Figure3.37). As 
expected, bands at ~0.3 and  5 were observed. 
To verify CXCL14 overexpression from the pCMV6-ENTRY-CXCL14 under transient 
transfection conditions, IN699 cells were transfected with 4μg of either pCMV6-
ENTRY-CXCL14 or pCMV6-mock. After 48 hours cells were lysed and RNA and total 
cell lysate were extracted. RNA was used to assess CXCL14 overexpression at the 
mRNA level by RT-PCR as described previously in Chapter 2.  An increase in the 
intensity of the CXCL14-specific band from cells transfected with the pCMV6-ENTRY-
CXCL14 compared with the pCMV6-mock cells confirmed the re-expression of 
CXCL14 in IN699 cells (Figure3.38).
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Figure 3.37 Confirmation of the presence of the CXCL14 ORF in the 
pCMV6-ENTRY through restriction mapping. 
A – Digestion of the pCMV6-ENTRY vector containing the CXCL14 ORF with XHO1 
and EcoR1 Products (~5 and 0.3bp) confirmed the presence of CXCL14. B – Schematic 
representation of the digestion of the CXCL14 expression construct with XHO1 and 
EcoR1, sites indicated. Vector map for the pCMV6-CXCL14-myc-DDK plasmid was 
taken from origene website.
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Figure 3.38 Confirmation of CXCL14 mRNA overexpression in transient 
transfected IN699 cells by RT-PCR. 
A- CXCL14 re-expression at the RNA level was confirmed using RT-PCR for pCMV6-
ENTRY-CXCL14 or the pCMV6-mock. GAPDH was used as an internal control. 
Comparison of CXCL14-specific band from cells transfected with the CXCL14 with the 
control cells indicated that CXCL14 is re expressed in 2 different clones (CXCL14-1 and 
CXCL14-2).
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To achieve stable transfection, IN699 cells were plated at 2 x 105 cells/well in a six well 
plate and were transfected 24 hours later with 4μg pCMV6-ENTRY-CXCL14 or 
pCMV6-mock. Cells were selected using G418 at a concentration of 250µg/ml, 
determined to be the lowest effective concentration for cell death. Colonies of 
transfected cells were clearly visible in the presence of G418 (250µg/mL) whereas non-
transfected cells died (Figure 3.39). 
 IN699 cells containing pCMV6-ENTRY-CXCL14 or pCMV6-mock were lysed after 10 
days and RNA was extracted. RT-PCR was used as described previously to determine 
CXCL14 expression.  Similar to the transient transfection, re expression of CXCL14-
specific band from cells transfected with pCMV6-ENTRY-CXCL14 compared to the 
control cells was observed (Figure 3.40).  In addition, quantitative real-time PCR was 
performed to confirm the re expression of transfected CXCL14 in IN699 short term 
culture (Figure 3.41). Quantitative real-time PCR, showed significant expression levels 
of CXCL14 in transfected cells compared to the pCMV6-mock control (P=1.62E-24). 
CXCL14 overexpression at the protein level was assessed using a total cell lysate 
preparation from the stably transfected cells comprising three pools of cells and 4 
individual clones and analysed by Western blot as previously described in Chapter 2. 
The anti-CXCL14 antibody hybridized to the recombinant human CXCL14, which 
migrated to approximately 13.2-Kd position. Pools of stably cloned cells transfected 
with the pCMV6-ENTRY-CXCL14 as well as individual stably cloned showed an 
increase in the levels of CXCL14 protein in comparison to the mock- pCMV6 (Figure 
3.42). The stably transfected IN699 individual clones were used for further functional 
analysis experiments.
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Figure 3.39 Individual colonies after selection with G481. 
Four colonies were picked and growth further for the confirmation of re expression 
analysis. C1, C2, C3, C4 indicate 4 different clones.
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Figure 3.40 Confirmation of CXCL14 mRNA overexpression in stable 
transfected IN699 cells by RT-PCR. 
A- CXCL14 re-expression at the RNA level was confirmed using RT-PCR for pCMV6-
ENTRY-CXCL14 or the pCMV6-mock. 4 clones of transfected CXCL14 were analysed. 
GAPDH was used as an internal control. Comparison of CXCL14-specific band from 
cells transfected with the CXCL14 with the control cells indicated that CXCL14 is re 
expressed.
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Figure 3.41 Confirmation of CXCL14 mRNA overexpression in stable 
transfected IN699 cells by qPCR. 
CXCL14 re-expression at the RNA level was confirmed using qPCR for pCMV6-
ENTRY-CXCL14 or the pCMV6-mock. GAPDH was used as an internal control.  
Results represent data (mean ± SD) from triplicate experiments. qPCR has been 
performed with the help of Dr Farjana Rowther ***P<0.001
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Figure 3.42 Confirmation of CXCL14 protein overexpression in stable 
transfected IN699 cells by Western blot 
CXCL14 overexpression at the protein level was assessed using a total cell lysate 
preparation from the stable transfected IN699 using western blot. 4 clones and 3 pools 
of transfected CXCL14 were analysed.  Anti-CXCL14 antibody labelled recombinant 
human CXCL14, which migrated to an approximately 13.2-Kd position was used. Cells 
transfected with the pCMV6-ENTRY-CXCL14 showed an increase in the levels of 
CXCL14 expression in comparison to the pCMV6-mock. 
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3.6.1 Colony formation assay to assess the effects of CXCL14 
re-expression on tumour cell proliferation 
A colony formation assay was performed to determine the inhibitory effects of re-
expression of CXCL14 on cell growth. IN699 cells were transfected with pCMV6-
ENTRY-CXCL14 or pCMV6- mock and 2 x 105 cells were seeded in 100 mm dishes and 
maintained in Hams F10 supplemented with 10% FCS and 250µg/ml G418.  Media 
was changed every 24 hours. After 21 days, the cells were fixed with 75% ethanol for 
30 min and stained with 0.2% crystal violet for visualization and colony counting. The 
results of the colony formation assays are shown in Figure 3.43. Re-expression of 
CXCL14 in IN699 cells significantly reduced the colony formation efficiency indicating 
a growth inhibitory role of CXCL14 in these cells. Only 30 colonies grew in the  pCMV6-
ENTRY-CXCL14 population of IN699 cells compared to 288 colonies in the pCMV6- 
mock cells, a decrease of more than 90% (p=0.0005).
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Figure 3.43 Effect of CXCL14 re expression on colony formation in IN699 short-term cell culture. 
Illustrative image of cells transfected with pCMV6-ENTRY-CXCL14 or pCMV6-mock following 21 days selection with G418 
(250µg/ml). Cell proliferation was assessed and colonies were counted using ImageJ software. Results represent data (mean ± SD) 
from triplicate experiments (***P < 0.001). 
  
 
*** 
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3.6.2 Assessment of the potential of CXCL14 re-expression to 
reduce the cell migration 
The ability of CXCL14 overexpression to reduce IN699 cell migration was determined 
using a transwell and a scratch assay as described in Chapter 2. 
For the scratch assay, pCMV6-ENTRY-CXCL14 and pCMV6-mock IN699 cells were 
grown to confluency. A scratch was created in the monolayer of cells using a sterile 
500μl pipette tip and the cells were observed for 24 hours. The area of the marked 
scratch was measured at 0 and 24 hours using the software ImageJ and is represented 
in Figure 3.344. The width of scratch reduced from 1500μm to 400μm in pCMV6-
mock IN699 cells at 0 and 24 hours respectively. This was significantly different to the 
pCMV6-ENTRY-CXCL14 IN699 cells, in which the width of the scratch reduced from 
1600μm to 1400μm (p=0.0005).
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Effect of ectopic expression of CXCL14 on migration 
 
  
Figure 3.44 The effect of CXCL14 re expression on migration of IN699 
cells assessed by scratch assay 
The effect of CXCL14 re expression on migration of IN699 cells using scratch assay. 
Migration is reduced in pCMV6-ENTRY-CXCL14 IN699 compared to pCMV6- mock 
IN699 as shown in representative images. Photographs of the cells were taken at 0 and 
24 hours at 10X magnification. The graph is representative of experiment in triplicate. 
The size of the scratch was measured at   0 and 24 hours, using the software ImageJ. 
Cell migration was expressed in length of the scratch (µm). The means ± SEMs for 3 
independent experiments are shown. ***P< 0.001 
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The transwell assay migration uses polycarbonate membrane inserts (8μm pore size) 
in a 24-well plate. The membrane serves as a barrier to discriminate migratory cells 
from non-migratory cells. Migratory cells are able to extend protrusions towards 
chemoattractants (via actin cytoskeleton reorganization) and ultimately pass through 
the pores of the polycarbonate membrane. Finally, the cells are removed from the top 
of the membrane and the migratory cells are stained and quantified. 
For the transwell assay, 5 x106 IN699 pCMV6-ENTRY-CXCL14 or pCMV6-mock cells 
were trypsinised and re-suspended in serum-free growth media. Media containing 
10% FCS (chemoattractant) was added to the lower well of the migration plate and the 
cell suspension solution to the inside of each insert. The non-migratory cells were 
removed and migratory cell were measured at 560nm in a plate reader. The 
experiment was performed in triplicate and a total of 9 counts were made (3 counts for 
each chamber) which were then averaged in order to give an estimation of the number 
of migrating cells. The number of migratory cells for pCMV6-mock was significantly 
higher compared to the number of migratory cells in pCMV6-ENTRY-CXCL14 
(P=0.0079) (Figure 3.45).
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Figure 3.45 The effect of CXCL14 re expression on migration of IN699 
cells assessed by transwell assay 
For the transwell assay, 5x106 IN699 pCMV6-ENTRY-CXCL14 or pCMV6-mock cells 
were trypsinised and re-suspended in serum-free growth media and added to the top 
of a Boyden chamber. The Boyden chambers were placed in 24 well plates containing 
complete grow media. After 24 hours, migrating cells were stained and counted under 
a microscope. (A) Representative fields showing reduced migration caused by CXCL14 
re expression. (B) The graph is representative of an experiment performed three times 
in triplicate (n=9; error bars ±SEM). Migration assay has been performed with the 
help of Dr Farjana Rowther **P<0.01 
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3.7 Effect of CXCL14 re-expression on other genes 
Chemokines regulate cell proliferation, apoptosis, angiogenesis, metastasis and 
tumour immunity, pathways that are critical in carcinogenesis (Hromas et al. 1999; 
Strieter et al. 2004; Darash-Yahana et al. 2009; Mu et al. 2009). Previously, a genome-
wide transcriptome array identified the CXCL5, CXCL12 and CXCL14 chemokines as 
common targets for silencing by promoter methylation in adenocarcinomas (Leng et 
al. 2012). The silencing of all these three genes were due to DNA hypermethylation 
which was reversible by pharmacological unmasking through treatment with 5-Aza-
dC. CXCL14 was shown to be a tumour suppressor gene because of its effect on tumour 
necrosis, cell cycle, apoptosis and growth of tumour xenografts  (Tessema et al. 2010; 
Cirincione et al. 2006; Hsu et al. 2007). Furthermore, re-expression of CXCL14 
affected the expression of more than thousand genes intensely (Tessema et al. 2010). 
Moreover, re-expression of CXCL14 has a profound effect on the genome altering the 
expression of more than 1000 genes (Tessema et al. 2010). Consistent with other in 
vitro and in vivo studies, SA Belinsky group showed that stable expression of CXCL14 
in H23 cells affected the expression of 30 genes that directly or indirectly inhibit cell-
cycle progression or promote apoptosis. The differential expression of 5 out of 30 
genes with the highest fold-change in expression after stable expression of CXCL14 in 
H23 cells was selected to be assessed in pCMV6-ENTRY-CXCL14 IN699 cells in this 
study, including: 
 CEBPD (8.14 fold change) Has an important role in IL-6-/STAT3-mediated 
growth arrest 
 RBP1 (4.30 fold change) Inhibits cell proliferation and induces expression of a 
senescence marker 
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 CASP4 7.68 Caspase 4 is an effector of apoptosis 
 RHOBTB2 8.08 Required for CXCL14 expression and is a direct target of E2F1 
with a short-term increase in cell cycle but in the long term induces apoptosis 
 TXNIP 20.02 Induces G1 cell-cycle arrest via ASK1 activation, ER stress, p38 
and JNK phosphorylation and stabilization of p27(kip1) 
Q- PCR was used to assess the expression level of these genes after stable expression 
of CXCL14 in IN699 short term cultures.  There was no significant change in 
expression levels of CASP4 (P= 0.056), CEPBD (p= 0.0546) and RHOBTB2 (P= 
0.0915) in pCMV6-ENTRY-CXCL14 IN699 cells compared to pCMV6-mock In699 
cells. However, there was a 6-fold increase in RBP1 and a 1.5-fold increase in TNX1 
expression that shows a significant increase of expression in RBP1 (P= 0.0003) and 
TNX1 (P= 0.00075).
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Figure 3.46 Effect of CXCL14 re expression on other genes assessed by 
qPCR. 
The effect of CXCL14 re expression assessed on 5 genes after stable expression of 
CXCL14 in IN699 short term cultures. The means ± SEMs for 3 independent 
experiments are shown. Migration assay has been performed with the help of Dr 
Farjana Rowther ***P< 0.001.
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3.8 Discussion 
The most frequent form of solid cancer and the leading cause of cancer-related deaths 
in children younger than 15 years of age are brain tumours (Astrocytoma 2004). In the 
paediatric population, about 400 new cases of primary CNS tumours are diagnosed 
per annum in the UK and the majority of these are astrocytoma 
(http://info.cancerresearchuk.org/cancerstats/types/brain/incidence/). 
Approximately one-fifth will be malignant astrocytoma (WHO grade III or IV) and less 
than 20% of these patients survive 2 years from diagnosis (Steliarova-Foucher et al. 
2005). It is highly probable that the biological and hence, clinical behaviour of 
paediatric astrocytoma is determined not only by changes at the DNA level but by both 
qualitative and quantitative differences in the levels of expression of a range of genes.  
Epigenetic aberrations have been shown to play an important role in the pathogenesis 
of the majority of cancers and one of the most widespread and powerful mechanisms 
is gene silencing through DNA methylation (Gentil & Maury 2007). Our current 
limitations in predicting the clinical outcome of paediatric astrocytoma based on 
traditional histological and clinical information accentuates the distinct management 
challenge presented by these tumours. An improved understanding of astrocytoma 
biology in children will help to redress this issue. 
In order to ascertain whether DNA methylation has a primary role in regulating 
differential gene expression, it is first necessary to identify candidate loci. Previous 
studies to identify candidate genes have used either a single functional assay (Jackson-
Grusby et al. 2001; Fouse et al. 2008) or differential methylation analysis (Suzuki et 
al. 2007; Weber et al. 2007). These methods on their own have the drawback of 
generating many indirect hits and false-positives or targets where it is not clear 
whether differential methylation is a consequence or a cause of transcriptional activity, 
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respectively. Furthermore, often these analyses are not validated by downstream 
functional experiments. 
The majority of methylation analyses in brain tumours have used bisulphite 
sequencing and/or methylation-specific PCR (MSP) to investigate methylation 
patterns in small subsets of genes.  However, the alternative methodology of 
pharmacological unmasking of methylated genes followed by global gene expression 
analysis and using oligonucleotide microarrays enables high throughput screening of 
the whole genome (Yang et al. 2004; Tokumaru, Yamashita, Osada, Nomoto, D.-I. 
Sun, et al. 2004). Thus, this work has used a combined approach of three 
complementary microarray strategies and functional approaches to identify candidate 
genes. 
 Affymetrix U133 plus 2.0 was used to identify differential gene expression 
following treatment with 5-Aza-dC in 1 short-term culture (IN699).  
 Affymetrix U133 was used for identifying differentially expressed genes in 11 
paediatric HGA tumour cultures compare to 2 normal human astrocyte 
cultures.  
 Illumina-Infinium 450K methylation array for DNA methylation analysed 20 
paediatric HGA tumour samples (comprising 15 short term cultures and 5 fresh 
frozen biopsies) to identify frequently differentially methylated genes compare 
to normal human astrocyte cells. 
Additionally, a highly stringent short-listing criteria for genuine targets at each 
experimental stage was utilised. This stringent multi-tiered approach has led to the 
identification of 6 candidate genes, the expression of which was upregulated when 
DNA methylation was removed pharmacologically. 
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3.8.1 Pharmacological unmasking of epigenetically silenced 
genes using 5-Aza-dC in IN699 short term culture 
The expression array data was generated from the total mRNA extracted from short-
term cultures of IN699 either treated or untreated with the demethylating drug 5-Aza-
dC. Analysis of the comparative gene expression with and without treatment can 
identify sets of genes that are up-regulated following de-methylation for each sample, 
suggesting gene methylation in the untreated sample is restricting expression. These 
arrays have the advantage of potentially identifying methylation that is more likely to 
be biologically relevant, as the result of de-methylation is gene re-expression in 
comparison to the Illumina 450K array where methylation of a particular probe may 
not necessarily influence expression of that gene, as discussed later.  However, it is 
also important to note that the up-regulated genes do not necessarily have to be 
themselves methylated. Methylation of upstream control genes, such as transcription 
factors, can also be removed and thus result in the up-regulation of their targets. This 
leads to a high degree of false positive gene selection and investigation of these genes 
often demonstrates no tumour specific DNA methylation within the cell lines (Morris 
2010; Dr C.J. Ricketts, personal communication). Nevertheless, 5-Aza-dC, in 
combination with microarray analysis has been successful in the identification of 
epigenetically silenced genes in many different tumours types including prostate, lung, 
melanoma, adult glioblastoma and renal cell carcinoma (Ostrow et al. 2009; Morris et 
al. 2011; Lodygin et al. 2005). 
The initial plan for this study was to use a pharmacological unmasking approach 
through treatment with the demethylating agent 5-Aza-dC followed by global 
expression microarray analysis to identify targets of epigenetic silencing mediated by 
CpG island methylation in 3-5 paediatric HGA cell cultures. However, due to the 
logistics of 5-Aza-dC treatment, only 1 one short-term culture was suitable for 
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pharmacological unmasking. In order to be able to perform an effective 5-Aza-dC 
treatment, a doubling time of less than 36 hours is needed (Bender et al. 1999). Cells 
would enter one or two S phases during 72 hours treatment with 5-Aza-dC in order to 
produce a 75% reduction in global methylation because the drug has no instant 
influence on the cells’ division. (Bender et al. 1999).   Using this approach, 2539 
potentially epigenetically silenced genes were identified in IN699.  
If additional suitable HGA cultures had been available for this study, it would have 
been possible to identify the commonly up-regulated genes in all cultures. This would 
have resulted in a reduced gene list that would be manageable for further confirmatory 
and validation work in a larger sample cohort.  
Subsequently, to overcome the limitations of working with only 1 sample, methylation 
array analysis was performed on a cohort of 20 tumour samples using the Illumina 
450K BeadChip. The list of 2539 re-expressed genes identified in IN699 was later 
combined with the list of methylated genes in IN699 from the 450k methylation array, 
resulting in 147 genes that are both methylated at their DNA level and re expressed 
following pharmacological unmasking. Using the DAVID functional algorithm, several 
cellular processes were identified in which these 147 genes are associated including 
cytokine-cytokine receptor pathway (CD70, BMPR1B, CCL8, CXCL14, IL18, TNFSF10, 
TNFRSF11B), P53 signaling pathway (CCNG2), Wnt signaling pathway (DAAM2) and 
G-protein coupled receptor protein signaling pathway (NMU, ELTD1, EDNRB),  
It was interesting to be able to compare results generated by these 2 different array 
platforms and experimental approaches in one short term cell culture (IN699). A small 
number of 147 genes (about 5%) was identified by comparing a list of up-regulated 
genes after treatment with 5-Aza-dC (2539 genes) and a list of methylated genes from 
450K methylation array analysis (3188 genes). There could be several reasons 
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responsible for this, including cell culture condition and different passage number 
used for each experiment, among others.  
Furthermore, it is likely to be due to high false positive rate in both techniques, 
combined expression array with pharmacological unmasking through treatment with 
5-Aza-dC can also de-methylate the upstream regulators and 450K methylation array 
has lots of probes outside promoter regions. Global demethylation can also result in 
inappropriate upregulation of some genes. Many genes can be indirectly upregulated 
by global demethylation. For instance, expression of a particular gene can be altered 
due to methylation of an upstream regulator of this particular gene. Therefore, up-
regulation of a particular gene may be a consequence of restored gene expression of its 
methylated upstream regulator by the demethylating treatment. 
3.8.2 Illumina Infinium HumanMethylation 450k 
BeadChip to identified methylated genes in paediatric 
HGA 
The improvements in array-based technologies have enabled the assessment of the 
molecular effects in large populations. With the introduction of the Illumina 450K 
Bead Array, analyses of the DNA methylation pattern across the genome with a high 
coverage of promoters, 5’UTRs, 1st Exons, gene bodies and 3’UTRs is possible. The 
ability to use a smaller amount of starting material and cost reductions has enabled 
many large scale methylation profiling studies to be conducted (Martinez et al. 2009; 
Christensen et al. 2011; Noushmehr et al. 2010; O’Riain et al. 2009). Some genes have 
been shown to be hypermethylated in multiple cancers e.g. p16INK4a, p14ARF and RB 
in tumours of the colon, prostate, pancreas and lung and gliomas  (Robertson et al. 
2000).  Other methylation events are specific for tumour types including hMLH1 in 
colon carcinoma, HAI-2/PB in hepatocellular carcinoma and Hsp47 in neuroblastoma 
(Tokumaru, Yamashita, Osada, Nomoto, D. Il Sun, et al. 2004; Yang et al. 2004). In 
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adult glioma, there is increasing evidence that epigenetic silencing of tumour genes 
through hypermethylation is a common event.  Hypermethylation has been observed 
in a number of genes including ABL, ER, HIC-1, MGMT p16INK4a, p14ARF, p73, PTEN, 
THBS1 and TIMP3 (Yu et al. 2004; Tokumaru, Yamashita, Osada, Nomoto, D.-I. Sun, 
et al. 2004). However, methylation studies in paediatric astrocytoma have not been 
widely reported (Gerges et al. 2013; Potter et al. 2008; Zhao et al. 2014). Identifying 
cancer-specific DNA hypermethylation events is not only extremely useful in 
understanding the mechanisms of tumour development, but also in identifying 
potential prognostic markers and therapeutic targets.  
In this study, 20 paediatric HGA samples were analysed using the 450k methylation 
array. Using this approach, the methylation status was examined directly, rather than 
as a consequence of 5-Aza-dC demethylation. A final list of frequently methylated 
genes in the sample cohort was integrated with the re-analysed gene list from the U133 
expression arrays. The methylation status was examined at the DNA level in 15 short-
term cultures, whereas the expression level was examined at the RNA level in 11 cell 
cultures. The genetic heterogeneity of HGA in both adults and children has been well-
established.  Hence, it was not expected that genes would be epigenetically silenced in 
100% of samples in this study. A cut-off of genes being methylated in 10 of 15 short-
term cultures and which there was no expression in at least 5 of 11 HGA cultures was 
used. This screening was important to identify and focus on the genes that were 
silenced by DNA methylation and investigate the contribution of DNA methylation in 
down regulation, thereby identifying genes with functional relevance. A list of 1546 
probes representing 1115 genes considered to be frequently hypermethylated in 
tumour samples produced from 450K methylation array along with 1947 genes from 
Affymetrix U133A array, resulted in 55 common genes. This list comprised genes 
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already known to be methylated in other cancers such as MGMT, SOX9, CXCL14 and 
KRT8 (Xie et al. 2015; Wu et al. 2013; Huang et al. 2013; Tessema et al. 2010; Salhia, 
Kiefer, Ross, Metapally, Martinez, Kyle N Johnson, et al. 2014)  proposing the gene list 
created was appropriate for further analysis. In addition, genes within the list were 
associated with functions or pathways involved in tumourigenicity demonstrating the 
list had produced a relevant set of methylated genes in HGA. 
3.8.3 Validation of candidate silenced genes 
It was important to ensure that the identification of the methylated genes was not an 
artefact of the in vitro environment. Therefore, 5 fresh frozen biopsies were used to 
screen the previously identified 55 genes on the basis that they were methylated in 4 
out of the 5 samples. Fourteen genes were identified and validated using RT-PCR. 
Finally, selection of the genes that were under expressed in more than 7 samples 
resulted in a final list of 6 genes. The expression array results were compared with 
those from RT-PCR for these 6 genes, where a good correlation. In addition, the 
methylation array was validated using CoBRA for the final 6 genes, the results for 
which were not satisfactory. The methylated probes around CpG island comprising 
TSS200, TSS1500 were assessed for the 14 candidate gens. Since the goal of this study 
was to identify functionally relevant genes, it was important to find the methylated 
probes on or around the close proximately of CpG islands. Methylation array analysis 
includes probes that are not only on or around the CpG islands and many of the 
methylated probes were away from the CpG island regions. Though, the CoBRA 
primers were designed upstream of and around the transcription start site (CpG 
island) as this seems to be the most likely region for hypermethylation that could result 
in gene inactivation. This could possibly explain why CoBRA analysis did not compare 
well with methylation array analysis as CoBRA did not cover regions where many 
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methylated probes were located. Having said that, this study successfully selected the 
most relevant regions (CpG island) with respect to identifying epigenetic gene 
silencing. Overall, the stringent criteria used for the global approaches in this study 
have enhanced the possibility of identifying genuine methylated target genes. It was 
found that most of the methylated probes were positioned in TSS1500, which makes 
this an interesting area for further investigation. Although this is beyond the scope of 
the present study, it is certainly worth pursuing to investigate any link between the 
methylation in TSS1500 and pathogenesis of HGA. This work could be important in 
the light of a recent study that identified regions of DNA that show differential 
methylation levels between different tissue types that are up to 2kb away from CpG 
islands, known as CpG shores (Irizarry et al. 2009). These regions have a median size 
of 255bp and have been suggested to be responsible for the majority of tissue 
differential methylation, rather than CpG islands (Irizarry et al. 2009).  
Traditionally DNA methylation analysis has solely focused on CpG islands, particularly 
within gene promoters, since it is here that gene regulation is primarily regulated. 
Irizarry et al (2009) showed the majority of altered DNA methylation sites in colon 
cancer to reside outside of CpG islands in regions up to 2kb distant in regions called 
CpG island shores. Moreover, these sites were shown to associate to gene expression. 
New evidence suggests that methylation of CpG island shores and shelf regions of low 
CpG density located outside the vicinity of traditional CpG islands are fundamental to 
gene silencing. For instance, Doi et al.2009 (Doi et al. 2009) have demonstrated a 
number of overlapping differentially methylated loci involved in normal tissue 
programming, epigenetic reprogramming to pluripotency and aberrant programming 
of cancer cells. Interestingly, these loci were predominantly contained within CpG 
island shores. These findings suggest that epigenetic changes encountered in cancer 
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are likely due to the reprogramming of the normal pattern of tissue specific 
differentiation and highlight the importance of CpG island shores/shelves in 
regulating transcription of specific loci. In the present study, the 6 most frequently 
silenced genes (CXCL14, PRR5L, ELTD1, ITGA2, KRT8 and NTM) also were re-
expression by treatment with 5-AzadC in 3 short-term cultures where the gene was 
methylated. Given that have enough time and money it was best to use  techniques 
such as MSP or sequencing based techniques such as pyrosequencing or bisulphite 
sequencing to narrow down the methylation status to a specific region in the gene 
sequence and validate methylation array outcomes. Using bisulphite sequencing 
method, up to several thousand clonally amplified single sequence reads per sample 
can be obtained, thus enabling a highly quantitative methylation analysis, which 
makes it possible to detect even small differences in methylation levels. 
3.8.4 Choice of control sample 
NHA was used as the control sample to minimize the false positive artefacts arising 
from the culture environment. However, the limitation posed due to working with one 
normal sample is recognized. Selecting appropriate normal samples for microarray 
experiments investigating gene expression and/or methylation in brain tumours is 
problematic for a number of reasons. Normal tissue from adjacent normal brain region 
of a tumour is not available from most patients, as the surgeon will try to preserve as 
much normal function as possible during resection. Although post-mortem normal 
brain samples from other individuals could be used, this introduces variation between 
tumour samples and normal controls due to variations in the human population and 
tumour locations (Oleksiak et al. 2002; Morley et al. 2004). It is also important to 
recognise that normal tissue has a different cellular content, morphology and function 
compared to tumour tissue in the same environment. Although tumour tissue is 
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heterogeneous, normal tissue is a balanced mixture of cell types, each contributing to 
normal tissue function. As we assume that astrocytoma has derived from astrocyte 
origin, using NHA at least gives some commonalty. 
3.8.5 Comparison of methylation in paired biopsy and cell 
culture HGA samples 
The understanding of HGA growth and development is challenging due to the 
heterogeneity of these tumours and reservations surrounding derived short-term cell 
cultures and established cell lines.  Artificial growth conditions invariably induce 
changes when tumour cells are cultured. There have been questions regarding how 
well the established cell lines or derived short-term cell cultures represent the tumour 
in situ. Apart from in vivo animal models, the only available materials for the study of 
tumours are surgical tissue, derived short-term cell cultures and established cell lines. 
Of course, gathering a large cohort of fresh tumour tissue is challenging. Therefore, 
the only source of accessible material for investigations and research remains as 
cultured tumour samples. These samples are useful since they increase the availability 
of tumour RNA and DNA and provide means to explore cell characteristics such as cell 
surface markers, proliferation rate, cell motility, chemoresistance and response to 
stimuli, containing growth factors, extracellular matrix components, proteases and 
adhesion molecules. The variations between biopsy and cultured tumour samples are 
well documented (Fabbri et al. 2007). It has been reported that some cell lines show 
more similar gene expression profiles to the tumour in situ than others. Several 
investigations have revealed less differences between primary tumour tissue and 
derived short term cell cultures (Ismail et al. 2000; Bignotti et al. 2006). This suggests 
that these cultures may represent the tumour in situ better than established cell lines. 
Therefore, it is apparent that utilising derived short-term cultures in the study of any 
tumour, rather than established cell lines, may alleviate differences between the 
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tumour of origin and the cultured cells. Culture would invariably impact gene 
expression, however, derived short terms cultures at low passage are less prone to 
acquire additional DNA alternations (Strom et al. 2003; Potter et al. 2009; Hickman 
et al. 2014). Although there was no significant difference in the number of methylated 
probes between cell cultures and solid samples in the overall cohort, for paired 
samples, the methylation level was higher in all 3 short-term cultures than biopsies 
from which they were derived. It is reasonable to suspect that the DNA methylation 
patterns might be different between the three original biopsies, and therefore between 
the 3 sets of short-term cultures. However, there was a high degree of commonality 
between the additional genes that were methylated only in cultures. These methylated 
genes were found to be involved in a number of pathways comprising: Axon guidance, 
Focal adhesion, Cell adhesion molecules (CAMs), Complement and coagulation 
cascades and ECM receptor-interaction. This is consistent with other studies showing 
pathway-specific differences that were significantly altered in cultures compared to 
tumour cells (Ertel et al. 2006). 
3.8.6 Final candidate genes 
A large number of abnormal gene methylation in different malignancies have been 
identified by several genome-wide methylation assays (Kim et al. 2006; Meissner & 
Jaenisch 2006; Shames et al. 2006; Jacinto et al. 2007; Bennett et al. 2008). A 
genome-wide integrated method that is able to identify novel genes silenced by 
methylation in cancer can be very useful. As this approach relies on not only the 
frequent differential expression, but also the frequent aberrant DNA methylation 
coupled with the response of densely methylated promoters to the demethylating 
agent 5-Aza-dC to confirm the potential functional relevance of candidate genes. Using 
this robust and effective genome-wide screen, six candidate genes were identified 
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(CXCL14, PRR5L, NTM, ITGA2, KRT8 and ELTD1), representing potential novel 
epigenetically silenced genes in paediatric HGA. 
3.8.7 CXCL14 
CXCL14 is located at 5q31.1 with a 803bp CpG island containing 82 CpGs. Chemokines 
are a superfamily of small chemotactic cytokines with molecular masses of 8-12 KDa 
that regulate cellular processes such as migration, proliferation, angiogenesis and 
tumour-related immunity (Mehrad et al. 2007; Tessema et al. 2010). They are also 
reported to regulate cell trafficking of various types of leukocytes through interaction 
with a subset of seven-transmembrane, G protein-coupled receptors (Kakinuma & 
Hwang 2006; Raman et al. 2007; Yoshimura et al. 1987). Chemokines are classified 
into four subgroups by the presence of conserved cytosine residues. The CXC 
subfamily in humans contains 16 members (CXCL1–14, 16 and 17) (Strieter et al. 2004; 
Kakinuma & Hwang 2006). A (Glu-Leu-Arg) (ELR) motif near the N-terminus of the 
molecule defines the property of a specific chemokine. CXCL1–3 and 5–8 are ELR-
positive chemokines, whereas CXCL4 and 9–11 members are lacking the ELR motif 
(Strieter et al. 2004). CXCL14/BRAK (CXC chemokine ligand 14/breast- and kidney-
expressed chemokine) is non-ELR chemokine plentifully expressed in most normal 
tissues. On the contrary, the majority of cancer cell lines and carcinomas do not 
express CXCL14, suggesting a tumour suppressor function (Mehrad et al. 2007; 
Kakinuma & Hwang 2006).  CXCL14 is reported to be down-regulated in several types 
of cancer including head and neck, oral, lung and prostate carcinoma (Hata 2012; 
Ozawa et al. 2006a; Song et al. 2010; Kakinuma & Hwang 2006). CXCL14 has 
previously been reported to be hyper methylated in lung cancer (Tessema et al. 2010). 
Dendritic cells (DC) are known as antigen-presenting cells detected in immature state 
in virtually every tissue, where they capture antigens followed by maturation and 
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migration to secondary lymphoid organs to activate naive antigen-specific T cells. The 
capacity of immature DC to migrate into the tumour site in search for antigens is a key 
to the successful induction of the antitumor immune responses (Song et al. 2010). 
Their absence in many malignant tissues is in agreement with the deficiency of 
effective antitumor immune responses in cancer patients (Iwamoto et al. 2003). The 
fact that CXCL14, a potent DC chemokine, is downregulated or absent in the malignant 
tissues suggests that CXCL14 may have a unique role in the tumour recognition by the 
immune system. Because DC could bind CXCL14 with high affinity, migrate to 
CXCL14-expressing tissues, and be activated by CXCL14 (Ozawa et al. 2006b). It was 
suggested that the downregulation of CXCL14 expression in tumour tissues might 
represent a new mechanism of tumour evasion, which allows tumour cells to escape 
recognition by antigen-presenting cells (Shellenberger et al. 2004).  
Identification of CXCL14 as a potential candidate genes in paediatric HGA through the 
stringent genome wide criteria was validated and showed methylation of CXCL14 in 7 
HGA short-term cultures and normal expression in cultured normal human 
astrocytes. The expression level of CXCL14 was examined by RT-PCR and 8 short term 
cultures showed down-regulation compared to cultured NHA, Re-expression of 
CXCL14 was confirmed in all 3 short-term cultures after treatment with 5-Aza-dC 
where it was methylated. Together with the CXCL14, interestingly there are other 
members of Chemokine signaling pathway and Cytokine-cytokine receptor (Figure 
3.47 and 3.48)  identified frequently to be methylated by DAVID, according to 450k 
methylation array that adding weight to CXCL14 being a candidate genes in paediatric 
HGA and makes this pathway favourable for further analysis and investigations in 
paediatric HGA. In order to determine the functional impact of down-regulation of 
CXCL14 in HGA, it was transiently and stably over-expressed in the IN699 short-term 
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culture. Re-expression of CXCL14 in IN699 cells, inhibited the colony formation 
significantly showing the effect on cell growth and reduced the migration rate 
significantly. Coupled with other studies showing its involvement in other tumour 
types, CXCL14 is likely to be relevant in the development of HGA and an excellent 
candidate gene for further analysis. 
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Figure 3.47 This figure illustrates the KEGG pathway, JAK-STAT signaling pathway 
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Figure 3.48 This figure illustrates the KEGG pathway, JAK-STAT signaling pathway
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3.8.8 ITGA2 
ITGA2 is located at 5q11.2 with a 774bp CpG island containing 62 CpGs. The ITGA2 
gene encodes the α2 subunit of the collagen receptor which creates a heterodimer with 
b1 to form integrin a2b1, a cell adhesion molecule normally expressed on a number of 
cell types, comprising haematopoetic cells, endothelial and epithelial cells. However, 
rather than occurring ubiquitously, expression of integrin a2 displays both cell type 
and differentiation specificity (Chin et al. 2015; O’Riain et al. 2009). ITGA2 is 
expressed in epithelial cells, endothelial cells and fibroblasts in numerous tissues and 
its altered expression has been linked to several cancer types (Bonkhoff et al. 1993; 
Kirchhofer et al. 1990; Pontes-Junior et al. 2009; Santoro et al. 1988; Takada et al. 
1988; Van Slambrouck et al. 2009). The role of ITGA2 expression in tumour 
malignancy is controversial with both increase and decrease expression linked to poor 
outcome and the progression of tumours to acquire an invasive, metastatic and 
aggressive tumour phenotype (Zutter et al. 1995; Klein et al. 1991; Koretz et al. 1991; 
Núñez-Ramírez et al. 2011). ITGA2 plays an essential role in tumour cell invasion, 
metastasis and angiogenesis and altered expression of ITAG2 has been associated to 
tumour prognosis in several solid tumours (Zutter et al. 1995). In breast cancer, 
decreased expression of ITGA2 is linked to poorly differentiated adenocarcinoma and 
re-expression of the ITGA2 resulted in a reversed phenotype from an invasive 
fibroblastoid to a less motile epitheloid cell (Zutter et al. 1995). Consistent with this, 
loss of ITGA2 expression is associated with an invasive tumour type in colon cancer 
(Koretz et al. 1991). In contrast, increased expression of ITGA2 is associated with a 
more malignant phenotype in anaplastic thyroid carcinoma (Dahlman et al. 1998), 
melanoma (Klein et al. 1991) and prostate cancer (Hall et al. 2006; Núñez-Ramírez et 
al. 2011; Van Slambrouck et al. 2009). ITGA2 expression appears to be regulated 
primarily at the transcriptional level and its regulation has been examined in 
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megakaryocytes (Zutter et al. 1995), epithelial cells (Ye et al. 1997) and fibroblasts (Xu 
et al. 1998). The understanding of its regulation is currently limited but, promoter and 
enhancer regions have been identified to the transcription start site (Zutter et al. 1995). 
In addition to transcription factors, epigenetic factors have also been shown to be 
important in the regulation of integrin gene expression (Jaenisch & Bird 2003). 
Overall, the regulation of ITGA2 expression plays a key role in the processes of cell 
differentiation, and altered adhesion, invasion and migration of tumour cells (Chin et 
al. 2015). 
3.8.9 ELTD1 
ELTD1 is located at 1p31.1 with a CpG island of 256bp containing 33 CpGs. ELTD1 is 
an orphan receptor protein of the adhesion GPCR family in the epidermal growth 
factor-seven-span transmembrane (EGF-TM7) receptor subfamily expressed in 
cardiomyocytes and vascular smooth muscle cells (VSMCs) of the developing rat heart 
(Bjarnadóttir et al. 2004; Kwakkenbos et al. 2004; Nechiporuk et al. 2001) ELTD1 is 
expressed as a highly glycosylated molecule, in monomeric and predominantly dimeric 
forms (Liu et al. 2005),. Studies of the recombinant rat ortholog indicate that ELTD1 
is expressed on the cell surface (Nechiporuk et al. 2001), and this has also been 
confirmed by FACs analysis of 293T cells overexpressing an N-terminally tagged 
human ELTD1.  Functionally, ELTD1 plays a key role in angiogenesis both in vitro and 
in vivo, and one proposed mechanism is via regulation of the sprouting process 
(Masiero et al. 2013). Recent studies have shown the ELTD1 is aberrantly expressed in 
the majority of tumour-associated endothelial cells compared to normal endothelial 
cells in renal, colorectal, and ovarian cancers (Masiero et al. 2013). ELTD1 silencing 
markedly impaired tumour growth in vivo despite the association between high 
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expression in tumour-associated endothelial cells and good prognosis in multiple 
cancer types (Masiero et al. 2013). 
3.8.10 NTM 
NTM is located at 11q25 with a CpG island of 382bp consisting of 35 CGs.  It is a 
member of the subfamily of immunoglobulin-like cell adhesion molecules and is 
differentially regulated during development of the central nervous system (Struyk et 
al. 1995). Cell adhesion molecules are involved in cell dispersal and invasion 
(Bogenrieder & Herlyn 2003). A recent association study showed that NTM and 11q25 
in general is associated with intelligence quotient (Pan et al. 2011; Sugimoto et al. 
2012). Studies have shown that NTM is involved in axonal fasciculation of specific 
cerebellar systems and may also be involved in the formation of excitatory synapses 
and their stabilization into adulthood (Pan et al. 2011). Little is known about the 
expression of NTM, but they appear to form hetero- and homomeric dimers and play 
an important role in neuronal growth and development (Gil et al. 2002; Lodge et al. 
2000; McNamee et al. 2002; Miyata et al. 2003; Reed et al. 2004). Notably, the 
expression of NTM in adult brain is higher than in fetal brain and it has been shown 
that in nervous system tumours, the expression of NTM was lower than that in normal 
brain tissue that suggests that NTM may be important in the development of nervous 
system and related to the occurrence of nervous tumour (Pan et al. 2011). Future 
functional studies are needed to confirm whether a loss of NTM function would 
enhance the invasive and metastatic potential of HGA tumour cells. 
3.8.11 PRR5L 
PRR5L is located at 11p13 with a 1472bp CpG island containing 124 CpGs, PRR5L 
(Proline-rich protein 5-like) is a protein linked with mTORC2 pathway. PRR5L 
interacts with rictor, independent of mTOR. PRR5L (Gan et al. 2012). Previous studies 
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have shown that despite of no significant effect of PRR5L on mTORC2-mediated Akt 
phosphorylation, PRR5L silencing inhibits Akt and S6K1 phosphorylation and reduces 
cell proliferation (Gan et al. 2012). PRR5L silencing impairs PDGF stimulated 
phosphorylation of S6K1 and Akt but moderately reduces epidermal growth factor- 
and insulin-stimulated phosphorylation (Woo et al. 2007). In addition, PRR5L, which 
is part of mTORC2, has been suggested to play a role in apoptosis in HeLa cells, but 
whether it is proapoptotic or anti-apoptotic remains unclear (Brunn et al. 1997). 
mTORC2 including its member PRR5L has shown to phosphorylates AGC protein 
kinases including protein kinase C (PKC) and regulates cellular functions such as cell 
migration (Gan et al. 2012). 
3.8.12 KRT8 
KRT8 is located at 12q13.13 with a CpG island of 382bp consisting of 35 CGs. Keratins 
are the largest family of intermediate filament proteins that have predominant 
expression in epithelia cells (Moll et al. 1982; Moll et al. 2008). Keratins form a 
complex with several proteins involved in signalling pathways including: cell cycle, 
apoptosis, membrane trafficking and cellular response to stress (Coulombe & Omary 
2002; Oshima et al. 2002; Owens & Lane 2003). The expression of keratins is 
regulated by both tissue type and also during differentiation (Galvin et al. 1989; Moll 
et al. 1990). In breast epithelium the basal/myoepithelial cells (proliferation 
compartment) express K5 and K14, while the luminal cells (differentiation 
compartment) express K8 and K18 (Logan C Walker et al. 2007; Moll et al. 1982). In 
breast cancer, reduced CK8/18 expression in conjunction with the basal-like 
phenotype and family history may improve investigators' ability to identify which 
tumours are likely to be associated with a BRCA1 germline mutation (Aiad et al. 2014) 
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It has been suggested that the keratins may have tissue specific functions due to their 
strictly regulated tissue and differentiation specific pattern of expression(Logan C. 
Walker et al. 2007). K8/18 when expressed together with VIMENTIN have been 
associated with drug resistance, invasion and metastasis in breast cell carcinomas and 
melanomas (Bauman et al. 1994; Hendrix et al. 1992; Hendrix et al. 1996). Other 
reports have suggested that the elevation of K18 expression in breast cancer patients 
correlates with favourable prognosis and that the loss of K8 in conjunction with 
aberrant expression of VIMENTIN correlates with early metastasis and poor prognosis 
(Iyer et al. 2013; Woelfle et al. 2004). K18 is the only type-I keratin in adult 
hepatocytes, together with its partner K8, and is the major type-I keratin in many 
colonic tumour cell lines (Omary et al. 2009). The markedly decreased keratin mRNA 
in CT26 and IEC-6 cells suggests that enhanced DNA methylation of the promoter 
regions of the keratin genes and consequent decreased transcription of the keratin 
genes may be a contributing factor to the observed decreased in K8/K18 mRNAs 
(Kwan et al. 2015).  It has been shown that  the knockdown of KRT8 increased 
migration and invasiveness, but increased apoptosis in epithelial cancer cells through 
up regulation of Fas receptor (Wu et al. 2014). 
Combination of different microarray strategies in this study has identified six novel 
candidate genes that are frequently methylated and downregulated in paediatric HGA. 
There is no previous report about these genes being methylated in paediatric 
astrocytoma. This method was useful in identifying novel methylated genes in the 
paediatric HGA indicating the effectiveness of this approach to identify novel 
candidate gens. In addition, these genes were shown previously to be associated with 
functions or pathways involved in tumourigenicity including cell adhesion, cell 
migration and regulation of proliferation, indicating the list had produced a relatively 
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credible and relevant set of methylated genes in paediatric HGA. Since it was not 
possible to assess the functional relevance of all the six genes, CXCL14 selected for 
further analysis. 
3.8.13 Functional analysis on CXCL14 
Functional analysis of CXCL14 was performed to validate and confirm the role of 
CXCL14 in HGA tumourogenesis. Aberrant methylation may eventually act as two 
crucial roles in cancer: as biomarkers for detection and prognosis, and targets for 
epigenetic therapy (Belinsky et al. 2003; Belinsky 2005; Gore et al. 2006; Yang et al. 
2006). CXCL14 may participate in both arenas. This study confirmed that the re 
expression of CXCL14 in the IN699 short-term cell culture significantly inhibited cell 
proliferation and colony formation. It has been shown that stable re-expression of 
CXCL14 in lung cancer derived cell lines, increases the expression level of 30 genes 
including CASP4, CEPBD, RHOBTB2, RBP1 and TNX1 that directly or indirectly 
inhibit cell-cycle progression or promote apoptosis (Tessema et al. 2010). Following 
stable transfection, effect of re-expression of CXCL14 in IN699 short-term cultures 
assessed on this five genes. The re-expression of CXCL14 did not have significant effect 
on CASP4, CEPBD, and RHOBTB2 that can be because of differences in tumour types. 
However, the expression of RBP1 and TNX1 increased significantly in CXCL14 
expression cells. This results suggest that CXCL14 expression possibly is central for 
several antitumour mechanism and its silencing could be critical for different cancer 
type including paediatric HGA. This result is consistent with other studies showing 
that CXCL14 inhibits cell migration in other cancer types including; Colorectal and 
head & neck cancer (Hata 2012).  
An appropriate epigenetic candidate gene for paediatric HGA must meet certain 
criteria including being frequently dis regulated by DNA methylation in paediatric 
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HGA cells, but not in the normal cells, also correlation of methylation with gene 
expression indicating functional significance for the initiation and progression of 
paediatric HGA is essential. Moreover, gene expression with and without treatment 
with 5-Aza-dC can identify sets of genes that are up-regulated following de-
methylation for each sample, suggesting DNA methylation in the untreated sample is 
restricting expression, thus, have functional relevance. The data presented in this 
chapter showed that the set of 6 novel candidate genes including CXCL14 has met 
these requirements.
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4 CHAPTER 4 Results 
5-Aza-dC as a Therapeutic Agent in 
Astrocytoma: A Preliminary Analysis 
4.1 Introduction 
Gene silencing by aberrant promoter DNA hypermethylation is one of the significant 
features of cancer. DNA methylation is a reversible process through pharmacological 
unmasking and this potential making it an attractive therapeutic target. Over the past 
few years, several DNA methyltransferase inhibitors (DNMTi) have been established. 
Many of them have the potential of epigenetic therapy (Jones & Baylin 2002). 
Two DNA methylation inhibitors, 5-Aza-dC and 5-azacitidin DNA methylation, 
showed to have profound effects on gene expression by altering the accessibility of 
DNA to transcription factors (Jeong et al. 2009). 5-Aza-dC is a nucleoside analogues 
which binds to and blocks the catalytic site of DNMTs after its incorporation into the 
DNA (Lyko & Brown 2005). Due to this covalent binding, the DNMT's are effectively 
trapped as adducts to DNA and hence, at high doses, are able to induce DNA damage 
and cytotoxicity (Ferguson et al. 1997; Gabbara & Bhagwat 1995; Santi et al. 1984; 
Karpf et al. 2001; Palii et al. 2008). The standard dose of 5-Aza-dc for in vitro global 
de-methylation experiments is 5µM and at this concentration some cytotoxicity has 
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been reported however, higher doses were too toxic for the patients (Karahoca & 
Momparler 2013a; Morris et al. 2008; Issa et al. 2004; Karpf et al. 2001). Since that 
5-aza-dC possibly have a dual mechanism of action, utilising relatively low dose of 5-
Aza-dcC may affect cell differentiation and proliferation by de-methylation leading to 
re-expression of genes that have previously been inactive and via non cytotoxic 
activity. Several clinical trials have shown that low-doses of 5-Aza-dC are well-
tolerated in patients with acute myelogenous leukemia and myelodyplasia (Plimack et 
al. 2007; Amanda F. Cashen et al. 2008; Atallah et al. 2007; Karahoca & Momparler 
2013a) and resulted in measurable progresses in overall quality of life and response 
rate (Tsai et al. 2012; Amanda F. Cashen et al. 2008). Considering that DNMTis have 
only been approved for the treatment of hematological malignancies, there are a lot to 
be learnt about their action in solid tumours.  
In the present study, the effects of 100nM 5-Aza-dC were assessed in paediatric HGA 
short-term cultures (Schrump et al. 2006; Amanda F. Cashen et al. 2008). The 
constancy of 100nM of 5-Aza-dC effect on proliferation and gene re expression after 
drug withdrawal was assessed in three HGA cultures. Following long-term treatment 
and subsequent culturing there was no cellular rejuvenation or any evidence of gene 
re-silencing. This study showed that transient exposure resulted in durable inhibition 
of cell growth and reduction in colony formation. Findings from this study can support 
our understanding of using 5-Aza-dC as a therapeutic agent for paediatric HGA. 
4.2 Effect of 5-Aza-dC on cell proliferation and viability 
In the present study, it has already been established that treatment of the HGA cell 
culture IN699 with 5µM 5-Aza-dC for 72 hours effected global demethylation with a 
concomitant reduction in cell viability of 18% compared to the untreated control cells 
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(results presented in Chapter 3). The effects of lower concentrations of 5-Aza-dC on 
cellular toxicity were also assessed in IN699 using the MTT assay and although the 
decrease in cell numbers was minimal after 72 hours, a dose dependent response was 
observed.   At concentrations of 2µM, 1µM, 500nM and 100nM, there was a reduction 
in cell viability of 13%, 11%, 7% and 6%, respectively, compared to the control cells 
(Figure 4.1).
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Figure 4.1 Determination of cell viability using MTT assay 
MTT cytotoxicity assay for IN699 short-term cell culture Result of MTT assay for 
evaluation of cell viability. Cells were exposed to the indicated concentration of 5-Aza-
dC at exposure time of 72 hours. In each day of treatment, the data are compared to 
the value of untreated cells on that day (considered 100% as a reference). Each values 
represents the mean of 3 independent experiments, error bars represent standard 
error. 
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4.3 Assessment of efficiency of low-dose (100nM) 5-
Aza-dC in demethylation 
To determine if low doses of 100nM 5-Aza-dC can also de methylate gDNA and 
reconstitute mRNA expression in IN699, the expression status of 5 genes was 
determined after treatment for 72 hours using RT-PCR.  KLHL53, MCJ, DIO1, LHX9 
and CXCL14 are all methylated in IN699 cells, as confirmed by CoBRA and described 
in Chapter 3, Figure 3.2 and Figure 3.14. Re-expression was observed in all 5 genes as 
illustrated in Figure 4.2.
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Figure 4.2 Expression analysis for selected known methylated genes. 
Expression results are shown for 5 known methylated genes; CXCL14, MCJ, DIO1, 
LHX9 and KLHL35. For each gene expression results are given with (+) and without 
(-) treatment with 5-Aza-dC (100nM). RT–PCR analysis showed re-expression of 
silenced genes in IN699 culture following treatment with 5-Aza-dC. GAPDH served as 
an internal control.
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4.4 Assessment of efficiency of low-dose (100nM) 5-
Aza-dC on Colony formation 
To determine the longer term effects of 5-Aza-dC on in vitro cell growth, colony 
formation assays were performed as described in Chapter 2.  Three short-term HGA 
cultures (IN699, IN3182 and IN178) were treated with 5µM or 100nM 5-Aza-dC in 
triplicate together with an untreated control. These concentrations were selected as 
5µM 5-Aza-dC is the standard dose for de-methylation experiments whereas 100nM 
5-Aza-dC is clinically relevant (Schrump et al. 2006).  From the MTT assay, there was 
a difference in reduction of cell viability of 12% between these concentrations. For all 
replicates, 2 x 105 cells were seeded in 100mm dishes and maintained in Hams F10 
with 10% FCS for 21 days. The results of the colony formation assays are shown in 
Figure 4.3. Treatment with both 5µM and 100nM 5-Aza-dC significantly inhibited 
colony formation by more than 90%, when compared to the respective untreated 
controls in all 3 cell cultures.  Interestingly, there was no difference in the reduction of 
colony formation between treatment with 5µM and 100nM 5-Aza-dC.
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Figure 4.3 Inhibition of colony formation after treatment with 5-Aza-dC 
(5µM and 100nM) in HGA cell cultures. 
Colony formation assay was used to measure the number of surviving colonies of the 
short term cultures (IN699, IN3182 and IN178). After treatment with 5-Aza-dC (5µM 
and 100nM) for 72 hours, colony formation was measured 21 days later.  The surviving 
number of colonies in short term cultures post-treated with 5-Aza-dC was less than 
20, which was significantly different from that of the control group, more than 250. 
For all panels, the means ± SEMs for 3 independent experiments are shown. ***P< 
0.001.
*** *** *** 
*** *** *** 
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4.5 Assessment of long-term growth rate in HGA cell 
cultures treated with 5-Aza-dC 
Having established that the clinically appropriate dose of 100nM 5-Aza-dC produced 
an equal decrease in colony formation as 5µM 5-Aza-dC, further experiments to assess 
the effects of 5-Aza-dC on cell proliferation were conducted using 100nM of 5-Aza-dC 
only. The long-term growth assay was carried out as described in Chapter 2.  Briefly, 
HGA cultures IN699, IN3182 and IN178 and NHA control cells were treated in 
triplicate for 72 hours before transferring 2x 105 cells into drug free medium for 7 days. 
The rate of proliferation was determined by calculating the population doubling level 
(PDL) every 7 days for 10 weeks with IN699 cells and for 7 weeks for IN3182 and IN178 
cells.  
The results of the long-term growth assay for IN699 are shown in Figure 4.4. For 
untreated control cells, the PDL were 4, 8 and 12 for weeks 1, 2 and 3, respectively.  In 
comparison, in cells treated with 100nM 5-Aza-dC, the PDL were reduced to 1, 2 and 
4 for these weeks. However, from week 3 onwards, the rate of population doubling for 
the 5-Aza-dC treated cells matched that of the control culture (3.6 PDL per week.)  
These findings were supported by microscopic analysis of the cultures at 100X 
magnification in which a reduction in the number of cells in each field can be seen after 
the appropriate 5-Aza-dC treatment (Figure 4.5).  It can be concluded that 3 days of 
treatment with 100nM 5-Aza-dC resulted in reduction of proliferation for 3 weeks, 
after which the growth rate increased and became comparable to the control culture 
(P<0.005).
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Figure 4.4 Effect of low-dose 5-Aza-dC treatment on long-term growth 
rate in IN699 cell culture  
Untreated control and 100nM 5-Aza-dC-treated cultures were monitored for 10 weeks 
and long-term growth curves were plotted. The red curve represents 5-Aza-dC treated 
cells whereas the blue curve represents the control.  Cell numbers were determined 
each week and population doublings (PD) were calculated in relation to the cell 
numbers at week 0. PDL were much lower for 5-Aza-dC treated cells (1, 2 and 4) when 
compared to control (4, 8 and 12) for weeks 1, 2 and 3 respectively. The initial 
treatment with 100nM 5-Aza-dC for 72 hours resulted in reduction of growth rate for 
3 weeks, after which the growth rate resumed and became comparable to the control 
culture. Green arrow indicates the re treatment times. Each value represents the mean 
of 3 independent experiments, error bars represent standard error.
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Figure 4.5 Microscopic analysis of IN699 culture after treatment with low-dose 5-Aza-dC 
The pictures above represent the microscopic analysis (brightfield; magnification 100X) for IN699 short term cultures for A) 
untreated B) 5-Aza-dC treated for 3 days and C) retreated biweekly after week 3 over a period of 9 weeks. The proliferation for treated 
IN699 culture reduced for the first 3 weeks, after which the cells recovered. In contrast, when the cells were re-treated, considerable 
reduction in proliferation was observed without recovery over a 9 week period. 
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A different response to the low dose treatment with 5-Aza-dC was observed in the 
other 2 HGA cultures as shown in the graphs in Figures 4.6 and 4.8 and in the 
corresponding micrographs in Figures 4.7 and 4.9. In contrast to IN699, 100nM 5-
Aza-dC did not induce a reduction in the growth rate until week 3, when the PDL in 
the treated cultures were 6.5 and 6.9 compared to 7.6 and 10.2 in the untreated 
controls for IN178 and IN3182, respectively (178, P=0.06 and 3182, P=0.0006). This 
could be due to the lower rate of proliferation and longer doubling time of these 2 
cultures. Furthermore, in both IN178 and IN3182, a very low rate of proliferation was 
maintained until week 5, after which cell viability was significantly reduced (178, 
P=0.0005 and 3182, P=0.0001). This is in contrast to IN699, 5-Aza-dC treatment 
impacted the cells immediately, but in which the cells also recovered after 3 weeks by 
matching the population doubling level (PDL) rate of its untreated control.   
The effect of 100nM 5-Aza-dC on NHA was also examined. Although a 3 day treatment 
with 100nM 5-Aza-dC markedly decreased the proliferation rate in 3 HGA short-term 
cultures the same concentration did not significantly affect the PDL in NHA (P=0.08) 
as shown in Figure 4.10 in the corresponding micrographs in Figure 4.11. Although it 
is worth noting that these normal astrocyte cells do not proliferate quickly in vitro, 
these results are consistent with clinical results for MDS/AML where anti-tumour 
response was produced while the normal bone marrow remained unaffected (Schmelz 
et al. 2005; Karahoca & Momparler 2013b).
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Figure 4.6 Effect of low-dose 5-Aza-dC treatment on long-term growth 
rate in IN178 cell culture 
Untreated control and 100nM 5-Aza-dC treated cultures were monitored for 7 weeks 
and long-term growth curves were plotted. The red curve represents 5-Aza-dC treated 
cells whereas the blue curve represents the control.  Cell numbers were determined 
each week and PDLs were calculated in relation to the cell numbers at week 0. Each 
value represents the mean of 3 independent experiments, error bars represent 
standard error. 
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Figure 4.7 Microscopic analysis of IN178 culture after treatment with low-dose 5-Aza-dC 
The pictures above represent the microscopic analysis (brightfield; magnification 100X) for IN178 short term cultures for A) 
untreated and B) 5-Aza-dC treated (3 days) cells over a period of 7 weeks. The proliferation for treated IN179 culture reduced 
considerably without recovery over a 9 week period in contrast to the control culture.
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Figure 4.8 Effect of low-dose 5-Aza-dC treatment on long-term growth 
rate in IN3182 cell culture 
Untreated control and 100nM 5-Aza-dC treated cultures were monitored for 7 weeks 
and long-term growth curves were plotted. The red curve represents 5-Aza-dC treated 
cells whereas the blue curve represents the control.  Cell numbers were determined 
each week and PDLs were calculated in relation to the cell numbers at week 0. Each 
value represents the mean of 3 independent experiments, error bars represent 
standard error.
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Figure 4.9 Microscopic analysis of IN3182 culture after treatment with low-dose 5-Aza-dC 
The pictures above represent the microscopic analysis (brightfield; magnification 100X) for IN3182 short term cultures for A) 
untreated and B) 5-Aza-dC treated (3 days) cells over a period of 7 weeks. The proliferation for treated IN179 culture reduced 
considerably without recovery over a 9 week period in contrast to the control culture. 
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Figure 4.10 Effect of low-dose 5-Aza-dC treatment on long-term growth 
rate in NHA 
Untreated control and 100nM 5-Aza-dC treated cultures were monitored for 5 weeks 
and long-term growth curves were plotted. The red curve represents 5-Aza-dC treated 
cells whereas the blue curve represents the control.  Cell numbers were determined 
each week and PDLs were calculated in relation to the cell numbers at week 0. Each 
value represents the mean of 3 independent experiments, error bars represent 
standard error.
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Figure 4.11 Microscopic analysis of NHA culture after treatment with low-dose 5-Aza-dC 
The pictures above represent the microscopic analysis (brightfield; magnification 100X) for NHA short term cultures for A) untreated 
and B) treated (3 days) cells over a period of 7 weeks. The proliferation profiles for both the control and 5-Aza-dC treated NHA culture 
were similar, thus indicating that the drug did not affect normal human astrocytes.
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4.5.1 Re-treatment of IN699 with low dose 100nM 5-Aza-dC 
As described above, a single 3-day treatment with 100nM 5-Aza-dC resulted in 
restricted growth of IN699 cells for the first 3 weeks, after which the cells recovered 
and demonstrated an equivalent rate of PDL to the untreated control cells. This 
response may be due to the high proliferation rate of this culture. Therefore, it is 
possible that a low dose regimen of 100nM 5-Aza-dC every two weeks could prolong 
the growth inhibitory effect. Furthermore, this is more comparable with patient 
therapeutic regimens. To test this hypothesis, IN699 cells were initially treated with 
100nM 5-Aza-dC for 72 hours and plated in fresh medium and the PDL calculated each 
week as described above.  Following this, cells were retreated with 100nM 5-Aza-dC 
for 72 hours at week 3 and then every two weeks from then onwards (100nM 5-Aza-
dC for 72 hours at week 5 and week 7). As can be seen in Figure 4.12, immediately after 
the first re-retreatment at week 3, the rate of cell proliferation slowed down for one 
week before increasing to a rate comparable to the untreated control and single 
treatment. Cell proliferation decreased again after the second re-treatment at week 5 
and continued to one further treatment resulted in complete cessation of growth after 
9 weeks.  At week 10, the PDL for retreated cells (14) was significantly different than 
that for treated cells (28) and the control cells (39) (P=0.0005). The cells were 
maintained in the culture for an additional 4 weeks with no further 5-Aza-dC 
treatment, No re-growth was observed.
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Figure 4.12 Effect of low-dose 5-Aza-dC re-treatment on long-term 
growth rate in IN699 
Untreated control and 100nM 5-Aza-dC treated (3 days) and retreated cultures were 
monitored for 10 weeks and long-term growth curves were plotted. The red curve 
represents 5-Aza-dC treated cells, the blue curve represents the untreated control and 
the curve green represent retreated cells.  Cell numbers were determined each week 
and PDLs were calculated in relation to the cell numbers at week 0. When the cells 
were retreated bi-weekly after the 3rd week, the PDL rate reduced and proliferation 
was observed to be considerably lower than the untreated and treated cell. Green 
arrow indicates the re treatment times. Each value represents the mean of 3 
independent experiments, error bars represent standard error.
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4.5.2 Differentiating effects of 5-Aza-dC on cellular 
morphology 
When IN699 cells were retreated with a bi-weekly regimen of 100nM 5-Aza-dC from 
week 3, the effect of the treatment was evident with microscopic analysis. Consistent 
reduction in cell proliferation was observed after retreatment (shown in Figure 4.5). 
In addition, significant elongation and increase in size of the cells was observed which 
could indicate that cells are incapable of dividing as illustrated in Figure 4.13 below. 
The elongation of the cells could be a result of differentiation following 5-Aza-dC 
retreatment. Cells also became enlarged and flattened with irregular outlines and 
nuclei became more circumscribed in phase contrast microscopy. The cytoplasm 
appeared granular with many inclusions and aggradations appearing to be cell debris 
increased. Morphologic changes were not limited to senescent-like morphology but 
represented other changes in the course of long-term culture. This is consistent with 
other studies reporting cell morphology changes after treatment with 5-Aza-dC which 
include giant cell size, increased cytoplasmic granularity and a single large nucleus 
(Lleonart et al. 2009; Wagner et al. 2008). Senescent cells, arrested in G1 phase of the 
cell cycle, remain viable and metabolically active (Kahlem et al. 2004). 
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Figure 4.13 Microscopic analysis of IN699 culture after re-treatment with low-dose 5-Aza-dC 
The pictures above represent the microscopic analysis (brightfield; magnification 100X) for IN699 short term cultures for re treated 
cells from week 11 to week 14. A indicates the flat cells with increase in size and B indicates the elongated cells.
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4.6 Gene re-expression analyses following treatment 
with 100nM 5-Aza-dC  
The ability of low doses of 100nM 5-Aza-dC to induce demethylation and concomitant 
gene re-expression over a sustained period was also assessed in IN699 cells. RT-PCR 
was used to determine re-expression of the methylated gene CXCL14 following 
treatment with 100nM 5-Aza-dC in the long-term growth assay for weeks 1 to week 3 
and subsequently after each re-treatment up to week 10, as shown in Figure 4.14.  As 
expected, after 72 hours exposure to 100nM of 5-Aza-dC, CXCL14 was re-expressed 
(week 1) and this was sustained for a further week.  However, at week 3, CXCL14 was 
silenced and this correlated with the rate of proliferation which increased from week 
3.  
At week 3, the cells were re-treated with 100nM 5-Aza-dC and the re-treated samples 
showed re-expression of CXCL14 at week 5 and this was sustained until week 9, most 
probably due to the repeat bi-weekly re-treatments (Figure 4.14). In contrast, no 
expression of CXCL14 was observed in the control or 5-Aza-dC treated cells at week 5, 
7 and 9. This is consistent with the growth and proliferation data and indicates that 
re-treatment of IN699 cells with a low dose of 5-Aza-dC induced sustained gene re-
expression and reduced proliferation. These results were confirmed using Q- PCR 
(Figure 4.15.) which showed significant re-expression of CXCL14 in 5-Aza-dC treated 
cells compared to control cells for weeks 1 (P= 0.0026) and 2 (P= 0.0012) only. In the 
re-treated cells, there was CXCL14 was re-expressed at week 4 and the level of 
expression increased compared to control cells and 5-Aza-dC treated cells (P= 0.0011) 
and also at weeks 5, 7 and 9, the increase in re expression was significantly higher (P= 
0.0003), (P= 0.0004), (P= 0.0001) respectively.
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Figure 4.14 Re-expression analysis after low-dose 5-Aza-dC treatment using RT-PCR for CXCL14 in IN699 culture 
IN699 culture treated with (+) and without (-) treatment with 5-Aza-dC for weeks 1, 2, 3, 5, 7 and 9 and re treated (++) for weeks 5, 
7 and 9. For treated cells, re expression of CXCL14 was observed for week 1 and 2, after which no gene expression was detected. In 
contrast, for re-treated cells sustained expression was seen over the period of the experiment. GAPDH served as an internal control.
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Figure 4.15 Re-expression analysis after low-dose 5-Aza-dC treatment 
using Q-PCR for CXCL14 in IN699 culture 
Graphs are shown for Q-PCR results for CXCL14 expression level in IN699 culture. 
IN699 culture treated with (+) and without (-) treatment with 5-Aza-dC for weeks 1, 
2, 3, 5, 7 and 9 and re treated (++) for weeks 5, 7 and 9. For treated cells, re expression 
of CXCL14 was observed for week 1 and 2, after which no gene expression was detected. 
In contrast, for re-treated cells sustained expression was seen over the period of the 
experiment. C, T and RT indicate Control, treated and re treated cells respectively. 
GAPDH served as an internal control. **P<0.01 and ***P<0.001
0
1000
2000
3000
4000
5000
6000
7000
8000
C T C T C T C T RT C T RT C T RT C T RT
Week 1 Week 2 Week 3 Week 4 Week 5 Week 7 Week 9
%
 E
xp
re
ss
io
n
 r
e
la
ti
ve
 t
o
 
u
n
tr
e
at
e
d
 C
o
n
tr
o
l
CXCL14 expression in low-dose 5-Aza-dC treated cells
**
**
**
***
***
***
 215 
 
4.7 FACS analysis of apoptosis in HGA short term 
cultures  
The proliferation assays described above indicate that treatment with 100nM 5-Aza-
dC has an inhibitory effect on HGA cell cultures. FACS analysis was performed on 
IN699 and IN3182 short term cultures in order to establish if the reduction in cell 
number was accompanied with an increase in apoptosis. 
FACS analysis was performed using Annexin V-FITC and PI as described in Chapter 
2, allowing discrimination of viable and non-viable cells and apoptotic cells from 
necrotic cells (Vermes et al. 1995). Cells were treated with 100nM of 5-Aza-dC for 72 
hours as described previously and flow cytometry analysis was performed weekly for 
9 weeks for IN699 and 7 weeks for IN3182. For IN699, cells were re-treated on weeks 
3, 5 and 7 to be consistent with the previous proliferation experiment. The results of 
apoptosis analysis are shown in Figures 4.16 and 4.17. There was no significant 
increase in apoptosis associated with 100nM 5-Aza-dC treatment, particularly for the 
first four weeks where there was only a small population of cells undergoing apoptosis 
(less than 10%) compare to the control cells with more than 90% of viability. There 
was a general trend of increased apoptosis in the following weeks. It was noted that 
the percentage of apoptosis was slightly higher in re treated cells on week 5, week 7 
and week 9. However, the apoptosis percentage throughout the experiment is less than 
20%, it can be concluded that this relatively low level of apoptosis is insufficient to 
account for the marked differences in proliferation levels seen following treatment 
with 5-Aza-dC. The apoptotic percentage throughout the experiment was even less 
evident in IN3182 (less than 10%). The results of apoptosis analysis for IN3182 are 
shown in Figures 4.18 and 4.19. This observation, of little apoptosis, is consistent with 
the cellular morphology of these cells that suggests they have entered a terminal 
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differentiation-like state where cell numbers are maintained through the absence of 
cell division rather than a crisis-like state where cell numbers are maintained through 
a balance between proliferation and apoptosis or necrosis(Evans et al. 2003) Hence, 
although, 5-Aza-dC induces inhibition of colony formation and proliferation, this is 
not through apoptosis. This result is consistent with similar studies where they 
assessed and confirmed that 100nM 5-Aza-dC produces no initial apoptosis in chronic 
myelogenous leukemia, but sharply reduces subsequent colony formation (Tsai et al. 
2012). It is likely that this reduction in proliferation without cell death is due to using 
relatively low doses that do not acutely kill cells and, thus, allow the sustained 
alterations in both gene expression patterns and phenotype.
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Figure 4.16 Bar graph of flow cytometer analysis apoptosis for IN699. 
Bar graphs are plotted to show the percentage of viable and apoptotic cells for week 1 to week 3 for 5-Aza-dC untreated and treated 
IN699 and for week 4 to week 9 for untreated, treated and retreated IN699.
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Figure 4.17-i- Flow cytometer analysis of apoptosis for IN699 
culture. 
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Figure 4.17-ii- Flow cytometer analysis of apoptosis for IN699 
culture. 
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Figure 4.17 Flow cytometer analysis of apoptosis for IN699 culture. 
Induction of apoptosis in IN699 short term cultures after treatment with 100nM of 5-Aza-dC were assessed by labelling the cells with 
Annexin-V and PI stains. This figure represents Annexin-V versus PI contour plots with quadrant gating for four populations. 
Viable/non apoptotic IN699 cells showed negative staining for both Annexin-V and PI and were fall into the quadrant 1. IN699 cells 
with early apoptosis that were positive for only Annexin-V were observed in quadrant 2. Late apoptotic IN699 cells with positive 
staining for both Annexin-V and PI were observed in quadrant 3. Cells or sometimes debris that shows positive staining for PI only 
were fall in to quadrant 4. 5-Aza-dC + indicates treatment and 5-Aza-dC ++ indicates re treatment.
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Figure 4.18 Flow cytometer analysis of apoptosis for IN3182. 
Bar graphs are plotted to show the percentage of viable and apoptotic cells for week 1 to week 7 for 5-Aza-dC untreated and treated 
IN3182.
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Figure 4.19-i- Flow cytometer analysis of apoptosis for IN3182. 
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Figure 4.19-ii- Flow cytometer analysis of apoptosis for IN3182. 
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Week 7 
  
Figure 4.19 Flow cytometer analysis of apoptosis for IN3182. 
Induction of apoptosis in IN3182 short term cultures after treatment with 100nM of 5-Aza-dC were assessed by labelling the cells 
with Annexin-V and PI stains. This figure represents Annexin-V versus PI contour plots with quadrant gating for four populations. 
Viable/non apoptotic IN699 cells showed negative staining for both Annexin-V and PI and were fall into the quadrant 1. IN3182 cells 
with early apoptosis that were positive for only Annexin-V were observed in quadrant 2. Late apoptotic IN3182 cells with positive 
staining for both Annexin-V and PI were observed in quadrant 3. Cells or sometimes debris that shows positive staining for PI only 
were fall in to quadrant 4. 
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4.8 GFAP staining for treated and untreated IN699 
Following this study, as microscopic analysis showed significant morphology changes 
including elongation and increase in size of the cells, considering the heterogeneity of 
HGA it was important to address the concern that the population cells after 
retreatment are still from astrocytic origin. Therefore, GFAP/VIMENTIN marker 
(Astrocyte marker) was used to prove that the cells under study were indeed from an 
astrocytic origin, even if it meant they were heavily de-differentiated. 
Due to the heterogeneity of glial tumours, no perfect astrocytoma-specific marker has 
been identified. The expression of the intermediate filament (IF) protein glial fibrillary 
acidic protein (GFAP) has been used extensively to identify astrocytes and astrocytic 
tumours immunohistochemically, but not all normal astrocytes or astrocytomas 
express GFAP. GFAP is a 50 kDa intra-cytoplasmic filamentous protein that 
establishes a portion of the cytoskeleton in astrocytes and which is thought to be 
important in astrocyte motility and shape by providing structural strength to astrocytic 
processes (Eng et al. 2000).  GFAP shares substantial structural homology with the 
other intermediate filaments (IF) in the central rod domain of the molecule (Huang et 
al. 2010). Four different IF proteins are expressed in astrocytes: GFAP, VIMENTIN, 
nestin and synemin. Their expression is dependent on developmental stage as well as 
astrocyte activity (Eliasson et al. 1999; Jing et al. 2007). Astrocyte precursors express 
VIMENTIN, nestin and synemin. In maturing astrocytes VIMENTIN expression is 
decreased while nestin and synemin are progressively replaced by GFAP (Lendahl et 
al. 1990). The cytoskeleton and process morphology of immature astrocytes are 
primarily made up of the intermediate filaments (IFs) VIMENTIN and nestin 
(Eliasson et al. 1999). As astrocytes mature, VIMENTIN and nestin are gradually 
replaced by another intermediate filament, glial fibrillary acidic protein (GFAP).   As 
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can be seen in Figure 4.20, there was no change in the number of cells which stained 
positively for both GFAP and VIMENTIN following treatment and re-treatment with 
5-Aza-dC.  Similarly, the intensity of staining remained constant.
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GFAP 
Control 5-Aza-dC treated 5-Aza-dC re-treated 
   
 
VIMENTIN 
Control 5-Aza-dC treated 5-Aza-dC re-treated 
   
Figure 4.20 Immunocytochemical staining for GFAP and VIMENTIN in 
IN699 culture. 
This figure shows astrocytes characterised by GFAP/VIMENTIN (green) staining. Cell 
nuclei are stained with Dapi (blue). The sample were analysed with confocal 
microscopy, 40X. In comparison with the IN699 control, IN699 treated and retreated 
showed no changes in the number of cells and the intensity of staining. 
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4.9 Discussion 
Cancer is a multifactorial disease with both genetic and epigenetic modifications 
contributing to its progression. For this reason, therapeutic strategies using drugs 
which target aberrant epigenetic mechanisms such as HDAC inhibitors or 
demethylating agents are a promising pathway to pursue. 5-azacitidine and its 
analogue 5-Aza-dC have proven effective in the treatment of haematological 
malignancies and recent work suggests that the benefits of 5-Aza-dC treatment may 
be transferable to solid tumours (Kantarjian et al. 2007; Issa et al. 2004; Tsai et al. 
2012). 5-Aza-dC was first synthesized by Pliml and Sorm (Elgemeie et al. 2000). It has 
been reported that 5-azacytidine and 5-Aza-dC could induce differentiation of mouse 
embryonic cells, and that this effect was complemented by a reduced DNA methylation 
(Taylor & Jones 1985). This was followed by studies indicating that 5-azacitidine and 
5-Aza-dC induced differentiation of leukemic cells in vitro (Antonio & Fiore 2015; 
Taylor & Jones 1985). These nucleoside analogues act as demethylating agents that 
integrate into DNA in position of the cytosine during DNA replication, and thus they 
are only active during S phase (Ghoshal et al. 2005). Once integrated into the DNA, 
they make a complex consisting active sites of DNMTs that covalently binds and traps 
these enzymes (Jones & Taylor 1980). This mechanism causes the depletion of active 
DNMTs and the demethylation of DNA after several cell divisions (Hellebrekers et al. 
2007). 5-azacytidine is incorporated into DNA and, to a lesser extent, RNA (hence 
interfering with protein translation) whereas 5-Aza-dC is incorporated only into DNA, 
and thus is a more efficient inhibitor of DNMTs (Qiu et al. 2010).  These therapeutic 
effects have been attributed to the ability of nucleoside analogues to reduction of DNA 
methylation and increase expression of suppressed genes, leading to cell 
differentiation and/or apoptosis (Stresemann & Lyko 2008).  Both drugs are cytotoxic 
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at high doses as DNA is irreparable after drug incorporation and cell death occurs 
(Derissen et al. 2013; Issa & Kantarjian 2009; Stresemann & Lyko 2008). Clinical 
studies have demonstrated that high dose 5-Aza-dC treatment regimens result in some 
clinical benefits in patients with malignancies including complete remission in a 
patient with acute lymphocytic leukemia(Momparler et al. 1985).  The first clinical trial 
on 5-Aza-dC in patients with acute leukemia was published in 1981 (Er et al. 1984). 5-
Aza-dC was approved for the treatment of myelodysplastic syndrome (MDS) in 2006 
and also shows anti-leukemic activity against acute myeloid leukemia (AML) (de Vos 
& van Overveld 2005; Jabbour et al. 2008). The first clinical studies of 5-Aza-dC in 
hematologic malignancies used 1500 to 2500 mg/m2 per course and the response rates 
with 5-Aza-dC as a single agent or in combination with other therapies were 30% to 
60% (Groeningen et al. 1986; Pinto & Zagonel 1993; Er et al. 1984).  
However, these regimens have been shown to be extremely toxic due to the poor 
hematologic status of these patients and have caused delayed and prolonged 
myelosuppression (Esteller 2008b; Stresemann & Lyko 2008). This is primarily due 
to the misconception that the drug is solely a cytidine analogue. However, its role as a 
DNMT inhibitor has been investigated extensively and it is now known that at lower 
doses the complex are degraded by the proteosome, DNA is restored and, in the 
absence of DNMTi, DNA synthesis is resumed (Patel et al. 2010; Ghoshal et al. 2005). 
Similarly, 5-azacitidine or 5-Aza-dC at low doses can re-activate silenced genes and 
consequently reduce proliferation, increase apoptosis/senescence and induce cell 
differentiation (Amatori et al. 2010; Karahoca & Momparler 2013a).  
Low-dose 5-Aza-dC minimizes toxicity while potentially retaining the inhibition of the 
activities of DNMT via incorporation into the DNA (Kantarjian et al. 2007) . The lowest 
reported total dose of 5-Aza-dC that has been used to treat a solid tumour is 50mg/m2, 
but this dose was accompanied by various adverse events such as neutropenia lasting 
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more than 7 days, fever, thrombocytopenia, and non-hematologic toxicity (Chu et al. 
2013). A study of natural killer cells showed hypomethylation due to low-dose 5-Aza-
dC (0.02–2.5μM) and cytotoxicity and increased methylation at higher doses 
(>2.5μM) (Kopp et al. 2013). Low-dose 5-Aza-dC is well-tolerated in patients with 
MDS, and the primary hematological toxicity is transient neutropenia, which is 
predictable and manageable (Amanda F Cashen et al. 2008; Plimack et al. 2007; 
Atallah et al. 2007; Karahoca & Momparler 2013a). Presently, two low-dose regimens 
for management of decitabine are approved by FDA: the original 6-weekly regimen of 
15 mg/m2 administered by continuous intravenous infusion over 3 hours repeated 
every 8 hours for 3 days (Derissen et al. 2013). The other regime is a 4-weekly regimen 
of 20 mg/m2 by continuous intravenous infusion over 1 hour repeated daily for 5 days 
The main advantage of this new regimen is the reduced infusion time, which enables 
treatment in the outpatient setting (Derissen et al. 2013). 
4.9.1 Effect of 5-Aza-dC on cell proliferation and viability 
Based on previous studies of preclinical and clinical data, low dose 5-Aza-dC has the 
potential to be an effective form of therapy in some patients with cancer. The work 
conducted in this thesis has provided evidence of 5-Aza-dC to re-active the methylated 
genes using expression analysis. The very low doses of 5-Aza-dC employed are 
equivalent to the nanomolar range that has shown clinical efficacy in responding 
patients with MDS/AML (Amanda F. Cashen et al. 2008; Tsai et al. 2012).  
5-Aza-dC is likely to have a dual mechanism of action. At high doses, 5-Aza-dC 
produces DNA adducts that results in DNA synthesis arrest and cytotoxicity (Jabbour 
et al. 2008).  At low doses it induces gene expression profile changes that favor 
differentiation, reduced proliferation, and/or increased apoptosis (Karahoca & 
Momparler 2013a). This dual antitumor activity has generated significant interest in 
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investigating hypomethylating agents as antineoplastic drugs and biologic response 
modifiers. Previous clinical trials have generated some promising results in non-solid 
tumours (Gollob et al. 2006; Er et al. 1984; Groeningen et al. 1986; Kantarjian et al. 
2007). More recently, there has been success in terms of reducing solid tumour size in 
clinical trials (Azad, Zahnow, Rudin, & Baylin, 2013; Gollob et al., 2006; Howell, Liu, 
& Khong, 2010; R L Momparler et al., 1997; Richard L Momparler, 2013; Samlowski 
et al., 2005; Thibault et al). The current study intended to mimic these trials by 
introducing 5-Aza-dC into cell cultures at regular intervals over a long period of time.  
MTT assays to assess effects of 5-Aza-dC proliferation in IN699 cultures revealed a low 
level of cytotoxicity over a short period of time of 72 hours. In contrast, colony 
formation studies showed that treatment with low doses of 5-Aza-dC significantly 
reduced the proliferative potential of 3 different HGA cell cultures. Although the drug 
does not kill the cells as soon as they are treated, it significantly restricts their long-
term growth, and inhibits tumor colony production. The results of the MTT and colony 
formation assay were encouraging, but the duration of these experiments was 
relatively short. It was crucial to understand the long-term effects and also further 
investigate the kinetics of growth. In this effort, long-term growth assays were 
conducted and cells were counted on a weekly basis. 
Proliferation of the cells was assessed over a long period of time in this study, where it 
was seen that the cells were viable but were unable to grow, suggesting that the drug 
had a cytostatic effect on the cells. Interestingly, there was a significant reduction in 
the growth rate when IN699 cells were initially treated with 100nM 5-Aza-dC, but the 
rate of proliferation recovered after a couple of weeks. In contrast, the growth rate of 
the other short term cultures (IN3182 and IN178) was impacted for 7 weeks, at which 
point the cells lost complete viability. This promising result could tentatively be 
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compared to the reduction of tumour load in vivo. Importantly, 5-Aza-dC treatment 
did not significantly alter the growth potential of NHA cultures suggesting low levels 
of cytotoxicity according to the long-term assay. 
IN699 cells have a greater proliferative potential than IN3182 and IN178 as evidenced 
by their significantly shorter doubling time (34 hours compared to 60 hours and 64 
hours, respectively). Therapy for patients often involves multiple doses of a drug 
(Jabbour et al. 2008; Karahoca & Momparler 2013a; Howell et al. 2010). Since this 
study was attempting to mimic a clinical trial, it was decided to administer the IN699 
cells with the drug using a biweekly regime. However, providing a biweekly dose after 
week 3 successfully prevented the recovery of cell growth. After this point, even though 
the cells were not treated with the drug any more, no recovery in cell growth was 
observed. Lack of recovery was also evidenced in microscopic evaluation, where the 
cells appeared flat, large and differentiated. The relationship between DNA 
methylation and differentiation studied by Taylor and Attadia, suggested that 5-Aza-
dC is able to promote differentiation and activate maturation of cells via 
hypomethylation. 
Microscopic evaluation of the cells revealed a considerable difference in their 
morphology and no mitosis was observed. Overall, the cells looked unhealthy and flat 
in shape indicative of a senescence-like state. Similar observations have been made in 
myeloid leukemia cells following 5-Aza-dC tretment (Grandjenette et al. 2014).  
Consistent reduction in cell proliferation was observed after retreatment, as the 
number of cells seen under the microscope was reduced considerably. Cells also 
became greatly enlarged with irregular and flat shape, and nuclei became more 
circumscribed in phase contrast microscopy, the cytoplasm appeared granular with 
many inclusions and aggradations appearing to be cell debris increased. These 
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senescence-like phenotypic changes could be a result of differentiation following drug 
retreatment. These results are consistent with other studies reporting cell morphology 
differentiated after treatment with 5-Aza-dC (Lleonart et al. 2009; Wagner et al. 
2008). Altered cell morphology characterized by large cell size, increased cytoplasmic 
granularity and a single large nucleus (Baba & Câtoi 2007; Lleonart et al. 2009; 
Grandjenette et al. 2014). Senescent cells, arrested in G1 phase of the cell cycle, remain 
viable and metabolically active (Kahlem et al. 2004; Lleonart et al. 2009).  
In general, exposure of HGA short term cultures to 100nM of 5-aza-dC for 3 days, 
followed by a bi-weekly treatment for 10 weeks (IN699) and single treatment of 100nM 
of 5-Aza-dC for IN3182 and IN178 produced a growth inhibitory response. This result 
is in agreement with findings from other studies, where a similar prolonged time to 
response was seen in patients with hematologic neoplasms (Oki et al. 2008; Silverman 
et al. 2002; Kantarjian et al. 2007) and colon cancer cell lines using 5-Aza-dC (Plumb 
et al. 2000). It was also seen that the growth of normal human astrocytes was not 
affected during the long term assay when cells were treated with low dose of 5-Aza-dC. 
NHA don't grow well in vitro as they stop growing after a few doubling numbers 
(Godard et al. 2003; Wong et al. 2005). They were seen to behave normally when 
treated with 5-Aza-dC, but the growth was limited. However, growth limitation was 
observed in the control experiment as well.  It should be noted here that this study 
worked with only one NHA population because of lack of availability. Future work 
should repeat the experiments with more NHA populations, which will make the 
findings more robust. 
This study also demonstrated that prolonged gene re-expression could be achieved 
when cells were treated with 100nM 5-Aza-dC. There was positive relationship 
between gene re expression and reduction of proliferation. Re-treatment of IN699 
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cells with a low dose of 5-Aza-dC induced sustained gene re-expression that was 
consistent with growth and proliferation data. It was evident that the gene silencing 
was correlated with the rate of proliferation which increased from week 3. Moreover, 
re treated samples from week 5 to week 9 showed re expression and correlated with 
decrease in proliferation. 
Epigenetic drugs are known to induce a strong change in histone/DNA methylation 
level enabling stable epigenetic programming and leading to sustained re-expression 
of a gene (Beltran et al. 2008). 5-Aza-dC has been considered a transient drug, but 
recently this view has been revised as transient exposure of 5-Aza-dC appeared to 
produce an anti-tumour ‘memory’ response in leukemic and epithelial tumour cells 
(Tsai et al. 2012). However, there is evidence, in some cases, that gene re-silencing can 
occur without the re-methylation of promoters. This appears to occur by the re-entry 
of nucleosomes into the promoter region of genes without the original methylation 
pattern being restored (Hesson et al. 2013). Such mechanisms explain the basis of 5-
Aza-dC resistance. 
Two hypotheses can be presented to explain the apparent induced senescent state of 
astrocytoma cells following 5-Aza-dC treatment: The first is that the drug re-expresses 
some specific gene following which those pathways are switched back on. For instance, 
it is known that the Rb pathway is inhibited in many cancers often by promoter 
methylation of CDKN2A (p16) or Rb itself (Pacifico & Leone 2007; Wajed et al. 2001; 
Xue et al. 2001; Patel et al. 2010). Other key tumour suppressor genes such as p53 are 
silenced by promoter methylation (Baylin 2005; Xue et al. 2001). It is possible that in 
these IN699 cells 5-Aza-dC induces the re-expression of some Rb pathway genes, 
inducing a G1/ S phase check (Moolmuang & Tainsky 2011; Zheng et al. 2012). There 
is no experimental evidence presented here to back this hypothesis, but as one possible 
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explanation it will be a part of the future experimental plan. The second hypothesis is 
that the specific genes being up-regulated are irrelevant at this point. This is because 
5-Aza-dC is changes the architecture of the DNA by removing methyl groups from the 
entire genome (Huan et al. 2015; Hellebrekers et al. 2007; Issa & Kantarjian 2009) 
and essentially turns on all methylated genes. Such fundamental changes in expression 
pattern induce premature senescence and cell differentiation (C. P. Gan, Hamid, Hor, 
Zain, Ismail, Wan Mustafa, Teo, Saunders & Sok Ching Cheong 2012; Kuilman et al. 
2010; Michalowsky & Jones 1989; Venturelli et al. 2013; Lleonart et al. 2009; Taylor 
& Jones 1985). 
4.9.2 FACS analysis 
The growth proliferation assays described above indicate that treatment with 100nM 
5-Aza-dC has an inhibitory effect on HGA cell cultures. FACS analysis was performed 
on IN699 and IN3182 short-term cultures in order to establish if the reduction in cell 
number was accompanied with an increase in apoptosis. The observation from this 
study revealed that the apoptosis level was not significant throughout the experiment 
for IN699 and it was even less evident for IN3182. 
This reflection, of little apoptosis, is consistent with the cellular morphology of these 
cells that proposes they have entered a terminal differentiation-like state and the cell 
numbers are maintained through the absence of cell division (Evans et al. 2003) 
Therefore the effect of 5-Aza-dC on inhibition of colony formation and proliferation is 
not through apoptosis. This result is consistent with similar studies where they 
evaluated and confirmed that 100nM 5-Aza-dC produces no initial apoptosis in 
chronic myelogenous leukemia, but significantly decreases the colony formation (Tsai 
et al. 2012).  
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Although it has been shown that epigenetic agents, such as 5-Aza-dC, can be used as 
monotherapies for hematologic cancers, accumulating evidence strongly suggests that 
these agents will be more effective when combined with conventional chemotherapies, 
enhancing the sensitivity to radiotherapy and cytotoxic agents (Kristensen et al. 2009; 
Cai et al. 2011). In a recent Phase I study 5-Aza-dC was combined with bortezomib for 
the treatment of elderly poor risk AML patients and the combination showed good 
preliminary activity since response rates were very encouraging (Blum et al. 2012).  
Sequential treatment of 5-azacytidine and lenalidomide in elderly patients with AML 
also showed encouraging clinical and biologic activity (Pollyea et al. 2012). 5-Aza-dC 
can activate proapoptotic pathways or inhibit oncogenic signaling cascades (Shin et al. 
2012), but does not directly induce the re-expression of caspase-8, which plays an 
important role in the chemotherapy resistance of tumours; therefore, 5-Aza-dC may 
increase the susceptibility of tumour cells to chemotherapy (Lotem & Sachs 2006; 
Chun et al. 2009).  
5-Aza-dC may also be used as an immune modulator to sensitize the tumour cells to 
tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) (Xu et al. 2007). 
Moreover, a preclinical study reported that decitabine improves the immune 
recognition of tumour cells by both methylation-regulated and nonmethylation-
regulated target antigens (Fonsatti et al. 2007). It is possible that the greatest impact 
of epigenetic therapy for cancer management will involve combination with current 
chemotherapeutic approaches. Reversing resistance or sensitizing cancers to multiple 
therapy types, including hormonal therapies, immunomodulatory therapies and 
standard chemotherapy, are now very promising and rational concepts.  
Drugs that affect the epigenetic machinery, including HDAC and DNMT inhibitors, 
are becoming increasingly more common as cancer therapeutics, particularly in 
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leukemias. Given their inherent lack of specificity on not only cell type but target gene 
of interest, it is important to better understand their actions and consequences at a 
molecular level and to identify pharmacologic agents with acceptable toxicity profiles. 
The study presented here shows that the epigenetic changes (e.g. re-expression) were 
sustained for a significant duration, when the cells were exposed transiently to a low 
dose of 5-Aza-dC. It is likely that this reduces proliferation without cell death is due to 
using relatively low doses that do not acutely kill cells and, thus, allow the sustained 
alterations in both gene expression patterns and appearance of a new phenotype to 
emerge. Thus, understanding how 5-Aza-dC influences these covalent modifications 
in connection with transcriptional activation will yield interesting insights into how 
these events become altered in disease states and perhaps how they can be addressed 
in therapy.
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5 Chapter 5 
Final Discussion and Future Work 
Paediatric astrocytoma is the most common form of solid cancer in children and the 
leading cause of cancer-related deaths in children younger than 15 years of age (Gerges 
et al. 2013). Approximately 400 new cases of primary CNS tumours are diagnosed in 
the paediatric population per annum in the UK and the majority of these are 
astrocytoma (Broniscer & Gajjar 2004). Approximately one-fifth will be malignant 
astrocytoma (WHO grade III or IV) and less than 20% of these patients survive 2 years 
from diagnosis (Kramárová & Stiller 1996). There is an urgent need to develop new 
therapeutic strategies which target specific genetic/epigenetic abnormalities present 
in these tumours. 
In adult astrocytoma, many of the genetic aberrations which are involved in tumour 
development have been identified.  Primary glioblastoma multiform (GBM) (WHO 
grade IV) may develop de novo without a clinical history of a pre-existing low-grade 
tumour and are considered to have amplification or overexpression of EGFR and 
MDM2 and homozygous deletion of p16INK4a (Smith et al. 2001).  In contrast, 
secondary GBM progress from lower grade tumours and have a high incidence of p53 
mutations and overexpression of PDGF-R6(Ichimura et al. 2000). The frequencies of 
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RB loss and/or mutation and CDK4 amplification are similar in both primary and 
secondary GBM (25% and 15% of cases, respectively) (Smith et al. 2001). Similarly, 
deletions on chromosome 10 are very common in both types of GBM although 
mutations of PTEN occur almost exclusively in primary GBM5 (Smith et al. 2001). 
However, extensive cytogenetic and molecular genetic analyses have been unable to 
demonstrate many of these patterns of genetic change in paediatric astrocytoma 
(Rickert et al. 2001). Previously in our laboratory, we have completed a genome-wide 
analysis of genetic loss and gain by comparative genomic hybridisation in a series of 
77 paediatric astrocytoma and have confirmed that these tumours do not share the 
characteristic genetic aberrations found in adult astrocytoma (Warr et al. 2001). 
Although we have identified some novel non-random regions of genomic imbalance in 
paediatric astrocytoma, including gains at 2q, 6q and 8q and losses of 20p and 22, 
these were present in only a subset of <20% of tumours.  Furthermore, in 
approximately 50% of malignant astrocytoma, no detectable regions of genetic loss or 
gain were present.  It is highly probable that the biological and hence, clinical 
behaviour of paediatric astrocytoma is determined not only by changes at the DNA 
level but by both qualitative and quantitative differences in the levels of expression of 
a range of genes.   
Epigenetic aberrations have been shown to play an important role in the pathogenesis 
of the majority of cancers and one of the most widespread and powerful mechanisms 
is gene silencing through DNA methylation (Baylin 2005). Methylation. DNA 
methylation alteration are a hallmark of cancer genomes and a common mechanism 
of tumour suppressor gene inactivation (McCabe et al. 2009). DNA methylation marks 
are also amenable to biomarker progress, for instance, some genes have been shown 
to be hypermethylated in multiple cancers e.g. p16INK4a, p14ARF and RB in tumours 
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of the colon, prostate, pancreas and lung and gliomas (Herman et al. 1995; Robertson 
& Wolffe 2000).  Other methylation events are more common in specific tumour types 
including hMLH1 in colon carcinoma, HAI-2/PB in hepatocellular carcinoma and 
Hsp47 in neuroblastoma (Margetts et al. 2008). In adult glioma, there is increasing 
evidence that epigenetic silencing of tumour genes through hypermethylation is a 
common event (Zheng et al. 2011). Also, the methylation status of MGMT is widely 
used to predict which glioma patients are most expected to benefit from alkylating 
drugs (e.g. temozolomide) (Kanemoto et al. 2014). However, methylation studies in 
paediatric astrocytoma have not been widely reported (Zhao et al. 2014; Gerges et al. 
2013). Assessment of DNA methylation changes in cancer genomes can highlight 
genes that may provide evidence of deregulated networks and pathways, and potential 
candidates for biomarker development. To support in this field of research, the work 
in this thesis intended to identify DNA methylation changes in paediatric HGA, 
presenting one study targeting to identify genes hypermethylated in paediatric HGA 
and their potential functional relevance and another study to assess the effect of low 
dose 5-Aza-dC therapy on paediatric HGA short term cultures. 
5.1.1 Genome wide analysis of paediatric HGA 
The initial goal of this study was to apply a combined approach of pharmacological 
inhibition of DNA methylation through treatment of paediatric HGA short-term cell 
cultures with 5-Aza-dC and whole genome expression array analysis to identify 
epigenetically silenced genes with potential tumour suppressor activity. Though, due 
to the necessity of 5-Aza-dC treatment, only one short-term culture was suitable for 
pharmacological unmasking. Consequently, to overcome the limitations of working 
with only 1 sample, this study has evolved to use methylation array analysis on a cohort 
of 20 tumour samples using the Illumina 450K BeadChip. Re-expression array 
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resulted in the list of 2539 re-expressed genes in IN699 after treatment with 5-Aza-
dC. This list were integrated with the list of methylated genes in IN699 from the 450k 
methylation array, resulting in 147 genes that are both methylated at their DNA level 
and re expressed following pharmacological unmasking. 
Recent technological developments have established multiple assays for genome wide 
analysis of DNA methylation and gene expression (Chin et al. 2011). One of the most 
recently developed methods is Illumina methylation array platforms.  In chapter three 
we used the Illumina Infinium Human Methylation 450k array on a cohort of 20 
paediatric HGA samples together with the Affymetrix U133A array for 11 HGA short-
term cultures (previously performed in our laboratory and re analysed for the purpose 
of this study) (Potter et al., unpublished data). 
This study was able to identify candidate genes by integration of the two 
aforementioned genome wide strategies. The 14 candidate genes (ATF3, RUNX1T1, 
MICAL2, PRR5L, PDE4D, PTPRE, KRT8, FABP5, NTM, ITGA2, GPR12, ELTD1, 
MYO5C, and CXCL14) were frequently downregulated according to the expression 
array and methylated according to the methylation array. This is a critical observation 
as it suggests that mechanisms other that gene deletion are responsible for down-
regulation of gene expression in paediatric HGA. These genes were also showed hyper 
methylation in 4 out of 5 fresh frozen biopsies which reduced the artefact of the in 
vitro environment and added another layer of sureness to the candidate genes. In 
addition, genes within the list were associated with functions or pathways involved in 
tumourigenicity demonstrating the list had produced a relevant set of methylated 
genes in HGA. 
This study eventually identified 6 candidate genes (PRR5, CXCL14, ELTD1, ITGA2, 
KRT8 and NTM) and confirmed that methylation was responsible for the silencing of 
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these 6 genes in HGA following treatment with 5-Aza-dC, thus having functional 
relevance.  
The RT-PCR validation provided good correlation with expression array, however the 
CoBRA validation for methylation array was not satisfactory. This can be due to some 
degree of intrinsic false positive rate in methylation array and the fact that CoBRA 
might not be the best validation assay for this kind of analysis as it is not a very 
sensitive, does not analyse many CpGs in the chosen region and only covers one 
amplified region. As the main aim of this study was to identify functionally relevant 
methylation, the focus centred on probes either on or around the CpG islands. Analysis 
of the CpG area by probe mapping on the CpG sequence showed that many of the 
methylated probes were away from the CpG island region. However, the CoBRA 
primers were designed upstream of, and around the transcription start site (CpG 
island) as this seems to be the most likely region for hypermethylation that results in 
gene inactivation, thus having biological relevance. This means that region in which 
the methylated probes were located may not have been covered by CoBRA analysis. 
This could possibly explain why CoBRA analysis did not compare well with 
methylation array analysis. CoBRA might have assessed regions that did not contain 
any methylated probes. Having said that, this study successfully selected the most 
relevant regions (CpG island) with respect to identifying epigenetic gene silencing. 
Overall, we believe that the stringent criteria used for the global approaches in this 
study have enhanced the possibility of identifying true methylated target genes. 
As it was not possible (due to time constraints) to assess the potential functional roles 
of these 6 genes in tumour formation, CXCL14 was selected for further functional 
analysis by stable re expression of this gene in one short term culture (IN699). CXCL14 
has been shown to express plentifully in most normal tissues. In contrast, the majority 
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of cancer cell lines and carcinomas do not express CXCL14, suggesting a tumour 
suppressor function (Mehrad et al. 2007; Kakinuma & Hwang 2006).  CXCL14 is 
reported to be down-regulated in several types of cancer including head and neck, oral, 
lung and prostate carcinoma (Ozawa et al. 2006a; Song et al. 2010; Kakinuma & 
Hwang 2006). Epigenetic silencing of CXCL14 via extensive promoter 
hypermethylation has not been reported previously in paediatric HGA tumours.  Re 
expression of CXCL14 in IN699 cells, significantly reduced the colony formation 
indicating a growth inhibitory role of CXCL14 in these cells. Moreover, the re 
expression of CXCL14 in IN699 cells inhibited the migratory potential of these cells. 
Furthermore, Q- PCR was used to assess the expression level of five genes after stable 
expression of CXCL14 in IN699 cells and a significant increase of expression in RBP1 
and TNX1P were observed. Coupled with other studies showing the involvement of 
CXCL14 in other tumour types, CXCL14 is likely to be relevant in the development of 
HGA and an excellent candidate gene for further analysis. 
The understanding of HGA growth and development is challenging due to the 
heterogeneity of these tumours and reservations surrounding derived short-term cell 
cultures and established cell lines. Many functional studies require short-term cell 
cultures and cell lines. It is therefore important that the differences and similarities of 
tumour tissue and derived cells in culture are studied. Cell culture does have an overall 
effect on gene expression without a doubt (Ismail et al. 2000; Bignotti et al. 2006). 
However, short-term cell cultures do have a molecular profile that represents the 
tumour of origin. There have been problems regarding how well the established cell 
lines or derived short-term cell cultures represent the tumour in situ. As collecting a 
large cohort of fresh tumour tissue is challenging, cultured tumour samples often 
remain the only source of available material for research. Previous studies have 
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compared the variation between biopsy and cultured tumour samples (Mueller et al. 
2007). It has been shown that there are fewer differences between primary tumour 
tissues and derived short term cell cultures (Bignotti et al., 2006; Ismail et al., 2000). 
This suggests that these cultures may represent the tumour in situ better than 
established cell lines. Therefore, utilising derived short-term cultures in the study of 
any tumour may reduce the differences between the tumour of origin and the cultured 
cells (Mueller et al. 2007).  Culture would invariably impact gene expression, however, 
derived short terms cultures at low passage are less prone to acquire additional DNA 
alternations (Hickman et al., 2014; Potter et al., 2009; Strom, Gabbard, Kelly, 
Cunningham, & Nienhuis, 2003). In this study, we showed that there was no 
significant difference in the number of methylated probes between cell cultures and 
solid samples in the overall cohort.  
The gene methylation profiles generated from the Illumina 450k array for 3 paired 
biopsy and culture HGA samples showed that the methylation level was higher in all 3 
short-term cultures than biopsies from which they were derived. It is possible that the 
DNA methylation patterns was different between the three original biopsies, and 
therefore between the 3 sets of short-term cultures. The data presented in this study 
indicates that the methylation status of short-term cell cultures is representative of the 
tumours from which they were derived.  However, it is apparent that the in vitro 
environment induces additional methylation events.   
5.1.2 Epigenetic Therapy 
Aberrant promoter DNA hypermethylation and consequent gene silencing is one of 
the crucial elements of cancer (Esteller 2006). DNA methylation is reversible through 
pharmacological unmasking and this potential makes it an attractive therapeutic 
target (Ostrow et al. 2009). Several DNA methyltransferase inhibitors have been 
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established in the past few years aimed to reactivate aberrantly silenced genes and lots 
of them have shown promising results in preclinical and clinical studies, emphasizing 
the importance of potential of epigenetic therapy (Rodríguez-Paredes & Esteller 2011). 
Epigenetic therapy may by-pass the problem of tumour heterogeneity by making the 
re-expression of multiple tumour suppressor genes instead of targeting single pathway 
alterations. De-methylating agents used at doses far below their maximum tolerated 
dose have demonstrated to be a effective therapy for acute myelogenous leukemia and 
myelodyplasia, and are now approved by the FDA for treatment of these cancers 
(Howell et al. 2010). Various clinical trials have shown that 5-Aza-dC treatment results 
in measurable improvements in overall quality of life and response rate, such as 
extending the median time to acute myeloid leukemia (AML) progression (Karahoca 
& Momparler 2013a; Issa & Kantarjian 2009). 
It is likely that the dose-dependent cytotoxicity utilized by DNMTi is responsible for 
the observed clinical efficiency. However, increasing dose often results in deceasing 
responses and many patients who are resistant to the classical cytotoxic drugs show 
favourable responses, arguing against the notion that cytotoxicity is primarily 
responsible for the observed efficacies (Issa et al. 2004). Furthermore, a recent study 
showed that transient exposure to low dose DNMTi results in durable antitumor 
effects on hematological and epithelial tumour cells with minimal acute DNA damage, 
cell cycle alterations and apoptosis, arguing against the possibility that DNA damage 
and cytotoxicity generated by DNMTi are primarily responsible for their therapeutic 
effects (Tsai et al. 2012). Given that DNMTi have only been approved for the treatment 
of hematological malignancies, much is to be understood about their action in solid 
tumours. If the therapeutic response of DNMTi is a result of DNA methylation 
inhibition, they should be effective across a spectrum of malignancies because 
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hematological malignancies do not harbour more or less DNA methylation changes as 
compared to other caner types (List et al. 2004). Since the long term goal is to 
demonstrate the validity of using DNMTi to treat solid tumours, there is a strong need 
to elucidate the mechanism underlying clinical efficacies of DNMTi. As yet, results 
indicate that similar antitumor responses were observed on one leukaemia cell line 
HL60 and two in two solid tumour cell lines HCT116 and T24 upon transient exposure 
to 5-Aza-dC, indicating the feasibility of extending the application of DNMTi to solid 
tumours (Xiao et al. 2008; Mossman & Scott 2011; Jabbour et al. 2008; Issa et al. 
2004). 
Furthermore, findings from this study can also assist to improve our understanding of 
using 5-Aza-dC as a therapeutic agent for paediatric HGA. It is also important to 
consider that 5-Aza-dC crosses the blood-brain barrier(Leone et al. 2008). There two 
FDA-approved epigenetic drug to use in the management of cancer, 5-azacitidin and 
5-Aza-dC (Rodríguez-Paredes & Esteller 2011). In this study the main focus was on 5-
Aza-dC. In Chapter 4, the stability of 100nM of 5-Aza-dC effect on proliferation and 
gene re expression after drug withdrawal was assessed using three short term 
paediatric HGA short term cultures (IN699, IN3182 and IN178). Transient exposure 
of 5-Aza-dC on Paediatric short term cultures resulted in durable reduction of their 
colony formation significantly (P=0.001). Furthermore, inhibition of cell growth 
assessed using long term growth assay (up to 10 weeks) and showed significant effect 
on proliferation. Although a 3 day treatment with 100nM 5-Aza-dC significantly 
decreased the proliferation rate in 3 HGA short-term cultures the same concentration 
did not have a significant effect on the PDL in NHA (P=0.08). Although it is worth 
noting that these normal astrocye cells do not proliferate quickly in vitro, these results 
are consistent with clinical results for MDS/AML where anti-tumour response was 
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produced while the normal bone marrow remained unaffected (Karahoca & 
Momparler, 2013; Schmelz et al., 2005). 
The IN699 short term culture behaved differently to the other cells used in this study 
following treatment with 100nM 5-Aza-dC. This was considered to be likely due to its 
higher proliferation potential. As such, in a separate experiment, these cells were 
treated with a low dose regimen of 100nM 5-Aza-dC every two weeks. It was 
considered that this was more comparable with patient therapeutic regimens. The 
every two week regime of low dose 5-Aza-dC resulted in complete cessation of growth 
after 9 weeks and although the cells were maintained in the culture for an additional 
4 weeks, no re-growth was observed. 
The effect of 100nM 5-Aza-dC in IN699 short term culture on gene expression assessed 
by Q-PCR showed significant and sustained re expression.  Sustained inhibition in cell 
growth and colony formation correlated with sustained gene re expression suggesting 
prolonging gene re expression might be fundamental in progressing epigenetic 
therapy.  
The effect of the treatment was evident with microscopic analysis. Consistent 
reduction in cell proliferation was observed after retreatment. In addition, significant 
elongation and increase in size of the cells was observed which could indicate that cells 
are incapable of dividing. The elongation of the cells could be a result of differentiation 
following 5-Aza-dC retreatment. Cells also became enlarged and flattened with 
irregular outlines. This is consistent with other studies reporting cell morphology 
changes after treatment with 5-Aza-dC which include giant cell size, increased 
cytoplasmic granularity and a single large nucleus (Lleonart et al. 2009; Wagner et al. 
2008). Considering the result of FACS analysis, the difference in uptake of Annexin V 
between control and 5-Aza-dC treated cells is not significant. This is consistent with 
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the cellular morphology of these cells that suggests they have entered a terminal 
differentiation-like state rather than a crisis-like state where cell numbers are 
maintained through a balance between proliferation and apoptosis or necrosis (Evans 
et al. 2003), although, 5-Aza-dC induces inhibition of colony formation and 
proliferation, this is not through apoptosis. This result is consistent with similar 
studies where they assessed and confirmed that 100nM 5-Aza-dC produces no initial 
apoptosis in chronic myelogenous leukemia, but significantly reduces colony 
formation (Tsai et al. 2012). Since that 5-Aza-dC is likely to have a dual mechanism of 
action, utilising relatively low dose of 5-Aza-dC may affect cell differentiation and 
proliferation by de-methylation leading to re-expression of genes that have previously 
been inactive and not via cytotoxic activity and cell death. 
 In many clinical studies a high proportion of patients tumours eventually become 
resistant to 5-Aza-dC (Karahoca & Momparler 2013a). Parallels to this have also been 
shown in vitro where, even following regular dosing with 5-Aza-dC, gene expression 
is permanently re-silenced in colorectal cell lines (Hesson et al. 2013). However, the 
results presented here are rather more promising. Following long-term treatment and 
subsequent culturing no cellular rejuvenation was observed nor was there any 
evidence of gene re-silencing. This may be indicative of fundamental differences in the 
biology of astrocytoma and other solid tumours. If this is the case, 5-Aza-dC may be a 
viable clinical choice to consider for HGA. Further work to determine this will be 
necessary. 
Promoters remethylate much slower than gene bodies, resulting in sustained DNA 
demethylation and subsequent gene reactivation, which may potentially responsible 
for the less tumorigenic phenotype of cancer cells produced by transient exposure to 
5-Aza-dC. 
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5.1.3 Conclusion and future work 
This study has identified a number of novel potential drivers including PRR5, CXCL14, 
ELTD1, ITGA2, KRT8 and NTM  that can be important in paediatric HGA development 
and progression and that detection of methylated DNA from these genes may provide 
novel biomarkers for assessing tumour progression and patient outcome. 
Furthermore, this study for the first time, provided with initial evidence that low-dose 
of 5-Aza-dC may be a useful therapeutic agent for management of HGA. In future 
work, confirmation of identified methylated candidate genes responsible for 
development of paediatric HGA in a larger scale study of HGA tissues will be beneficial.  
Moreover, investigation of the ability of a selection of candidate genes to suppress 
astrocytoma cell growth by re-expressing them in HGA cultures will be useful. The 
molecular function of CXCL14 in driving the initiation and progression of paediatric 
HGA should also should be investigated. In addition, other candidate genes identified 
by the integrative 450k methylation array and expression array should be evaluated 
for their potential as epigenetic biomarkers in HGA. Molecular functions of these 
candidate genes should be investigated in future work for the purpose of better 
understanding the biology of this highly aggressive tumour. To continue the 
assessment of 5-Aza-dC as a therapeutic agent in HGA, combination therapy with 
other demethylation/deacetylating agents would be helpful. Also, to examine the effect 
of 5-Aza-dC on morphology changes and differentiation will be informative. Also, 
starting with in vivo animal model for further assessment of low-dose 5-Aza-dC 
therapy should be conducted.
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APENDIX I - RT-PCR primer sets 
Forward (F) and Reverse (R) are shown for each gene analysed for expression analysis.  
Name of Gene Primer sequence (5’-3’)  
GAPDH-F CATGTTGCAACCGGGAAGGA  
GAPDH-R GCCCAATACGACCAAATCAGAGA  
BETA-ACTIN-F AGCGAGCATCCCCCAAAGTT  
BETA-ACTIN-R GGGCACGAAGGCTCATCATT  
RunX1t1-F ACCTGTGGATGTGAAGACGCA  
RunX1t1-R AGGCTGTAGGAGAATGGCTCGT  
MYO5C-F ACAGGAGGCCGTTGGAAAAC  
MYO5C-R TAATCCAGCTCCGTTCCATCC  
ATF3-F CTAAGGATTTTCAGCACCTTGCC  
ATF3-R GGGCTACCTCGGCTTTTGTGA  
GPR12-F GAGCCAAGAGGACAGGGGTTA  
GPR12-R TTAGCAGGAACATGGGTGCT  
KRT8-F GGACCTGCAGGAAGGGATCT  
KRT8-R TCTGGTTGACCGTAACTGCG  
PDE4B-F CTGGTACTTCACGCCACCTT  
PDE4B-R CTAGCAGCTGGGGACCTCTT  
PTRPE-F GAAGCAGAGGAAAGCTGTGG  
PTRPE-R GGTCATTGGGAAGGATGTTG  
FABP5-F TTTTAGGTGATTTTTTTGGTTTTTT  
FABP5-R TCTTCCTTCCAACTACTAAACTATAACC  
ITGA2-F CAGGGCAGGAAAGCCTGCCAGG  
ITGA2-R AAGCTGTCCAGAGGGCTTCTCTCC  
ELTD1-F ATTAGGTAGGGAATGGAGTTTAGGA  
ELTD1-R ATCCAATCCCCTACAAAAAATTAAT  
KLHL35-F CGGCCGCGGAGATTCATGGAC  
KLHL35-R AAGCCACCCACCGCGAACAG  
MCJ-F GCGCTACGCTGAGTACTTGC  
MCJ-R AGATAAGACTGTGGTCAATC  
LHX9-F GCCAAGGACGGTAGCATTTA  
LHX9-R TTGCAAGAGGGTCTCGAAGT  
DIO1-F CAAGATGGCTGGGCTTTT  
DIO1-R CTTCCTCTGGGTTGTAGTTCC  
NTM-F CTCTCTCACACCCTCGGCTT  
NTM-R GGCACTCCTTGGAAGAGACACA  
MICAL2-F CTGAGGCCCGTGGATTCTTG  
MICAL2-R TGATTGGAGCCCAAGCTACG  
PRR5L-F ACCTTCCCCGATTCCAAG  
PRR5L-R GCGATTTTCACCTTCACACA  
CXCL14-F GTGGACGGGTCCAAATGCAA  
CXCL14-R CCAGGCGTTGTACCACTTGA  
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APENDIX II – CoBRA primer sets 
Forward (F) and Reverse (R) are shown for each gene analysed for methylation 
analysis. 
Name of Gene Primer sequence (5’-3’)  
LHX9-F AGGTTTTTTGTGTAGAGATGTGTT  
LHX9-R AATACACCAAACTATCCTTCATACC  
DIO1-F TGTATTAGTAGGTAAAGAAAAGAGTGT  
DIO1-R CTCCCAAATAACTAAAATTACAAAC  
MCJ-F AAGTATATAAAGTTTTTTGAGGGTT  
MCJ-R CAAAACTCACCAATCTCTACTAATC  
ELTD1-F CCTCCCGCTCCTAGTGGTTT  
ELTD1-R AGCATTTTCGCCACAGGACT  
ITGA2-F AAACACCTCACCTTAACTC  
ITGA2-R TTTATTTAGGGAAAAATAGAGAAA  
CXCL14-F GTTGTTTTTTGTTGTTGTTGG  
CXCL14-R CCAAACCCAAACTATACCCTAAC  
PRR5L-F GAAGTTAATTAGAGAGAGAGTTT  
PRR5L-R AATAAAAATAAATCAACCCCAA  
NTN-F TTTTGGTTTTGAATGTAGTGGT  
NTN-R CCCACTAATCAAAACTACTCTA  
KRT8-F TTTAGGTGATTTTTTTGGTTTT  
KRT8-R TCTTCCTTCCAACTCTAAACTA  
KLHL35-F TGGTTTTTGGGTTTGTAGAG  
KLHL35-R CATCAAAACCTTTACTATCCACC  
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APENDIX III – 147 genes that are both methylated (450k methylation array) and re-
expressed (Affymetrix array). 
 
Gene Symbol Gene Name 
ABCA5 ATP-binding cassette, sub-family A (ABC1), member 5  
ANK1 ankyrin 1, erythrocytic  
AP3B1 adaptor-related protein complex 3, beta 1 subunit  
AQP12A aquaporin 12A  
AQP12B aquaporin 12B  
BCORL1 BCL6 co-repressor-like 1 
BEX1 brain expressed, X-linked 1 
BIN3 bridging integrator 3  
BMPR1B bone morphogenetic protein receptor, type IB  
C16orf62 chromosome 16 open reading frame 62  
C20orf11 chromosome 20 open reading frame 11  
C2orf84 
chromosome 2 open reading frame 84; hypothetical protein 
LOC375190  
C3orf15 chromosome 3 open reading frame 15  
C6orf141 chromosome 6 open reading frame 141  
C7orf57 chromosome 7 open reading frame 57  
C8orf58 chromosome 8 open reading frame 58  
CBLN1 cerebellin 1 precursor  
CCDC152 coiled-coil domain containing 152  
CCL8 chemokine (C-C motif) ligand 8  
CCNG2 cyclin G2  
CD70 CD70 molecule  
CLEC2B C-type lectin domain family 2, member B  
COL7A1 collagen, type VII, alpha 1  
COX17 COX17 cytochrome c oxidase assembly homolog (S. cerevisiae)  
COX7B2 cytochrome c oxidase subunit VIIb2 
CPAMD8 C3 and PZP-like, alpha-2-macroglobulin domain containing 8  
CRYBB2 crystallin, beta B2  
CSMD1 CUB and Sushi multiple domains 1  
CXCL14 chemokine (C-X-C motif) ligand 14  
CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1  
DAAM2 dishevelled associated activator of morphogenesis 2  
DCAF4L2 WD repeat domain 21C  
DHRS7B dehydrogenase/reductase (SDR family) member 7B  
DMC1 
DMC1 dosage suppressor of mck1 homolog, meiosis-specific 
homologous recombination (yeast)  
EBP emopamil binding protein (sterol isomerase)  
ECHDC2 enoyl Coenzyme A hydratase domain containing 2  
EDNRB endothelin receptor type B  
ELOVL5 
ELOVL family member 5, elongation of long chain fatty acids 
(FEN1/Elo2, SUR4/Elo3-like, yeast)  
ELTD1 EGF, latrophilin and seven transmembrane domain containing 1  
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ENPP4 
ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative 
function) 
ENPP5 
ectonucleotide pyrophosphatase/phosphodiesterase 5 (putative 
function) 
ERO1LB ERO1-like beta (S. cerevisiae)  
FA2H fatty acid 2-hydroxylase 
FABP4 fatty acid binding protein 4, adipocyte  
FABP7 fatty acid binding protein 7, brain  
FMN2 formin 2 
FRZB frizzled-related protein  
FSTL4 follistatin-like 4 
GAL galanin prepropeptide  
GFM1 G elongation factor, mitochondrial 1  
GPR176 G protein-coupled receptor 176 
GRIP1 glutamate receptor interacting protein 1  
H19 
H19, imprinted maternally expressed transcript (non-protein 
coding)  
HEG1 HEG homolog 1 (zebrafish)  
HOXD3 homeobox D3  
HPCA hippocalcin  
HSPA2 heat shock 70kDa protein 2  
HYI hydroxypyruvate isomerase homolog (E. coli)  
ICMT isoprenylcysteine carboxyl methyltransferase  
ID3 
inhibitor of DNA binding 3, dominant negative helix-loop-helix 
protein 
IL18 interleukin 18 (interferon-gamma-inducing factor) 
INO80B INO80 complex subunit B 
ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)  
KCNT2 potassium channel, subfamily T, member 2  
KDM2B lysine (K)-specific demethylase 2B  
KIAA1632 KIAA1632  
LGALS3 lectin, galactoside-binding, soluble, 3  
LYPD6 LY6/PLAUR domain containing 6  
MAGEA1 
melanoma antigen family A, 1 (directs expression of antigen MZ2-
E)  
MAGEA4 melanoma antigen family A, 4  
MANSC1 MANSC domain containing 1  
MED9 mediator complex subunit 9  
MICAL2 
microtubule associated monoxygenase, calponin and LIM domain 
containing 2  
MMP13 matrix metallopeptidase 13 (collagenase 3)  
MYEF2 myelin expression factor 2  
NAA11 ARD1 homolog B (S. cerevisiae)  
NAP1L2 nucleosome assembly protein 1-like 2  
NEFH neurofilament, heavy polypeptide  
NEFL neurofilament, light polypeptide  
NEUROD2 neurogenic differentiation 2 
NMNAT1 nicotinamide nucleotide adenylyltransferase 1  
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NMU neuromedin U  
NOV nephroblastoma overexpressed gene  
NTM neurotrimin  
NUDT10 nudix (nucleoside diphosphate linked moiety X)-type motif 10 
NXT2 nuclear transport factor 2-like export factor 2  
OR8D1 olfactory receptor, family 8, subfamily D, member 1  
PAGE1 P antigen family, member 1 (prostate associated)  
PAQR8 progestin and adipoQ receptor family member VIII  
PASD1 PAS domain containing 1  
PCDH17 protocadherin 17  
PCDHB5 protocadherin beta 5  
PCDHB7 protocadherin beta 7  
PDE4D 
phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 
dunce homolog, Drosophila)  
PION pigeon homolog (Drosophila)  
PLEKHG4B 
pleckstrin homology domain containing, family G (with RhoGef 
domain) member 4B  
POU3F2 POU class 3 homeobox 2  
POU4F1 POU class 4 homeobox 1  
PRR5L proline rich 5 like  
PTCHD1 patched domain containing 1  
PTGS2 
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase)  
PTPN14 protein tyrosine phosphatase, non-receptor type 14  
RAB39B RAB39B, member RAS oncogene family  
RAB7A RAB7A, member RAS oncogene family  
RIMBP2 RIMS binding protein 2  
RNF144A ring finger protein 144A  
RNF220 ring finger protein 220  
ROBO3 roundabout, axon guidance receptor, homolog 3 (Drosophila)  
RPH3AL rabphilin 3A-like (without C2 domains)  
SALL2 sal-like 2 (Drosophila)  
SCIN scinderin  
SELM selenoprotein M  
SEMA3E 
sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3E  
SH2D4A SH2 domain containing 4A  
SPSB4 splA/ryanodine receptor domain and SOCS box containing 4  
SPTBN1 spectrin, beta, non-erythrocytic 1  
SQRDL sulfide quinone reductase-like (yeast)  
ST6GALNAC5 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 5  
ST8SIA1 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1  
STXBP6 syntaxin binding protein 6 (amisyn)  
SYCE1 synaptonemal complex central element protein 1  
TAF4B 
TAF4b RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 105kDa  
TCTEX1D1 Tctex1 domain containing 1 
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TFCP2 transcription factor CP2  
THBS4 thrombospondin 4  
TKTL2 transketolase-like 2 
TMED9 transmembrane emp24 protein transport domain containing 9  
TMEM161B transmembrane protein 161B  
TMEM17 transmembrane protein 17 
TNFRSF11B tumor necrosis factor receptor superfamily, member 11b  
TNFSF10 tumor necrosis factor (ligand) superfamily, member 10  
TRIM15 tripartite motif-containing 15  
TRIM68 tripartite motif-containing 68  
TTC30A tetratricopeptide repeat domain 30A  
USP44 ubiquitin specific peptidase 44  
WDR72 WD repeat domain 72  
YOD1 YOD1 OTU deubiquinating enzyme 1 homolog (S. cerevisiae)  
ZIK1 zinc finger protein interacting with K protein 1 homolog (mouse)  
ZNF257 zinc finger protein 257  
ZNF300 zinc finger protein 300  
ZNF395 zinc finger protein 395  
ZNF518B zinc finger protein 518B 
ZNF536 zinc finger protein 536  
ZNF585B zinc finger protein 585B  
ZNF677 zinc finger protein 677  
ZNF711 zinc finger protein 711  
ZNF831 zinc finger protein 831  
 
